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  Vorwort	  Angiogenese	   ist	   das	   Neuwachstum	   von	   Gefäßen	   aus	   einem	   bereits	   existierenden	  Gefäßnetzwerk.	  Ein	  besseres	  Verständnis	  der	  Angiogenese	  könnte	  zu	  neuen	  Therapien	  zerebraler	   Läsionen	   führen,	   z.B.	   bei	   Tumorerkrankungen	   oder	   nach	   Schlaganfall.	   Ein	  weiterer	   Hoffnungsträger	   für	   die	   Regeneration	   geschädigten	   Hirngewebes	   sind	  transplantierte	   Stammzellen.	   Diese	   Dissertation	   handelt	   von	   der	   Entwicklung	  magnetresonanztomographischer	   Verfahren	   zur	   Bildgebung	   der	   Angiogenese	   und	  transplantierter	  Stammzellen.	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1 Introduction	  
One	  of	   the	  challenges	  of	  basic	  neurological	   research	   is	   to	   identify	  potential	   targets	   for	  treatment	  of	  diseases,	   for	  which	   little	  or	  no	   therapeutic	  options	  exist	   today.	  Examples	  are	  brain	   tumors,	   stroke,	  or	   aging-­‐related	  diseases	   such	  as	  Alzheimer’s	  or	  Parkinson’s	  disease.	   A	   shift	   of	   paradigm	   has	   been	   proposed,	  motivated	   by	   advances	   in	  molecular	  biology,	  cellular	  biology,	  and	  genomics,	  towards	  manipulating	  the	  molecular	  and	  cellular	  events	   underlying	   the	   disease,	   which	   would	   be	   an	   appealing	   and	   efficient	   way	   of	  treatment.	   In	   this	   context,	   angiogenesis,	   i.e.	   the	   regrowth	   of	   new	   vessels	   from	   the	  existing	  vascular	  network,	   has	  been	   identified	   as	   a	  major	  player	   in	   the	  progression	  of	  brain	   tumors	   and,	   more	   recently,	   in	   regeneration	   after	   stroke.	   Another	   intriguing	  approach	  to	  treat	  cerebral	  lesions	  has	  been	  triggered	  by	  advances	  in	  stem	  cell	  research.	  Donation	   of	   stem	   cells	   to	   the	   damaged	   brain	  may	   help	   to	   replace	   damaged	   tissue	   or	  improve	  tissue	  at	  risk	  through	  release	  of	  protective	  factors.	  However,	   before	   angiogenesis-­‐targeted	   therapies	   and	   stem	   cell	   implantations	   can	   be	  used	  for	  the	  treatment	  of	  patients,	  their	  action	  and	  role	  need	  to	  be	  better	  understood	  in	  animal	   models	   of	   disease.	   Here,	   development	   of	   noninvasive	   imaging	   tools	   is	   of	  importance	   to	   better	   understand	   the	   spatio-­‐temporal	   profile	   of	   pathophysiological	  processes	  in	  the	  individual	  animal	  and	  to	  have	  quantitative	  measures	  for	  the	  response	  to	  molecular/cellular	   therapy.	   In	   this	   dissertation,	   the	   potential	   of	   magnetic	   resonance	  imaging	  (MRI)	  to	  image	  angiogenesis	  and	  stem	  cell	  implantations	  is	  exploited.	  MRI	  is	  a	  particularly	  powerful	  modality	  due	   to	   its	   (i)	   noninvasiveness	   (non-­‐ionizing	   radiation),	  (ii)	  high	   tissue	  penetration	  depth,	   (iii)	  high	  spatial	   resolution	  compared	   to	  most	  other	  imaging	  modalities,	  (iv)	  high	  flexibility	  in	  image	  generation,	  which	  can	  be	  optimized	  to	  visualize	   the	   tissue/biological	   process	   of	   interest,	   and	   (v)	   good	   scaling	   properties,	   i.e.	  many	  methods	  established	  in	  small	  animals	  can	  potentially	  be	  translated	  to	  humans.	  In	   the	   following	  paragraphs,	   angiogenesis	   and	   its	   role	   in	   brain	   tumor	   and	   in	   ischemic	  stroke	  will	   be	  briefly	   introduced.	  Furthermore,	  basic	   terms	  used	   in	   stem	  cell	   research	  will	  be	  discussed	  including	  prospects	  of	  stem	  cell	  therapy	  of	  the	  central	  nervous	  system,	  particularly	  after	  stroke.	  Modalities	  that	  allow	  to	  image	  angiogenesis	  and	  implanted	  cells	  will	  be	  reviewed	  with	  a	  focus	  on	  MRI	  methods.	  
1.1 Angiogenesis	  Angiogenesis	   is	   the	   growth	   of	   new	   vessels	   from	   an	   existing	   vascular	   network.	  Angiogenic	  processes	  are	  strictly	  regulated	  in	  the	  healthy	  adult	  brain	  but	  can	  be	  highly	  upregulated	   under	   pathological	   conditions	   such	   as	   ischemia,	   metabolic	   challenge,	  mechanical	  stress,	  or	  inflammation	  [1],	  [2].	  The	  pathology	  leads	  to	  an	  imbalance	  of	  pro-­‐	  and	  anti-­‐angiogenic	  molecules	  towards	  the	  pro-­‐angiogenic	  factors,	  the	  most	  prominent	  being	   vascular	   endothelial	   growth	   factor	   (VEGF-­‐A)	   and	   its	   primary	   receptor	  VEGFR-­‐2.	  Many	  more	  pro-­‐angiogenic	  molecules	  have	  been	  identified	  including	  others	  of	  the	  VEGF	  family	   (VEGF-­‐B	   to	   D,	   placenta	   growth	   factor	   PlGF,	   and	   VEGFR-­‐1),	   fibroblast	   growth	  factor	  (aFGF,	  bFGF),	  transforming	  growth	  factor	  beta	  (TGF-­‐β),	  neuropilins,	  angiopoietins	  (Ang-­‐1	   and	   2)	   and	   their	   receptors	   Tie-­‐1	   and	   Tie-­‐2,	   and	   erythropoietin	   (Epo).	  Upregulation	   of	   these	   molecules	   is	   often	   accompanied	   by	   downregulation	   of	   anti-­‐angiogenic	   factors,	   e.g.	   thrombospondin	   and	   angiostatin	   [3],	   [4].	   The	   imbalance	   of	  factors	   leads	   to	   destabilization	   of	   vessel	   walls	   and	   subsequent	   proliferation	   of	  endothelial	   cells,	   formation	   of	   microvessel	   branches,	   followed	   by	   stabilization	   of	   the	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new	   vessel	   walls,	   and	   finally	   perfusion	   of	   the	   newly	   formed	   vasculature	   [5].	   The	  different	  stages	  of	  angiogenesis	  are	  illustrated	  in	  Fig.	  1.	  
	  
1.1.1 Angiogenesis	  in	  tumors	  Small	   carcinomas	   are	   supplied	   with	   oxygen	   and	   nutrients	   by	   the	   already	   existing	  vasculature	   by	   diffusion	   through	   tissue.	   Even	   for	   strongly	   proliferating,	   i.e.	   very	  malignant	   tumor	   cells	   the	   high	   number	   of	   newly	   formed	   cells	   can	   for	   a	   long	   time	   be	  compensated	   by	   high	   number	   of	   cells	   undergoing	   apoptosis	   due	   to	   the	   lack	   of	  supporting	  vasculature.	  In	  this	  stage,	  tumor	  size	  is	  usually	  restricted	  to	  a	  few	  mm3	  [6].	  For	  many	  tumor	  types,	  however,	  a	  part	  of	   the	   tumor	  cells	  can	  start	   to	  upregulate	  pro-­‐angiogenic	  and	  downregulate	  anti-­‐angiogenic	  factors,	  which	  leads	  to	  recruitment	  of	  new	  capillaries	  and	  allows	  the	  whole	  tumor	  to	  grow	  further.	  This	  “angiogenic	  switch”	  is	  a	  key	  step	   in	   the	   progression	   of	   primary	   tumors	   and	   metastases	   [7].	   Its	   importance	   has	  triggered	   the	   development	   of	   substances	   for	   anti-­‐angiogenic	   tumor	   therapies,	   mainly	  inhibitors	   of	   VEGF	   and	   its	   receptors	   [8],	   [9],	   which	   also	   holds	   for	   the	   drugs	   used	   in	  studies	   of	   this	   dissertation:	   Bevacizumab	   (commercial	   name	  Avastin,	   Roche)	   and	  PTK	  787	  (commercial	  name	  Vatalanib,	  Novartis).	  However,	  results	  in	  the	  clinic	  are	  variable.	  Unsolved	   problems	   include	   resistance,	   toxicity,	   or	   a	   change	   of	   tumor	   phenotype	   in	  response	   to	   therapy	   from	   angiogenic	   to	   infiltrative	   phenotype	   as	   seen	   for	   example	   in	  brain	  tumors	  [10],	  [11].	  
1.1.2 Angiogenesis	  after	  stroke	  In	  an	  ischemic	  stroke,	  a	  blood	  clot	  blocks	  a	  supplying	  artery	  in	  the	  brain,	  which	  leads	  to	  decreased	   blood	   flow	   to	   brain	   tissue	   and	   finally	   to	   permanent	   cell	   loss	   and	   loss	   of	  function	  associated	  with	  the	  damaged	  area	  of	  the	  brain.	  The	  ischemia	  triggers	  a	  complex	  cascade	   of	   molecular	   events,	   some	   of	   which	   can	   promote	   angiogenesis	   [4],	   [12].	   The	  most	  dominant	  contribution	  to	  angiogenesis	  is	  hypoxia	  in	  affected	  tissue,	  which	  induces	  stabilization	   of	   hypoxia-­‐inducible	   transcription	   factor	   alpha	   (HIF-­‐α)	   and	   subsequent	  upregulation	   of	   VEGF-­‐A	   and	   its	   main	   receptor	   VEGFR-­‐2.	   The	   time	   scale,	   by	   which	  
	  
Figure	  1:	  Angiogenesis	  in	  the	  adult	  brain.	  A	  pathological	  condition	  (1)	  can	  stimulate	  upgregulation	  of	  pro-­‐angiogenic	  
and	  downregulation	  of	  anti-­‐angiogenic	  factors	  (2).	  Subsequently,	  vessels	  become	  permeable,	  endothelial	  cells	  start	  to	  
proliferate	   and	   endothelial	  progenitor	   cells	  are	   recruited	   from	  the	   blood	   stream.	  Endothelial	   cells	  migrate	  and	   form	  
new	  vascular	  buds	  (3).	  After	  stabilization	  of	  vessel	  walls	  (4)	  the	  newly	  formed	  vessel	  is	  perfused	  (5).	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upregulation	  of	  pro-­‐angiogenic	  molecules	  and	  subsequent	  new	  vessel	   formation	  occur	  after	   ischemia,	  begins	  within	  a	   few	  hours	  after	   the	   infarct	  and	  cumulates	  over	   several	  days	   [4].	   In	   1994,	   Kuprinski	   and	   colleagues	   reported	   vessel	   sprouting	   and	   increased	  microvessel	  densities	  in	  the	  peri-­‐infarct	  zone	  on	  post-­‐mortem	  tissue	  of	  stroke	  patients,	  which	  was	  correlated	  with	   longer	  survival	   times	  [13].	  Almost	  a	  decade	   later,	   the	  same	  group	  was	  then	  the	   first	   to	  detect	  angiogenesis	  after	  experimental	  stroke	   in	  rats	  using	  vascular	   casts	   and	   electron	   microscopy	   [14].	   Since	   angiogenesis	   bears	   promise	   to	  restore	   blood	   flow	   to	   damaged,	   ischemic	   tissue,	   pro-­‐angiogenic	   therapy	   of	   stroke	   has	  been	   under	   investigation	   in	   animal	   studies,	   e.g.	   by	   delivery	   of	   growth	   factors	   or	   cells	  [15],	  [16].	  
1.2 Imaging	  angiogenesis	  
1.2.1 Overview	  Since	  angiogenesis	  is	  an	  important	  contributor	  to	  outcome	  in	  brain	  tumor	  and	  in	  stroke,	  the	  ability	  to	  examine	  this	  process	  noninvasively	  with	  imaging	  would	  be	  of	  great	  benefit.	  Imaging	  modalities	   to	   study	   the	  molecular	  events	  of	   angiogenesis	   (steps	  1-­‐2	  of	  Fig.	  1)	  include	  fluorescence,	  bioluminescence,	  or	  MR	  imaging	  of	  vessel-­‐specific	  “reporter	  genes”,	  i.e.	   artificial	   proteins	   that	   are	   detectable	   by	   imaging	   and	   that	   are	   expressed	   only	   in	  presence	  of	   the	   specific	  molecule	  of	   interest.	   This	   requires	  however	   the	   generation	  of	  transgenic	  cells,	  thus	  is	  almost	  exceptionally	  applicable	  in	  animals	  due	  to	  safety	  issues.	  Permeability	   of	   vessels	   (step	   3	   of	   Fig.	   1)	   can	   be	   detected	   with	   dynamic	   contrast	  enhanced	  MRI.	  A	  T1	  contrast	  agent	  (usually	  Gadolinium-­‐based)	  is	  administered	  i.v.	  and	  leakage	  of	   the	   agent	   into	   the	   tissue	   is	   detected	   via	   decrease	  of	   the	  T1	   relaxation	   time.	  Perfused	   vessels	   (step	   5	   of	   Fig.	   1)	   can	   be	   directly	   detected	   via	   angiography	   (MRI	   or	  computed	   tomography),	   by	   changes	   in	   perfusion	   (positron	   emission	   tomography,	  computed	  tomography,	  ultrasonography,	  dynamic	  susceptibility	  contrast	  MRI	  or	  arterial	  spin	   labeling	   techniques),	  by	  changes	   in	  blood	  volume	  (contrast-­‐enhanced	  MRI),	  or	  by	  changes	  in	  blood	  oxygenation	  through	  the	  blood-­‐oxygen-­‐level	  dependent	  (BOLD)	  effect	  [17–20].	   Again,	   MRI	   represents	   one	   of	   the	   most	   appealing	   modalities	   although	   the	  resolution	  is	  too	  low	  (~100	  µm)	  to	  directly	  detect	  newly	  formed	  microvessels	  (~10	  µm).	  Despite	   this	   drawback,	   important	   statistical	   microvessel	   characteristics	   can	   be	  calculated	   from	  MRI	   data	   by	  mathematical	   modeling	   of	   the	   vascular	   network.	   In	   this	  dissertation,	  steady-­‐state	  contrast-­‐enhanced	  MRI	  (SSCE	  MRI)	  was	  optimized	  and	  used	  to	  assess	   blood	   volume,	   mean	   vessel	   density,	   and	   mean	   vessel	   size.	   The	   mathematical	  model	   and	   experimental	   strategy	   underlying	   SSCE	   MRI	   are	   introduced	   in	   the	   next	  sections.	  
1.2.2 Steady	  state	  contrast	  enhanced	  MRI	  
Basic	  principle	  The	   basic	   strategy	   of	   SSCE	  MRI	   is	   outlined	   in	   Fig.	   2.	   The	  MRI	   signal	   from	   a	   vascular	  network	  is	  measured	  before	  injection	  of	  an	  intravascular	  contrast	  agent	  and	  again	  after	  the	   contrast	   agent	   is	   equilibrated	   in	   the	   blood	   (is	   in	   a	   steady	   state).	   A	   mathematical	  model	   can	   be	   used	   to	   predict	   the	   changes	   in	   MRI	   signal	   intensities,	   which	   generally	  depend	  on	  the	  geometry	  of	  the	  vascular	  network.	  If	  the	  model	   is	  bijective	  (i.e.	   forward	  and	   backward	   problem	   are	   solved	   unambiguously),	   measurements	   of	   MRI	   signal	  changes	  due	  to	  injection	  of	  the	  agent	  allow	  conclusions	  about	  vessel	  geometry.	  This	  can	  be	  used	  for	  biological	  applications.	  In	  the	  next	  section	  the	  most	  commonly	  used	  model	  of	  MRI	  signal	  in	  vasculature	  is	  introduced.	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Cylinder	  model	  of	  the	  vasculature	  In	   the	   cylinder	   model,	   tissue	   is	   assumed	   to	   consist	   of	   an	   intravascular	   compartment	  (blood)	  and	  an	  extravascular	  compartment	  (tissue),	  which	  exhibit	  a	  constant	  difference	  in	   magnetic	   susceptibility	   χ .	   Vessels	   are	   modeled	   as	   randomly	   distributed,	   infinitely	  long	  cylinders.	  Analytical	  expressions	  of	  the	  MR	  signal	  from	  a	  voxel	  were	  developed	  in	  the	  works	  of	  Haacke,	  Yablonskiy,	  Kiselev,	  and	  Posse	  by	  solving	  the	  Bloch/Bloch-­‐Torrey	  differential	  equations	  for	  the	  case	  of	  one	  vessel	  and	  by	  averaging	  over	  all	  diffusion	  paths	  and	   possible	   vessel	   positions	   and	   radii	   [21–24].	   The	   procedure	   is	   outlined	   for	   the	  extravascular	   signal	   in	   Fig.	   3	   along	   the	   lines	   of	   Kiselev	   and	   Posse	   [22].	   Under	   certain	  assumptions,	   which	   will	   be	   discussed	   in	   more	   detail	   in	   chapter	   3.1,	   the	   signal	  contribution	  of	   the	   cylinders	   can	   simply	  be	  described	  by	   shifts	   of	   relaxation	   rates,	   i.e.	  
1 T2 = R2→ R2 + ΔR2 	  for	   the	   spin	   echo	   experiment	   and	  1 T2* = R2*→ R2* + ΔR2* 	  for	   the	  gradient	  echo	  experiment.	   In	  other	  words,	   the	  signal	  post-­‐injection	   is	  characterized	  by	  an	   additional	   monoexponential	   decay	   compared	   to	   the	   signal	   pre-­‐injection	  
Spost = Spre ⋅exp −B ⋅ t( );    B = ΔR2 / ΔR2* .	  
	  
Figure	  2:	  Basic	  principle	  of	  steady	  state	  contrast-­‐enhanced	  MRI.	  A	  (super)	  paramagnetic	  contrast	  agent	  is	  injected	  into	  
the	   blood	   pool	   and	   spreads	   homogeneously	   over	   the	   vascular	   network	   of	   a	   certain	   geometry	   (left).	   This	   leads	   to	   a	  
change	  in	  MRI	  signal	  as	  shown	  here	  on	  representative	  coronal	  gradient	  echo	  images	  of	  a	  healthy	  rat	  brain	  before	  and	  
after	  superparamagnetic	  iron	  oxide	  injection	  (right).	  The	  challenges	  are	  to	  find	  a	  good	  set	  of	  parameters	  describing	  the	  
vascular	   geometry	   and	   to	   find	   a	   model,	   which	   not	   only	   quantifies	   the	   changes	   in	   MRI	   signal	   given	   the	   vascular	  
geometry	   but	   also	   solves	   the	   inverse	   problem.	   This	   can	   be	   used	   to	   probe	   the	   vasculature	   with	   MRI	   in	   biological	  
applications.	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  Importantly,	  a	  sensitivity	  of	  ΔR2 	  to	  the	  mean	  vessel	  radius	  R 	  within	  a	  voxel	  was	  found	  in	  the	  analytical	  expressions	  and	  confirmed	  by	  Monte-­‐Carlo	  simulations	  of	  Boxermann	  et	  al.	  [25].	  ΔR2* 	  depends	  on	  volume	  fraction	  of	  the	  intravascular	  compartment,	  i.e.	  blood	  volume	  fraction	  ξ0 .	  	   ΔR2 = 0.694 ⋅ 2πγχB0( )2 3D1 3ξ0R−2 3 	   (1) 	  	   ΔR2* = 43πγχB0ξ0 	   (2) 	  Dennie	  et	  al.	  were	   the	   first	   to	  demonstrate	  how	  this	  can	  be	  used	   in	   the	  experiment	   to	  measure	  changes	  of	  vessel	  morphology	  due	  to	  angiogenesis	  in	  tumors	  [26].	  Since	  then,	  the	  experimental	  framework	  has	  been	  developed	  further	  and	  is	  commonly	  referred	  to	  as	  “vessel	   size	   imaging”	   [27].	   The	   (slightly	   modified)	   framework	   was	   also	   used	   for	   this	  dissertation	   and	   is	   illustrated	   in	   Fig.	   4.	   Changes	   in	   relaxation	   rates	  ΔR2 	  and	  ΔR2* 	  are	  assessed	   by	   spin	   echo	   and	   gradient	   echo	  MRI,	   respectively.	   The	   changes	   in	   relaxation	  rates	   are	   relative	  measures	   of	   blood	   volume	   in	   small	   vessels	   (ΔR2 )	   and	  overall	   blood	  volume	  (ΔR2* ).	  Additional	  measurements	  of	  diffusivity	  in	  tissue	  D 	  and	  of	  susceptibility	  changes	  in	  blood	   χ 	  allow	  calculation	  of	  mean	  vessel	  radius	   R 	  and	  areal	  vessel	  density	  
N 	  via	  equations	  (1)	  and	  (2)	  (in	  cgs	  units	  [27–30]):	  
	  
Figure	  3:	  Analytical	  model	  of	  MR	  signal	  in	  a	  network	  of	  randomly	  distributed	  cylindrical	  vessels.	  Two	  basic	  mechanisms	  
attenuate	   the	  MR	   signal	   near	   a	   cylindrical	   vessel	   of	   radius	   ,	   angle	   	  to	   the	   external	   field	   ,	   and	   susceptibility	  
difference	   	  compared	  to	   tissue.	  First,	   the	  additional	  magnetic	  field	  of	   the	  vessel	   leads	  to	  a	  shift	  of	   the	  basic	  Larmor	  
frequency	   ,	   thus	   to	  a	   loss	   of	  phase	   coherence	  of	   spins	  at	  different	  positions	   (A).	  Second,	   spins	   can	  diffuse	  
through	  the	  field	  gradient	   	  during	  the	  imaging	  experiment	  and	  pick	  up	  a	  random	  phase.	  The	  diffusion	  leads	  to	  
an	  exponential	  decay	  in	  the	  magnetization	  density	   	  (first	  term	  denotes	  phase	  offset	  described	  in	  (A),	  second	  term	  
the	  diffusion	  effect)	   after	  averaging	  over	  all	  diffusion	  paths	   that	  end	  at	   	  (B).	  This	  exponential	   factor	   is	  well	  known	  
from	   diffusion	   MRI.	   MR	   signal	   from	   a	   voxel	   containing	   many	   cylinders	   is	   obtained	   via	   averaging	   over	   ,	   which	   is	  
equivalent	  to	  averaging	  over	  positions,	  orientations,	  and	  radii	  of	  all	  cylinders	  in	  the	  voxel	  (C).	   :	  gyromagnetic	  ratio,
:	  diffusivity	  of	  tissue,	   :	  mean	  diffusion	  length	  during	  MR	  experiment,	   :	  integration	  over	  position,	  orientation,	  
and	   radius	   of	   the	   nth	   cylinder.	   Equations	   are	   only	   shown	   for	   the	   extravascular	   compartment.	   The	   complete	  
mathematical	  description	  can	  be	  found	  in	  [22].	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1.3 Neural	  stem	  cells	  
1.3.1 General	  properties	  Neural	   stem	   cells	   (NSCs)	   are	   immature,	   proliferating	   cells	   that	   can	   generate	   all	  major	  cells	   of	   the	   central	   nervous	   system,	   i.e.	   are	  multipotent,	   and	   that	   have	   the	   capacity	   of	  self-­‐renewal	  [31]	  although	  more	  stringent	  definitions	  exist	  [32].	  NSCs	  are	  the	  progeny	  of	  embryonic	   stem	   cells.	   They	   can	   themselves	   differentiate	   into	   neuronal	   and	   glial	  progenitor	   cells	   and	   finally	   give	   rise	   to	  mature	   neurons	   and	   glia	   (Fig.	   5).	   It	   was	   long	  believed	  that	  NSCs	  only	  play	  a	  role	  during	  embryonic	  and	  fetal	  development.	  However,	  it	  is	  known	  today	  that	  NSC	  niches	  exist	   in	  the	  adult	  brain,	  predominantly	  in	  the	  granular	  layer	  of	  the	  dentate	  gyrus	  in	  the	  hippocampus	  and	  in	  the	  subventricular	  zone	  [33],	  [34].	  The	  NSCs	  of	  the	  adult	  brain	  can	  give	  rise	  to	  new	  neurons	  (neurogenesis).	  In	  the	  healthy	  
	  
Figure	   4:	   Typical	   SSCE	   MRI	   data	   acquisition	   and	   post-­‐processing	   framework	   for	   imaging	   blood	   volume,	   vessel	   size	  
(radius),	   and	   vessel	   density.	   Gradient	   echo	   and	   spin	   echo	   MR	   images	   are	   acquired	   pre	   and	   post	   i.v.	   injection	   of	  
superparamagnetic	   iron	   oxide	   particles.	   From	   the	   changes	   in	   signal,	   changes	   in	   relaxation	   rates	   	  and	   	  are	  
calculated,	  which	  are	  relative	  measures	  of	  blood	  volume.	  Together	  with	  measurements	  of	  tissue	  diffusivity	  and	  blood	  
susceptibility,	   absolute	   vessel	   size	   and	   vessel	   density	  maps	   are	   generated.	   Representative	   coronal	   brain	   images	   of	   a	  
healthy	  rat	  before	  and	  after	  contrast	  agent	  injection	  (30	  mg	  Fe/kg)	  are	  shown.	  TE:	  echo	  time.	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mammalian	  brain,	  neural	  progenitor	  cells	   from	  the	  subventricular	  zone	  migrate	   to	   the	  olfactory	  bulb	  and	  generate	  new	  neurons	  [34]	  whereas	  adult	  hippocampal	  neurogenesis	  is	   speculated	   to	   play	   a	   role	   in	   accommodating	   the	   brain	   to	   establish	   a	  more	   complex	  neuronal	  network	  [35].	  NSCs	  are	  highly	  investigated	  for	  therapies	  of	  neurological	  disorders	  such	  as	  Parkinson’s	  disease,	  stroke,	  and	  multiple	  sclerosis,	  since	  the	  clinical	  syndromes	  of	  these	  diseases	  are	  caused	   by	   a	   loss	   of	   glia	   and	   neurons	   [36].	   Two	  major	   strategies	   are	   proposed:	   (i)	   to	  “boost”	  neurogenesis	  or	  to	  prevent	  cell	  death	  of	  endogenous	  NSCs	  and	  (ii)	  implantation	  of	  NSCs	  to	  replace	  damaged	  tissue	  [37].	  The	  latter	  will	  be	  introduced	  in	  more	  detail	   in	  the	  following	  section	  with	  a	  focus	  on	  stroke.	  
	  
1.3.2 Neural	  stem	  cell	  implantation	  in	  the	  healthy	  and	  stroke-­‐damaged	  brain	  To	   generate	   the	   large	   number	   of	   cells	   needed	   for	   implantations,	  NSCs	   can	   be	   derived	  from	   embryonic	   stem	   cells,	   the	   fetal	   or	   the	   adult	   brain	   and	   expanded	   in	   vitro	   in	  neurosphere	   [38]	  or	  monolayer	   [39],	   [40]	  cultures.	  Alternatively,	  NSCs	  can	  be	  derived	  from	   induced	   pluripotent	   stem	   (iPS)	   cells	   [41].	   These	   cells	   are	   generated	   by	   genetic	  modification	   of	   differentiated	   cells,	   e.g.	   skin	   cells,	   a	   process	   also	   referred	   to	   as	  reprogramming	  or	  de-­‐differentiation.	  Despite	  the	  high	  impact	  of	  this	  technology,	  which	  resulted	   in	   the	   Nobel	   price	   in	   physiology	   or	  medicine	   for	   one	   of	   the	   pioneers	   Shinya	  Yamanaka	  in	  2012,	  there	  is	  still	  debate	  on	  safety	  of	  iPS	  cells	  and	  whether	  or	  not	  iPS	  cells	  are	   equivalent	   to	   normal	   stem	   cells	   [42].	   The	   NSCs	   used	   in	   this	   dissertation	   were	  provided	   by	   our	   collaborator	   Zaal	   Kokaia	   from	   the	   Laboratory	   of	   Neural	   Stem	   Cell	  Biology	  and	  Therapy,	  Department	  of	  Clinical	  Sciences,	  Stem	  Cell	  Center,	  Lund,	  Sweden.	  They	   are	   derived	   from	   the	   human	   fetal	   brain	   and	   expanded	   in	   vitro	   as	   neurospheres.	  Since	  these	  NSCs	  are	  of	  human	  origin	  they	  represent	  a	  particularly	  promising	  candidate	  for	  a	  clinical	  translation	  [37].	  In	  previous,	  invasive	  studies	  in	  Lund,	  these	  cells	  were	  well	  characterized	   in	   terms	   of	   differentiation	   potential,	   survival,	   and	   integration	   into	   host	  tissue	   both	   in	   the	   healthy	   rodent	   brain	   and	   under	   pathological	   conditions	   [43–47].	  Importantly,	  tumor	  formation	  was	  never	  observed	  in	  vivo.	  Implantation	   in	   the	   healthy	   rodent	   brain	   is	   used	   to	   study	   survival,	   migration,	   and	  differentiation	   of	   NSCs	   under	   in	   vivo	   conditions.	   In	   studies	   of	   this	   dissertation,	   NSCs	  were	  implanted	  in	  the	  adult	  mouse	  brain	  and	  the	  neonatal	  rat	  brain.	  Since	  the	  neonatal	  
	  
Figure	  5:	  Schematic	  illustration	  of	  different	  stem	  cell	  levels	  of	  potency	  and	  commitment	  for	  differentiation	  into	  neurons	  
and	   glia.	   Black	   arrows	   indicate	   default	   pathway	   for	   development	   of	   specialized	   cells	   and	   fate	   restriction.	   Rounded	  
arrows	  indicate	  the	  capacity	  for	  self-­‐renewal.	  Modified	  from	  [46].	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brain	   is	   rich	   in	   instructive,	   developmental	   signals	   it	   serves	   as	   an	   intermediate	   step	  between	   the	   artificial,	   controlled	   in	   vitro	   environment	   and	   the	   less	  plastic	   adult	   brain	  [46].	  Moreover,	  immune	  response	  and	  risk	  of	  graft	  rejection	  is	  lower	  in	  neonates	  than	  in	  adults	   [48–50],	   rendering	   pharmacological	   immune	   suppression,	   e.g.	   with	   the	   drug	  Cyclosporine,	   unnecessary.	   This	   is	   particularly	   important	   for	   long-­‐term	   studies	   since	  most	   immunosuppressants	   are	   toxic	   and	   should	   not	   be	   used	   for	   longer	   times	   (>	   4	  weeks).	  A	  large	  number	  of	  reports	  on	  human	  NSC	  implantation	  studies	  after	  stroke	  exist	  for	  rats	  [44],	   [45],	   [51–54],	   but	   also	   for	   mice	   [55],	   Mongolian	   gerbils	   [56],	   and	   non-­‐human	  primates	  [57].	  The	  cells	  survived	  robustly	  depending	  on	  the	  proximity	  of	  the	  graft	  to	  the	  lesion,	   migrated	   predominantly	   towards	   the	   damaged	   area	   and	   the	   migrating	   cells	  mainly	   differentiated	   to	   cells	   with	   neuronal	   phenotype	   [58].	   A	   reduction	   of	   infarct	  volume	   compared	   to	   control	   animals	   was	   observed	   in	   [56].	   Neurological	   function	   of	  stroke	  animals	  with	  NSC	  implantation	  improved	  significantly	  compared	  to	  controls	  that	  received	   a	   vehicle	   transplant	   [51],	   [55],	   [56].	   However,	   functional	   improvement	   after	  cell	   implantation	   in	   stroke	   is	   generally	  believed	   to	  be	   rather	  due	   to	   release	  of	   trophic	  factors	   than	   direct	   tissue	   replacement.	   These	   factors	   possibly	   promote	   endogenous	  repair	  mechanisms,	  reduce	  cell	  death,	  and	  stimulate	  angiogenesis	  and	  neurogenesis	  [59].	  Before	  NSC	  implantations	  can	  be	  used	  for	  the	  treatment	  of	  stroke	  patients	  a	  number	  of	  fundamental	   questions	   need	   to	   be	   answered	   [60]:	   Which	   patients	   would	   profit	   most	  from	  such	  a	  treatment	  (age,	  anatomical	  location	  and	  size	  of	  the	  lesion,	  …)?	  What	  is	  the	  best	   cell	   type?	  What	   is	   the	   optimal	   timing	   and	   site	   for	   implantation?	  Which	   delivery	  route	  should	  be	  preferred?	  What	  numbers	  and	  concentration	  of	  cells	  should	  be	  used	  and	  how	  can	  graft	  rejection	  by	  the	  host	  immune	  system	  be	  avoided?	  	  As	   cell-­‐mediated	   regeneration	   processes	   develop	   continuously	   over	   long	   times,	  noninvasive	   imaging	   is	   essential	   to	   answer	   some	   of	   these	   questions.	   Noninvasive	  imaging	   allows	   to	   follow	   the	   cells	   in	   space	   and	   time	   over	   long	   periods	   and,	   ideally,	  permits	  to	  assess	  their	  functional	  fate	  [61].	  In	  turn,	  imaging	  can	  provide	  readouts	  of	  host	  response	   to	   the	   cellular	   therapeutic.	   For	   example,	   lesion	   size	   can	   be	  measured	   on	   T2	  weighted	  MRI	  and	  functional	  recovery	  can	  be	  assessed	  by	  functional	  MRI	  [62].	  
1.4 Imaging	  implanted	  neural	  stem	  cells	  
1.4.1 Overview	  The	  discrimination	  of	  implanted	  neural	  stem	  cells	  from	  surrounding	  cells	  in	  brain	  tissue	  is	   very	   challenging	   since	   the	   physical	   properties	   of	   implant	   and	   tissue	   are	   almost	  identical.	  Thus	  it	  is	  necessary	  to	  label	  the	  cells	  for	  detection	  with	  imaging.	  In	  principal,	  two	  labeling	  approaches	  exist:	  genetic	  labeling	  and	  external	  labeling	  before	  implantation.	  For	  genetic	  labeling,	  a	  gene	  (the	  “reporter	  gene”)	  is	  introduced	  in	  the	  DNA	  of	  cells.	  The	  genetically	   modified	   cell	   is	   forced	   to	   produce	   a	   foreign	   protein,	   which	   can	   either	   be	  directly	  detected	  or	  enhances	  binding	  of	  a	  substance	  (the	  “reporter	  probe”)	  detectable	  by	   imaging.	  For	  external	   labeling,	  cells	  are	   forced	   to	   take	  up	  a	  detectable	  agent	  before	  implantation.	   If	   the	   cells	   keep	   the	   label	   after	   implantation,	   the	   agent	   can	   be	   used	   to	  indirectly	   locate	   the	   cells	  with	   imaging.	  External	   labels	  have	   the	  disadvantage	  of	   label	  dilution	  when	   the	   cells	   divide	   after	   implantation.	   Furthermore,	   an	   external	   label	  may	  still	  remain	  in	  place	  when	  the	  cells	  die	  leading	  to	  false	  positive	  signal.	  On	  the	  other	  hand,	  the	   chemistry	   of	   external	   labels	   can	   be	   optimized	   to	   a	   much	   higher	   extent,	   which	  generally	   leads	  to	  higher	  sensitivity	  compared	  to	  reporter	  gene	  approaches.	  Moreover,	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genetic	   labeling	   requires	   generation	   of	   genetically	   modified	   cells,	   which	   raises	   safety	  issues	   for	   use	   in	   humans	   whereas	   external	   labels	   can	   be	   chemically	   designed	   as	   to	  minimize	  adverse	  effects.	  In	  the	  following,	  an	  overview	  of	  labels	  and	  imaging	  modalities	  is	  given	  (reviewed	  in	  [63–65]).	  For	  optical	  imaging,	  the	  most	  prominent	  reporter	  gene	  is	  the	  green	  fluorescent	  protein	  (GFP),	  which	  originates	   from	  the	  genome	  of	   jellyfish.	  Upon	  excitation	  with	   light	   in	   the	  ultraviolet	   range,	   the	  protein	  emits	   green	   light,	  which	   can	  be	  detected	  with	  an	  optical	  camera.	   Numerous	   other	   fluorescent	   proteins	   of	   different	   excitation/emission	   spectra	  are	  available	  nowadays	  for	  planar	  or	  tomographic	  fluorescence	  imaging.	  External	  labels	  for	  optical	   imaging	  include	  a	  wide	  range	  of	   fluorophores	  or	  quantum	  dots,	  which	  yield	  order	   of	   magnitude	   higher	   light	   emission.	   Another	   class	   of	   optical	   reporter	   genes	   is	  represented	  by	  the	  luciferases	  of	  the	  firefly,	  click	  beetle,	  renilla,	  gaussia,	  or	  some	  types	  of	  bacteria.	  Genetically	  modified	  cells	  produce	  the	   luciferase	  and	  are	  detected	  via	   light	  emission	  during	  an	  enzymatic	  reaction	  with	  an	  exogenously	  delivered	  substrate.	  Since	  luciferases	   are	   absent	   in	   normal	   tissue	   of	   mammals,	   cells	   can	   very	   sensitively	   be	  detected	  against	  background.	  However,	  scattering	  and	  absorption	  of	  light	  in	  tissue	  limits	  the	  use	  of	  optical	  imaging	  to	  cell	  culture	  or	  small	  animals.	  In	  vivo,	  the	  typical	  penetration	  depth	  is	  only	  a	  few	  mm	  and	  3D	  tomographic	  methods	  are	  in	  their	  infancy.	  Still,	  optical	  methods	  remain	  the	  Gold	  standard	  for	  histology.	  Therefore,	  novel	  imaging	  approaches,	  as	   presented	   in	   this	   dissertation,	   need	   to	   be	   verified	   by	   optical	   techniques,	   e.g.	  microscopy	  on	  brain	  slices.	  Positron	   emission	   tomography	   (PET)	   and	   single-­‐photon	   emission	   computed	  tomography	   (SPECT)	   sensitively	   detect	   radioisotopes	   or	   positron	   emitters	   in	   vivo	   in	  deep	   tissues,	   e.g.	   the	   brain.	   They	   allow	   acquisition	   of	   true	   3D	   tomographic	   data.	  However,	  the	  spatial	  resolution	  is	  poor	  (>	  1	  mm),	  approximately	  one	  order	  of	  magnitude	  lower	   than	   in	  MRI.	   An	   example	   of	   a	   PET/SPECT	   reporter	   gene	   is	   the	   herpes	   simplex	  virus	  type	  1	  thymidine	  kinase.	  Externally	  administered,	  radiolabeled	  probes	  for	  PET	  and	  SPECT	  detection	  accumulate	  only	  in	  cells	  expressing	  the	  herpes	  thymidine	  kinase.	  Cells	  can	   also	   be	   pre-­‐labeled	   with	   a	   radionuclide	   and	   tracked	   with	   PET/SPECT	   after	  implantation.	  Due	   to	   radioactive	  decay	  of	   the	   tracer,	   this	   is	   only	  useful	   for	   short-­‐term	  studies	  with	  time-­‐spans	  at	  the	  order	  of	  tracer	  half-­‐life.	  Of	   all	   imaging	   modalities,	   MRI	   is	   the	   least	   invasive	   and	   provides	   most	   detailed	  anatomical	   information	   of	   deep	   tissues.	   Most	   isotopes	   used	   for	   MRI	   are	   stable,	   thus	  enabling	  long-­‐term	  studies.	  Reporter	  genes	  for	  MRI	  may	  be	  classified	  in	  four	  categories:	  (i)	  metalloproteins	  that	  promote	  iron	  accumulation	  detectable	  via	  the	  T2/	  T2*	  effect,	  (ii)	  cell	   surface	   molecules	   that	   specifically	   bind	   an	   externally	   administered	   MR	   contrast	  agent,	  (iii)	  enzymes	  which	  turn	  on	  the	  contrast	  of	  an	  externally	  administered	  agent,	  (iv)	  proteins	  detectable	  via	  the	  chemical	  exchange	  saturation	  transfer	  effect	  [62].	  However,	  MR	  reporter	  genes	  are	  still	  in	  their	  infancy	  and	  wide-­‐spread	  use	  has	  been	  hampered	  by	  low	  sensitivity	  and	  safety	  issues	  [64].	  The	  most	  widely	  used	  external	  labels	  for	  MRI	  cell	  tracking	   are	   superparamagnetic	   iron	   oxide	   particles	   (SPIOs).	   Cells	   labeled	  with	   SPIOs	  are	   traced	   with	   conventional	   1H	   MRI	   via	   their	   T2	   and	   T2*	   effect.	   More	   recently,	  fluorinated	   labels	   are	   investigated	   for	   cell	   detection	   with	   19F	   MRI.	   Advantages	   and	  drawbacks	  of	  these	  cell	  tracking	  methods	  will	  be	  introduced	  in	  the	  following	  sections.	  
1.4.2 Cell	  tracking	  with	  1H	  MRI	  MRI	  of	  cells	   that	  have	  been	   labeled	  with	  SPIO	  contrast	  agents	  before	   implantation	  can	  provide	   insight	   into	   location	  and	  –	   less	  reliably	  –	  numbers	  of	  grafted	  cells.	  Using	  SPIO	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labels,	  our	  group	  was	  the	  first	  to	  noninvasively	  image	  migration	  of	  implanted	  stem	  cells	  from	   the	   healthy	   towards	   the	   stroke-­‐damaged	  hemisphere	   [67].	  However,	   the	  murine	  stem	   cell	   line	   (C17.2)	   used	   in	   that	   study	   carries	   an	   oncogene	   for	   more	   convenient	  handling	  in	  cell	  culture	  thus	  is	  not	  well	  suited	  for	  therapy.	  Later	  studies	  by	  other	  groups	  employed	  long-­‐term	  1H MRI	  of	  SPIO	  labeled,	  clinically	  more	  relevant,	  human	  NSCs	  in	  the	  neonatal,	   healthy	  adult,	   and	   the	   stroke-­‐induced	   rat	  brain	   [68].	  These	   revealed	  distinct	  migration	  patterns	  of	  cells	  depending	  on	  their	  microenvironment.	  	  SPIOs	  usually	  consist	  of	  an	   iron	  oxide	  crystal	  core	  (magnetite,	  Fe3O4)	  surrounded	  by	  a	  dextran/carboxydextran	  coating.	  Depending	  on	  the	  hydrodynamic	  diameter,	  iron	  oxide	  particles	   are	   categorized	   in	   micron-­‐sized	   iron	   oxide	   particles	   (MPIOs,	   ~1	   µm),	   SPIOs	  (50-­‐180	  nm),	   ultrasmall	   SPIOs	   (USPIOs,	   10-­‐50	   nm),	   or	   very	   small	   SPIOs	   (VSPIOs,	   <10	  nm)	   [69].	   For	   this	   dissertation,	   the	   commercially	   available	   dextran-­‐coated	   SPIO	  formulation	  Endorem	  (~200	  nm,	  Guerbet,	  France)	  was	  used	  for	  all	  studies.	  NSCs	  take	  up	  the	  particles	   through	  endocytosis,	   and	   endosomes	   filled	  with	   SPIOs	   accumulate	   in	   the	  cytoplasm.	   In	   the	   large	   magnetic	   field	   of	   an	   MRI	   scanner,	   the	   magnetization	   of	  intracellular	   SPIOs	   generates	   a	   broader	   magnetic	   field	   distribution	   in	   the	   voxel	  containing	  the	  cell(s).	  Effectively,	  this	  induces	  faster	  dephasing	  of	  nearby	  1H spins,	  i.e.	  a	  signal	  dropout	  on	  T2/	  T2*	  weighted	  MR	  images.	  As	  many	  1H nuclei	  in	  the	  surrounding	  of	  the	  contrast	  agent	  particles	  are	  affected	  in	  their	  MR	  signal,	  the	  method	  is	  very	  sensitive	  when	  cells	  are	  imaged	  against	  magnetically	  homogeneous	  background	  (Fig.	  6	  A).	  In	  vivo,	  however,	   the	   hypointensity	   generated	   by	   SPIO	   labeled	   cells	   can	   easily	   be	   confounded	  with	   other	   sources	   of	   magnetic	   inhomogeneities	   such	   as	   blood	   vessels	   (iron	   in	  hemoglobin)	  or	  dense	  anatomical	  structures	  such	  as	  bone	  and	  cartilage	  (Fig.	  6	  B).	  The	  specificity	  of	  the	  contrast	  induced	  by	  cells	  may	  become	  even	  worse	  under	  pathological	  conditions	  (e.g.	  bleedings,	  iron	  accumulations	  in	  scars).	  Furthermore,	  the	  underlying	  T2/	  T2*	  contrast	  mechanisms	  make	  quantification	  of	  cell	  numbers	  in	  a	  region	  of	  interest	  very	  difficult.	   For	   homogeneous	   solutions	   of	   contrast	   agent,	   e.g.	   in	   water,	   iron	   oxide	  concentrations	   c 	  can,	  for	  a	  wide	  range,	  be	  assessed	  through	  the	  simple	  proportionality	  of	  relaxation	  rates	  R1 ~ c 	  and	  R2* ~ c .	  Usually,	  the	  same	  holds	  true	  for	  cell	  concentrations	  (Fig.	  6	  C).	  For	  clusters	  of	  cells,	  an	  analytical	  model	   is	  needed	  to	  quantify	  cell	  densities.	  Such	  models	  exist,	  e.g.	   for	  small	  cylindrical	  shapes	   in	  analogy	  to	  chapter	  1.2.2	  or	  small	  spherical	  “blobs”	  of	  cells.	  Again,	  calculations	  usually	  lead	  to	   R2* ~ ccells .	  However,	  even	  for	  homogeneous	   cell	   distribution	   or	   simple	   shapes,	   the	   signal	   may	   decay	   too	   fast	   to	   be	  sampled	  with	  MRI,	  especially	  for	  high	  iron	  oxide	  densities.	  Generally,	  the	  cell	  graft	  forms	  an	   arbitrary	   shape	   and	   cells	   are	   heterogeneously	   distributed	   within	   the	   graft.	   Both	  shape	   and	   distribution	   are	   not	   known	   a	   priori.	   The	   magnetic	   field	   distribution	   then	  becomes	  too	  complex	  rendering	  quantification	  of	  cell	  densities	  very	  challenging.	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1.4.3 Cell	  tracking	  with	  19F	  MRI	  Due	   to	   the	   drawbacks	   of	   iron	   oxide	   labels,	   a	   new	   class	   of	   fluorinated	   labels	   for	   cell	  tracking	   with	   MRI	   has	   emerged	   over	   the	   past	   few	   years	   since	   the	   seminal	   paper	   by	  Ahrens	  et	  al.	  in	  2005	  [70].	  The	  stable	  isotope	  19F	  is	  >99%	  abundant	  in	  nature.	  It	  has	  the	  second	   highest	   gyromagnetic	   ratio	   after	   1H (γ 19F /γ 1H =0.94),	   thus	   has	   only	   17%	   less	  equilibrium	  MR	  signal	  (i.e.	  signal	  at	  defined	  concentration	  neglecting	  relaxation	  times).	  In	  order	  to	  track	  cells	  with	  fluorine	  agents,	  cells	  are	  pre-­‐labeled,	  and	  both	  1H and	  19F	  MRI	  are	   performed	   after	   implantation.	   As	   the	   Larmor	   frequencies	   of	   1H and	   19F	   are	   well	  separated	  by	  6%,	   signal	   from	  one	  nucleus	  does	  not	   “leak”	   into	   the	   image	  of	   the	  other	  nucleus.	  The	  conventional	  1H image	  provides	  anatomical	  context	  whereas	  the	  19F	  image	  intensity	  depends	  only	  on	  in	  vivo	  concentrations	  of	  19F.	  When	  the	  19F	  image	  is	  acquired	  in	  the	  same	  position	  of	   the	  animal,	   it	  can	  be	  overlaid	  on	  the	  1H image	  and	  cells	  can	  be	  located	  in	  the	  body.	  Since	  the	  19F	  magnetization	  is	  detected	  directly	  -­‐	  in	  contrast	  to	  the	  indirect	  mechanism	  for	  detection	  of	  iron	  oxide	  labels	  discussed	  in	  the	  previous	  section	  –	  cell	   tracking	   with	   19F	   MRI	   is	   considerably	   less	   sensitive	   (Fig.	   7	   A).	   Therefore,	   most	  studies	   employed	   perfluorocarbon	   (PFC)	   based	   cellular	   labels,	   since	   these	   contain	   a	  large	  number	  of	   19F	  per	  molecule	   [71].	  One	  of	   the	  main	   advantages	  of	   19F	  MRI	   is	   that	  endogenous	  19F	  concentrations	  in	  the	  body	  are	  well	  below	  detectability	  (<<10-­‐3	  mol/L).	  This	  guarantees	  that	  only	  labeled	  cells	  contribute	  to	  the	  signal	  on	  a	  19F	  MR	  image	  with	  no	  confounding	  background	  signal	  (Fig.	  7	  B).	  It	  is	  noted,	  that	  this	  statement	  is	  not	  true	  for	   anesthetized	   animals	   since	   the	   most	   widely	   used	   and	   most	   convenient	   gas	  anesthetics	   (e.g.	   Halothane,	   Isoflurane)	   are	   fluorinated	   gases.	   These	   gases	   can	  accumulate	  in	  MR	  detectable	  concentrations	  especially	  in	  fatty	  tissue.	  This	  can	  be	  used	  to	  study	  the	  uptake	  and	  elimination	  of	  these	  gases	  in	  vivo	  [72]	  but	  it	  is	  confounding	  for	  cell	   tracking	   studies.	  Thus	   it	   is	  necessary	   to	   switch	   to	   alternative	   forms	  of	   anesthesia.	  Due	   to	   the	   direct	   detection	   of	   19F,	   the	   19F	   MR	   signal	   is	   simply	   proportional	   to	  concentration	   S19F ~ c19F .	   If	   the	   average	   19F	   loading	   per	   cell	   is	   known	   and	   a	   reference	  tube	  with	  defined	  19F	  concentration	  is	  placed	  next	  to	  the	  object	  of	   interest,	   this	  can	  be	  used	  to	  quantify	  cell	  density	  directly	  from	  the	  image	  data	  [73]	  (Fig.	  7	  C).	  
	  
Figure	   6:	   1H MRI	   of	  magnetically	   labeled	   cells.	   A:	   A	   cell	   (yellow	   sphere)	   loaded	   with	   SPIO	   particles	   can	   effectively	  
dephase	  spins	  in	   its	  vicinity	  (black	  arrows)	   inducing	  a	  hypointensity	  on	  MR	  images	  compared	  to	  spins	  in	  background	  
tissue	   (green	   arrows).	   One	   cell	   can	   affect	   many	   spins	   enabling	   very	   sensitive	   detection	   against	   homogeneous	  
background.	  B:	  Gradient	  echo	  MR	  image	  of	  a	  rat	  with	  intrastriatal	  implantation	  of	  100,000	  SPIO	  labeled	  human	  NSCs.	  
Cells	   are	   clearly	   depicted	   as	   a	   hypointensity	   (white	   arrow).	  However,	   the	   graft	   can	   easily	   be	   confounded	  with	   other	  
sources	  of	  magnetic	  inhomogeneities,	  e.g.	  blood	  vessels	   (red	  arrow).	  C:	  Quantification	  of	  cell	  numbers	  can	  be	  possible	  
for	  homogeneous	  distribution	  of	  cells,	  spherical,	  cylindrical	  and	  other	  simple	  geometric	  shapes	  for	  which	  the	  magnetic	  
field	  distribution	  can	  be	  calculated.	  However,	  a	  cell	  graft	  is	  usually	  arbitrarily	  shaped	  and	  cell	  distribution	  within	  the	  
graft	  is	  not	  known	  rendering	  quantification	  very	  challenging.	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  Most	  published	  studies	   focused	  on	   tracking	  and	  quantification	  of	  PFC	   labeled	   immune	  cells.	   In	   vivo	   19F	  MRI	   of	   dendritic	   cells	   and	   T-­‐cells	  was	   shown	   after	   focal	   injection	   or	  intravenous	   infusion	   of	   cells	   for	   therapeutic	   purpose	   in	   rodent	   models	   of	   cancer	  vaccination	   [70],	   [74–77],	   diabetes	   [78],	   or	   inflammation	   [79].	   In	   a	   proof	   of	   concept,	  Ruiz-­‐Cabello	  et	  al.	  showed	  the	  feasibility	  to	  detect	  C17.2	  murine	  NSCs	  after	  implantation	  to	   the	  healthy	  adult	  mouse	  brain	   indicating	  that	  19F	  MRI	  may	  be	  a	  valuable	   tool	   in	   the	  field	  of	  brain	  cell	  replacement	  therapy	  [80].	  	   	  
	  
Figure	  7:	  MRI	  of	  19F	  labeled	  cells.	  A:	  19F	  spins	  (red	  arrows)	  within	  a	  cell	  (red	  sphere)	  are	  directly	  detected	  in	  the	  19F	  MR	  
experiment.	  1H MR	  signal	  of	  proton	  spins	  in	  the	  vicinity	  (black	  arrows)	  is	  unchanged.	  High	  19F	  concentrations	  in	  the	  mM	  
range	  are	  needed	  to	  be	  detectable	  by	  19F	  MRI,	  thus	  cell	  detection	  is	  considerably	  less	  sensitive	  than	  using	  SPIO	  labels.	  B:	  
19F	  MR,	  anatomical	   1H MR,	  and	  merged	   images	  of	  a	  mouse	  with	   intrastriatal	  implant	  of	  300,000	  PFC	  labeled	  murine	  
neural	  stem	  cells	  (white	  arrow).	  19F	  image	  interpolated	  to	  1H resolution	  and	  pseudo-­‐colored	  for	  the	  merged	  image.	  Due	  
to	  absence	  of	  19F	  in	  the	  body,	  only	  the	  cell	  graft	  generates	  significant	  signal	  on	  the	  19F	  image.	  C:	  As	  long	  as	  the	  number	  
of	  cells	  within	  a	  voxel	  exceeds	  the	  detection	  limit,	  quantification	  is	  possible	  via	  a	  linear	  relationship	  of	  image	  intensity	  
and	   cell	   number.	   This	   holds	   for	   arbitrary	   geometric	   distribution	   of	   cells	   within	   the	   voxel,	   i.e.	   graft	   shape	   and	  
distribution	  do	  not	  need	  to	  be	  known	  a	  priori	  for	  quantification.	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1.5 Aims	  of	  this	  dissertation	  The	   aims	   of	   this	   dissertation	   were	   to	   develop	   and	   optimize	   MRI	   methods	   to	   image	  angiogenesis	  and	  implanted	  neural	  stem	  cells.	  The	  detailed	  aims	  were	  to:	  1. Implement	   and	   optimize	   SSCE	   MRI	   to	   image	   vessel	   size	   and	   density.	   This	  included	   the	  design	  of	  a	   transmit	   radiofrequency	  (RF)	  coil,	  optimization	  of	  MRI	  pulse	  sequences,	  and	  the	  development	  of	  MRI	  data	  analysis	  strategies.	  2. Design	  a	  setup	  for	  in	  vitro	  MRI	  and	  develop	  image	  data	  processing	  strategies	  for	  analysis	  of	  in	  vivo	  MRI	  of	  SPIO	  labeled	  NSCs.	  3. Develop	  a	  setup	  for	  19F	  MRI	  including	  design	  of	  dedicated	  RF	  coils,	  holders	  for	  in	  vitro	  and	  in	  vivo	  MRS	  and	  MRI.	  4. Evaluate	   cell	   detection	   limits	   of	   19F	   MRI	   of	   NSCs,	   improve	   sensitivity	   by	  optimization	  of	  MRI	  pulse	  sequences,	  and	  develop	  cell	  quantification	  strategies.	  In	   contrast	   to	   a	   purely	   methodological	   work,	   I	   wanted	   to	   prove	   the	   usefulness	   of	  developed	  hardware	  and	  methods	   in	  biological	  studies	   in	  collaboration	  with	  biologists	  and	  physicians.	  We	  therefore	  aimed	  to	  (corresponding	  papers	  as	  numbered	  in	  the	  next	  chapter):	  1. Follow	  vascular	  changes	  in	  tumors	  and	  in	  response	  to	  anti-­‐angiogenic	  treatment	  (papers	  I+II)	  2. Follow	  vascular	  changes	  after	  stroke	  (paper	  III).	  3. Monitor	  the	  fate	  of	  NSCs	  after	  implantation	  (papers	  IV-­‐VI).	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Abstract
Purpose: Inhibition of angiogenesis has shown clinical success in patients with cancer. Thus, imaging approaches that allow
for the identification of angiogenic tumors and the detection of response to anti-angiogenic treatment are of high clinical
relevance.
Experimental Design: We established an in vivo magnetic resonance imaging (MRI) approach that allows us to
simultaneously image tumor microvessel density and tumor vessel size in a NSCLC model in mice.
Results: Using microvessel density imaging we demonstrated an increase in microvessel density within 8 days after tumor
implantation, while tumor vessel size decreased indicating a switch from macro- to microvessels during tumor growth.
Moreover, we could monitor in vivo inhibition of angiogenesis induced by the angiogenesis inhibitor PTK787, resulting in a
decrease of microvessel density and a slight increase in tumor vessel size.
Conclusions: We present an in vivo imaging approach that allows us to monitor both tumor microvessel density and tumor
vessel size in the tumor. Moreover, this approach enables us to assess, early-on, treatment effects on tumor microvessel
density as well as on tumor vessel size. Thus, this imaging-based strategy of validating anti-angiogenic treatment effects has
high potential in applications to preclinical and clinical trials.
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Introduction
In the past years preclinical and clinical studies have
demonstrated the essential role of angiogenesis for initiation of
tumor growth [1,2]. Treatment strategies inhibiting angiogenic
processes mainly targeting the vascular endothelial growth factor
(VEGF) and its receptor (VEGFR) have been implicated in clinical
trials. Thus, non-invasive methods to visualize and to monitor
tumor angiogenesis, and its inhibition, respectively, are of high
clinical relevance.
Currently, dynamic contrast enhanced magnetic resonance
imaging (DCE-MRI) is in clinical use for the assessment of anti-
angiogenic treatment effects [3,4]. DCE-MRI represents an
indirect measure of angiogenesis since it mainly reflects leakage
of the vascular bed by measuring the transfer of contrast agent into
the interstitial space. Due to high VEGF levels within tumors
vascular leakage is increased in tumor microvessels. Thus, DCE
imaging is proposed to be an accurate marker to detect therapeutic
VEGF inhibition. Gadolinium-based contrast agents are mostly
used for DCE-MRI.
Dennie et al proposed the use of the ratio of gradient echo and
spin echo relaxation rate changes (DR*2/DR2) after injection of a
high molecular weight contrast agent to measure average
microvessel density within a voxel [5]. These authors found a
good correlation between the MRI derived in vivo data and
histology. Based on these findings Jensen and Chandra proposed
to map the ratio of Q=DR2/(DR*2)
2/3 and demonstrated that Q
is dependent on water diffusion but independent of the
concentration of the contrast agent [6]. Because of the
heterogeneity of diffusion within tumors and changes of diffusion
during tumor growth [7] we sought to establish a multi-echo spin
echo sequence that takes the tumor diffusion into account for the
determination of tumor microvessel density and tumor vessel size.
In this study, we present an in vivo MRI approach that allows
for simultaneous assessment of tumor microvessel density and
vessel size by the use of a superparamagnetic iron oxyde (SPIO) at
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a very high spatial resolution. We validated the accuracy of this
approach by monitoring tumor angiogenesis and detecting
response to the VEGFR/PDGFR tyrosine kinase inhibitor
vatalanib in a NSCLC xenograft model in mice.
Materials and Methods
Cell Culture
We used the NSCLC cell line H1975 [8]. Cells were maintained
in RPMI 1640 supplemented with 10% heat inactivated fetal
bovine serum (FBS, Roche Diagnostics, Mannheim, Germany),
1% penicillin and 1% streptomycin (P/S, Life Technologies) at
37uC in a 5% CO2/95% air atmosphere.
Xenograft model
All animal procedures were in accordance with the German
Laws for Animal Protection and were approved by the local
animal committee and the local authorities (LANUV, Recklin-
ghausen, reference number: 8.87-50.10.31.08.331).
Tumors were generated by s. c. injecting 56106 H1975 tumor
cells into nu/nu athymic male mice as described recently [8]
(Janvier, Europe). In the first set, we longitudinally measured
animals on days 1 (n = 4), 4 (n = 6, 2 sacrificed for immunohis-
tochemistry), 8 (n = 6, 2 sacrificed for immunohistochemistry), 14
(n = 6, 2 sacrificed for immunohistochemistry), 21 (n = 6, 2
sacrificed for immunohistochemistry) after tumor cell injections.
In the second set, animals were randomized into two groups,
vehicle treated (control) and vatalanalib (PTK787) treated. Vehicle
and PTK787 animals were studied on day 8 (start of treatment) 14,
and 21 after tumor cell implantation (vehicle n = 6, PTK787 n= 6;
2 sacrificed for immunohistochemistry on day 21). Mice were
treated daily by oral gavage of 75 mg/kg PTK787. PTK787 was
dissolved at 1% DMSO and 0.5% Tween 80 in distilled water. All
controls were dosed with the same volume of vehicle (1% DMSO
and 0.5% Tween 80).
Immunohistochemistry
After the last MRI measurements, animals were sacrificed and
s.c. tumors were extracted. Tumors were embedded in tissue
freezing medium (Jung, Nussloch, Germany) and cut in 10-mm
frozen sections. Hematoxylin Eosin staining on the tissue was
performed according to standard protocols. Microvessel density
was assessed with CD31 staining (1:50 dilution, Mat.-No. 550274,
BD PharmingenTM). CD31 positive endothelial cells or cell cluster
were counted. In order to determine the mean number of
microvessel density within the tumor, the number of CD31
positive cells was determined by 3 different areas with maximal,
moderate, and minimal endothelial density. The mean number of
microvessels was determined as (F1+F2+F3)/3.
Magnetic Resonance Imaging (MRI)
All experiments were performed on an experimental animal
scanner at 7T (Bruker BioSpec; Bruker) equipped with a gradient
set of 400 mT/m. Radio frequency (RF) irradiation and signal
detection was achieved with custom-built coils: a 8-cm-diameter
Helmholtz coil arrangement for RF excitation, and a 16 mm
diameter surface coil for signal detection.
To determine DR2 and DR2* maps multi slice multi spin echo
(MSME) and multi gradient echo (MGE) pulse sequences,
respectively, were performed before and after injection of iron
oxide nanoparticles (EndoremH, Guerbet Inc.) at a dose of 30 mg
Fe/kg. The postcontrast image acquisition was delayed by 2 min
to ensure a steady-state distribution of contrast agent in the
vascular network.
MSME and MGE MR images were obtained with the same
Field of View (FOV) (16 mm616 mm), and matrix size (64664),
and a slice thickness of 0.3 mm (Matrix size 25062506300 mm2).
MSME was acquired with TR=5000 ms and TE= (10.9,
21.8,…,109)ms. MGE was acquired with TR=1400 ms and
TE= (4, 8,…,32) ms with a 60u hermite pulse.
To map the apparent diffusion coefficient (ADC) of water, two
diffusion-weighted images with b= 300, b= 800 s/mm2, in both, x
and z directions of the gradient system were acquired, together with
a reference image (b<0 s/mm2) at the following parameters: voxel
size= 0.560.2560.3 mm3, zero-filled to 0.2560.2560.3 mm3,
matrix 64664. The total scan time was 49 min and 16 seconds.
We started the measurement with the ADC map. Then, we
acquired the MSME andMGE pre CA-injection datasets. The post
injection scan time was 16 min and 38 sec. The signal intensity after
contrast agent injection was stable within half an hour.
Data analysis
The co-registration of the images was performed using FSL
software (FLIRT, Oxford, UK). IDL was used for image
processing (Interactive data language, ITT, VIS). We used a
volume of interest (VOI) of the entire tumor to assess the global
values of the ADC, MDI and VSI. The in-house developed
software VINCI was used for volume of interest (VOI) analysis of
MR images [9].
The ADC map was calculated from the diffusion-weighted
images with a mono-exponential fit of the signal intensity of the
three different b values (b0, 300, 800 s/mm
2).
The DR*2 maps were determined with the second echo
(TE=8 ms) by
DR!2~ 2
3
dvj0~
ln (
GEpre
GEpost
)
TE
ð1Þ
[10,11] and a modified calculation for multi-spin echo
sequences with the third echo (TE= 32.7 ms)
DR2~0:694dv
2=3j0#
2=3ADC1=3R{2=3~
ln (
SEpre
SEpost
)
TE
ð2Þ
[12] (j0 =Blood Volume fraction; dv=2pcDXB0= frequency
shift, #=number of 180u pulses; R=Vessel Size Index (VSI)
DX= changes in the susceptibility, B0=magnitude of the
magnetic field, c=gyromagnetic ratio). The prefactor 0.694 had
been calculated in [12].
Based on equation (2) we calculated the microvessel density
index (MDI) from
MDI~j0=(2pR
2)~1:327#2
Q3
ADC
~1:327#2
(
DR2
(DR2 ! )2=3 )
3
ADC
ð3Þ
As such, measurement values are independent of the local
contrast agent concentration. The process is schematically
depicted in Fig. 1.
The combination of equation (1) and (2) leads to the term of the
VSI
In-Vivo Imaging Microvessel Density
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VSI~R~0:425#(
ADC
dv
)1=2(DR2=DR!2)3=2;
dv~2pDXB0 with DX~1|10
-3:
(DX~susceptibility change)
ð4Þ
[13].
Statistical analysis
Statistical tests were performed using SPSS software (release
18.0 SPSS, Inc., Chicago. IL.USA). To assess statistical signifi-
cance we used the Spearman correlation and the t-test. Statistical
significance was set at p,0.05. Values are indicated as mean and
standard deviations.
Results
Model
Equation (2) considers the number of 180u-pulses (#) within the
MSME sequence. The calculation of the VSI map and the MDI
map are based on equation (2). To our knowledge, we take for the
first time the number of 180u-pulses into account by calculating
VSI and MDI maps.
Comparison of the image derived MDI values with
histology
In order to validate our image-derived data for microvessel density
we compared theMDI values to the in vitro microvessel density. The
in vitro microvessel density index was immunohistochemically
assessed by CD31 positive microvessels at different time points
directly after the MRI measurements. Here, we found a significant
correlation between the in vivo derived MDI values and the
microvessel density index of CD31 positive cells (r= 0.8, p=0.0006;
Spearman correlation) (Fig. 2). Furthermore, tumor areas with high VSI
values showed also large vessel size in histology (Fig. 2A).
Monitoring tumor microvessel density and vessel size
We analyzed the growth of tumor microvessels as detected by
the MDI map from day 1 to day 4, 8, 14, and 21. Already one day
following s.c. inocculation of the tumor xenograft we observed
high intra- and subcutaneous MDI values around the tumor. On
day 4 we found an increasing number of tumor microvessels
within the tumor (MDI value: 198628). The maximum was
reached 8 days after tumor cell inocculation (MDI value: 297673).
The MDI values then slightly decreased at day 14 (247694) and
day 21 (230672). We did not find significant changes between day
1 and 4, day 4 and 8, day 8 and 14, day 14 and 2. Of note, at later
time points we found a rather homogeneous distribution of the
microvessels within the center as well as in the outer rim of the
tumor (Fig. 3). This was accompanied with a homogeneous, rather
low ADC value on days 14 and 21 (Fig. 3).
Using maps of the vessel size index (VSI) we estimated the vessel
diameter over time. Interestingly, we found inverse behavior of the
vessel size and vessel density changes: an increase in MDI from day 4
to day 14 was accompanied by a decrease in VSI, indicating a switch
from larger to smaller vessel sizes (VSI, day 4: 68.7640.8; day 14:
50.761.8). Tumor vessels with larger diameter were found in the
outer rim of the tumor with their diameter still increasing during the
following days (Fig. 3).
Figure 1. Schematic of data calculation for the microvessel density index (MDI) and the vessel size index (VSI).
doi:10.1371/journal.pone.0019592.g001
In-Vivo Imaging Microvessel Density
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ADC values showed a decrease within the first 8 days reflecting
a decline in extracellular diffusion, most probably due to an
increase in tumor cell density.
Response to PTK787 treatment
We determined the potential of our protocol to assess response
to anti-angiogenic treatment. Tumors were grown for 8 days and
MDI, ADC and VSI were measured. We then started PTK787
treatment and monitored response to treatment after 6 and 13
days by calculating percentage changes in MDI, VSI and ADC.
Already after 6 days of oral PTK787 treatment, we found a
significant decline in the MDI values in comparison to the vehicle
group (p = 0.021) (see Table 1 and Fig. 4). This was confirmed
after 13 days of treatment (p = 0.005). In contrast, the VSI
decreased in the control group over time whereas in the treated
tumors the VSI remained nearly stable at day 6 and even
increased till day 13. This indicates a switch from macro- to micro-
vessels in the vehicle group. On the other hand, PTK787
treatment induces the inverse effect resulting in a shift from
micro- to macrovessels.
In parallel we observed a decrease in the ADC value after 6
days of PTK787 treatment whereas there was nearly no change in
the ADC in the vehicle treated tumors. The ADC value then
increased till day 13 during PTK787 treatment (Tab. 1 and Fig. 4).
Discussion
In this study we demonstrate the feasibility to non-invasively
determine microvessel density in an experimental NSCLC model
by the use of the MRI derived MDI map. Moreover, we propose a
Figure 2. Comparison of the image derived values of MDI and VSI to CD31 positive endothelial cell staining. (A) a vehicle treated (upper
row) tumor presenting a high microvessel density index (MDI (1/mm2)) in MRI and a low vessel index (VSI (mm)). The PTK787-treated tumor (lower row)
presents low MDI values with high VSI values. (B) correlation between CD31 positive vessels per area unit and the imaged derived MDI values (n= 10).
doi:10.1371/journal.pone.0019592.g002
In-Vivo Imaging Microvessel Density
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protocol permitting simultaneous monitoring of tumor vessel size
(VSI) and tumor microvessel density (MDI). We show that the
values obtained by the MDI map reflect the microvessel density as
assessed by immunohistochemical CD31 staining. Most impor-
tantly, the MDI allows to monitor PTK787 induced reduction in
microvessel density as early as 6 days after start of treatment.
Finally, repetitive MR imaging reveals a shift of vessel diameter
toward larger lumen in PTK787 treated tumors in vivo.
Currently, there are numerous anti-angiogenic agents in clinical
trials ([14]; http://www.cancer.gov/clinicaltrials). Likewise, new
imaging modalities are required that allow to monitor tumor
microvessel density growth and the detection of anti-angiogenic
treatment effects. As reported previously, MR imaging offers the
detection of capillaries with a diameter of 10 to 30 mm, reflecting
the range of the diameter of tumor microvessels [6,10]. Jensen [15]
first proposed the Q-map for the assessment of microvessel density
in vivo. Based on this approach, Wu et al found reasonable Q-map
values within the healthy mouse brain when comparing the results
with histological analysis [16]. However, as indicated by Jensen in
2006 [15], the diffusion within the tissue affects the calculation of
microvessel density (cf. Eq. 3). This is particularly true for tumor
tissue since the diffusion within the tumor is highly variable.
Therefore, we established a new protocol for vessel density
imaging that includes the ADC map, to take the function of the
diffusion heterogeneity within the tumor into consideration for the
determination of the MDI. Herewith, we received a clear
improvement of the vessel density values, as demonstrated with
the significant correlation to the microvessel density assessed by
immunohistochemistry. Of note, the same calculation without the
ADC map showed no correlation to immunohistochemically
assessed by microvessel density (data not shown).
The theoretical description of Kiselev et al [11] has been made
for a single echo experiment. Nevertheless, multi echo experiments
were used to calculate the Q-maps or the VSI [17]. The gradients
for the 180 degree pulses induce diffusion weighting. By using
multi spin echo sequences this diffusion weighting is usually not
considered. Therefore, the calculation of delta R2 via the fitting on
multi echo sequences leads to incorrect results for the VSI and
MDI. Thus, we applied the correction factor as suggested by
Figure 3. Longitudinal investigation of vascular dynamics during tumor growth. Simultaneous in vivo monitoring of tumor depiction with
T2-weighted imaging, microvessel density (MDI), vessel size (VSI) and apparent diffusion coefficient (ADC) during tumor growth on day 1, day 4, day
8, day 14, and day 21 (D1, D4, D8, D14, D21).
doi:10.1371/journal.pone.0019592.g003
Table 1. Percent changes (relative to day 0) in T2, MDI, VSI
and ADC values after 6 days and 13 days of PTK787/vehicle
treatment.
PTK787 treated Vehicle treated
day 6 day 13 day 6 day 13
Mean SD mean SD mean SD mean SD
T2 24.79 3.85 20.93 16.85 25.69 5.08 222.55 16.85
MDI 2225.10 169.88 2199.52104.80 41.30 2.17 23.82 23.22
VSI 215.85 64.90 31.63 26.60 2194.2045.30 253.10 87.90
ADC 214.61 18.32 11.71 11.45 0.22 26.72 2.84 18.97
doi:10.1371/journal.pone.0019592.t001
In-Vivo Imaging Microvessel Density
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Kiselev [12] to take the diffusion weighting into account. As the
correction factor is considered in the formula (3) and (4) both the
second and the third echo can be used. However, by using further
180u-pulses we found an increase of the obtained MDI that did not
reflect the results from the immunohistochemistry. Thus, we
conclude that it is important to use a spin echo sequences with the
appropriate echo time to calculate the MDI and VSI.
We have presented a new strategy for the simultaneous
estimation of the vessel size index (VSI) and the microvessel density
index (MDI) by the use of a multi spin echo sequence. With this tool,
we could demonstrate in vivo that in untreated tumors the decrease
in the mean tumor vessel size is paralleled by an increase in
microvessel density. These findings are in line with a study by Drevs
et al. [18] who observed a shift of vessel diameter toward larger
lumen in PTK787 treated tumors in comparison to the vehicle
group in vitro. This observation is reasonable since it reflects the
sprouting of smaller tumor microvessels from pre-existing larger
vessels during tumor growth that is inhibited by PTK787.
After 6 days of PTK787 treatment, we found a decrease in the
ADC value. It is well known that inhibition of VEGF/VEGFR2
results in a reduction in vascular permeability [19]. We hypothesize
that the PTK787 induced decline in vessel permeability reduces
interstitial edema and, thus, intra-tumoral diffusion that is reflected
by the observed decrease in ADC map. Moreover, after 13 days of
treatment there was again a slight increase in the ADC value most
probably due to necrotic tumor transformation [20,21,22,23].
Finally, we have demonstrated that the MDI method permits
the characterization of microvessel density in vivo in longitudinal
studies. Further, the MDI detected the PTK787 treatment
induced reduction of microvessel density as early as 6 days of
treatment. This is of high clinical interest since it allows for
monitoring effects of anti-angiogenic treatments based on the
growth and sprouting of tumor microvessels. Of note, the iron
oxide nanoparticle EndoremR is a true intravascular contrast
agent with a long plasma half-life (T1/2.2.5 h) [24], already
approved for human use. Severe side effects have been reported
for the gadolinium based contrast agents [25]. Thus, Endorem
represents a highly promising contrast agent for clinical studies.
Moreover, using Gd-complexes the changes of the signal induced
by the susceptibility is weak. Since Endorem is a paramagnetic CA
the changes of the local susceptibility in the steady state is much
higher than induced by gadolinium complexes.
In summary, we present an in vivo imaging approach for
simultaneous monitoring of tumor microvessel density (MDI) and
tumor vessel size (VSI). This approach enables the early
assessment of treatment effects on microvessel density as well as
on tumor vessel size. Thus, this imaging method bears high
potential for monitoring anti-angiogenic treatment effects in
preclinical and clinical trials.
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doi:10.1371/journal.pone.0019592.g004
In-Vivo Imaging Microvessel Density
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19592
	  	   31	  
Author Contributions
Conceived and designed the experiments: RTU MH JFJ PB-S SV.
Performed the experiments: RTU JFJ PB-S MU MD. Analyzed the data:
RTU JFJ PB-S. Contributed reagents/materials/analysis tools: RTU MH
MU SV. Wrote the paper: RTU JFJ PB-S MH.
References
1. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nat Med 1: 27–31.
2. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:
932–936.
3. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, et al. (2009) Phase I and
biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in
patients with refractory solid malignancies. J Clin Oncol 27: 4718–4726.
4. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, et al. (2007) Phase I
clinical study of AZD2171, an oral vascular endothelial growth factor signaling
inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045–3054.
5. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, et al. (1998)
NMR imaging of changes in vascular morphology due to tumor angiogenesis.
Magn Reson Med 40: 793–799.
6. Jensen JH, Chandra R (2000) MR imaging of microvasculature. Magn Reson
Med 44: 224–230.
7. Eis M, Els T, Hoehn-Berlage M (1995) High resolution quantitative relaxation
and diffusion MRI of three different experimental brain tumors in rat. Magn
Reson Med 34: 835–844.
8. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, et al. (2008) Early
detection of erlotinib treatment response in NSCLC by 39-deoxy-39-[F]-fluoro-
L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3:
e3908.
9. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, et al. (2004) Fast and robust
registration of PET and MR images of human brain. Neuroimage 22: 434–442.
10. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, et al. (2001) Vessel size
imaging. Magn Reson Med 45: 397–408.
11. Kiselev VG, Posse S (1999) Analytical model of susceptibility-induced MR signal
dephasing: effect of diffusion in a microvascular network. Magn Reson Med 41:
499–509.
12. Kiselev VG (2010) Spin Echo Amplitude in Biological Tissue with Implications
for Vessel Size Imaging. Joint Annual Meeting ISMRM-ESMRMB, Stockholm
(01-07052010) 1: 1792 (Proc.).
13. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, et al. (2009) Assessment of
vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel
size imaging. J Magn Reson Imaging 29: 1125–1133.
14. Ivy SP, Wick JY, Kaufman BM (2009) An overview of small-molecule inhibitors
of VEGFR signaling. Nat Rev Clin Oncol 6: 569–579.
15. Jensen JH, Lu H, Inglese M (2006) Microvessel density estimation in the human
brain by means of dynamic contrast-enhanced echo-planar imaging. Magn
Reson Med 56: 1145–1150.
16. Wu EX, Tang H, Jensen JH (2004) High-resolution MR imaging of mouse brain
microvasculature using the relaxation rate shift index Q. NMR Biomed 17:
507–512.
17. Lin CY, Chang C, Cheung WM, Lin MH, Chen JJ, et al. (2008) Dynamic
changes in vascular permeability, cerebral blood volume, vascular density, and
size after transient focal cerebral ischemia in rats: evaluation with contrast-
enhanced magnetic resonance imaging. J Cereb Blood Flow Metab 28:
1491–1501.
18. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, et al. (2002) PTK787/
ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine
kinase inhibitor, affects the anatomy of the tumor vascular bed and the
functional vascular properties as detected by dynamic enhanced magnetic
resonance imaging. Cancer Res 62: 4015–4022.
19. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 307: 58–62.
20. Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, et al. (2008) Monitoring
response to chemotherapy of non-Hodgkin’s lymphoma xenografts by T(2)-
weighted and diffusion-weighted MRI. NMR Biomed 21: 1021–1029.
21. Valonen PK, Lehtimaki KK, Vaisanen TH, Kettunen MI, Grohn OH, et al.
(2004) Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene
therapy-induced programmed cell death in vivo: correlation with cell density.
J Magn Reson Imaging 19: 389–396.
22. Chenevert TL, McKeever PE, Ross BD (1997) Monitoring early response of
experimental brain tumors to therapy using diffusion magnetic resonance
imaging. Clin Cancer Res 3: 1457–1466.
23. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, et al. (2005)
Evaluation of the functional diffusion map as an early biomarker of time-to-
progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A
102: 16759–16764.
24. Schwarz AJ, Reese T, Gozzi A, Bifone A (2003) Functional MRI using
intravascular contrast agents: detrending of the relative cerebrovascular (rCBV)
time course. Magn Reson Imaging 21: 1191–1200.
25. Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, et al. (2008)
Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast
agents at four American universities. Radiology 248: 799–806.
In-Vivo Imaging Microvessel Density
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19592

	  	   33	  
	   	  
Non-­‐invasive	  imaging	  of	  glioma	  vessel	  size	  and	  densities	  in	  correlation	  with	  tumour	  cell	  proliferation	  by	  small	  animal	  PET	  and	  MRI	   II	  

	  	   35	  
ORIGINAL ARTICLE
Non-invasive imaging of glioma vessel size and densities
in correlation with tumour cell proliferation by small animal
PET and MRI
Thomas Viel & Philipp Boehm-Sturm & Sara Rapic &
Parisa Monfared & Bernd Neumaier & Mathias Hoehn &
Andreas H. Jacobs
Received: 8 March 2013 /Accepted: 9 May 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract
Purpose Angiogenesis is a key event in the progression of
glioblastomas (GBM). Our goal was to measure different
anatomical and physiological parameters of GBM vessels
using steady-state contrast-enhanced magnetic resonance
imaging (SSCE-MRI), together with the assessment of bio-
chemical parameters on GBM proliferation and angiogene-
sis using [11C]methyl-L-methionine (MET) and 3′-deoxy-
3′-[18F]fluorothymidine (FLT) and positron emission to-
mography (PET). We focused on how these anatomical
and biochemical read-outs correlate with one another and
with immunohistochemistry.
Methods SSCE-MRI together with 11C-MET and 18F-FLT
PET were performed 3 weeks after intracranial implantation
of human GBM spheroids in nude rats (n=8). Total cerebral
blood volume (tCBV), blood volume present in
microvessels (μCBV), vessel density and size were calcu-
lated. Rats were treated with bevacizumab (n=4) or vehicle
(n=4) for 3 weeks. Imaging was repeated at week 6, and
thereafter immunohistochemistry was performed.
Results Three weeks after implantation, MRI showed an
increase of vessel density and μCBV in the tumour com-
pared to the contralateral brain. At week 6, non-treated rats
showed a pronounced increase of 11C-MET and 18F-FLT
tumour uptake. Between weeks 3 and 6, tCBV and vessel
size increased, whereas vessel density and μCBV decreased.
In rats treated with bevacizumab μCBV values were signif-
icantly smaller at week 6 than in non-treated rats, whereas
the mean vessel size was higher. Accumulation of both
radiotracers was lower for the treated versus the non-
treated group. Most importantly, non-invasive measurement
of tumour vessel characteristics and tumour proliferation
correlated to immunohistochemistry findings.
Conclusion Our study demonstrates that SSCE-MRI en-
ables non-invasive assessment of the anatomy and phys-
iology of the vasculature of experimental gliomas.
Combined SSCE-MRI and 11C-MET/18F-FLT PET for
monitoring biochemical markers of angiogenesis and
proliferation in addition to vessel anatomy could be
useful to improve our understanding of therapy response
of gliomas.
Keywords Glioblastoma . Angiogenesis . Proliferation .
MRI . PET
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Introduction
Treatment of patients with glioblastoma (GBM) remains
challenging, and mean survival of these patients is currently
limited to 1–3 years [1]. Due to the essential role of angio-
genesis during tumour development, treatments targeting
vascular development are being evaluated in preclinical
and clinical studies [2, 3]. However, despite promising re-
sults in animal models [4], anti-angiogenic treatments in
patients with gliomas may result in tumour resistance and
the development of an infiltrative tumour phenotype [5].
Therefore, non-invasive molecular imaging methods
allowing a longitudinal assessment of the tumour vascula-
ture together with tumour proliferation and progression are
essential to fully understand the dynamic changes of glio-
mas during therapy [6, 7].
Dynamic contrast-enhanced MRI (DCE-MRI) is in clin-
ical use for the assessment of brain tumour vasculature [8].
DCE-MRI measures changes in T1, T2 or T2* relaxivity
due to leakage of a contrast agent into the extravascular
space [9]. Adapted MR sequences allow the calculation of
parameters such as blood or plasma volume, fraction of the
extravascular/extracellular space, blood-to-tissue transfer
constant or blood flow [10]. Another approach was intro-
duced by Dennie et al. based on the ratio of gradient and
spin echo relaxation rate changes (ΔR*2/ΔR2) after injec-
tion of an iron oxide-based superparamagnetic contrast
agent of high molecular weight [11]. Since ΔR2*/ΔR2 in-
creases with increasing vessel size, this method enables
calculation of the average vessel size within a voxel, which
reveals an additional important parameter of the angiogenic
process. Based on these findings, Jensen and Chandra pro-
posed to map the ratio of Q = ΔR2/(ΔR*2)
2/3. Indeed, for a
certain threshold of the concentration of the contrast agent,
in combination with appropriate echo times, Q has the
advantage of being independent of the concentration of the
contrast agent [12]. Q depends only on intrinsic tissue
properties such as water diffusivity and has been shown to
correlate with vessel density [13, 14]. Recently, Ullrich et al.
improved the imaging protocols for vessel density and size
calculation by including diffusion-weighted MR sequences
to take into account that diffusion is not homogeneous
inside tumour tissue [15].
In the current study, we evaluated the use of steady-state
contrast-enhanced MRI (SSCE-MRI) sequences developed
by Ullrich et al. [15] in an intracranial rat model of human
GBM. We combined SSCE-MRI with [11C]methyl-L-methi-
onine (MET) and 3′-deoxy-3′-[18F]fluorothymidine (FLT)
small animal positron emission tomography (PET). The
overall purpose of the study was to assess how the physio-
logical read-outs obtained by MRI correlate with the bio-
chemical read-outs obtained by PET at various biological
tumour stages and in response to an anti-angiogenic
treatment. It should be pointed out that the focus of this
work was the evaluation of the imaging methodologies with
validation of the imaging findings by immunohistochemical
methods. The results concerning the use of these imaging
techniques for monitoring response to bevacizumab should
be regarded as preliminary.
Materials and methods
Tissue culture
Tissue samples from a human glioblastoma were minced into
∼0.5 mm fragments and placed into 80 cm2 tissue culture
flasks (Nunc) base-coated with 0.75 % agar (Difco). The
spheroids were maintained in a standard tissue culture incu-
bator with 5 % CO2 and 100 % relative humidity at 37 °C.
Spheroids with diameters between 400 and 600 μm were
selected for intracerebral implantation.
Animal experiments
All animal procedures were in accordance with the German
Laws for Animal Protection and were approved by the local
animal care committees. Nude rats were housed at constant
temperature (23 °C) and relative humidity (40 %), under a
regular light/dark schedule. Food and water were freely
available.
Intracranial implantation of glioblastoma spheroids into
the cortex of nude rats (n=8) was performed as described
previously [16]. Three weeks after spheroid implantation,
sequential small animal PET and MRI were performed.
Thereafter, rats were divided into two groups. Rats in the
first group received weekly intravenous (i.v.) injections of
10 mg/kg bevacizumab (Roche, Mannheim, Germany),
whereas rats in the second group were injected with saline
(100–150 μl). After 3 weeks of treatment, sequential small
animal PET/MRI were performed again on each rat, except
for one non-treated rat, which died before the final 11C-MET
PET. After the last imaging session, rats were deeply
anaesthetized and perfused transcardially with saline for
5 min, followed by 4 % paraformaldehyde (PFA) for
2 min. Brains were post-fixed in PFA overnight.
Small animal PET
Rats were anaesthetized with isoflurane (induction 3.0 %,
maintenance 1.0–2.0 %; DeltaSelect) vaporized in a mix of
O2 and N2O (1:2). Body temperature was measured using a
rectal probe and maintained at 37 °C using a feedback con-
trolled system (medres, Cologne, Germany). Rats were im-
aged using a R4 microPET scanner (Concorde Microsystems,
Inc., Knoxville, TN, USA).
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Radiochemical synthesis of 11C-MET and 18F-FLT was
performed as described previously [17, 18]. No-carrier-
added 11C-MET was injected i.v. at a dose of 30 MBq/rat.
Small animal PET images were acquired over 30 min,
starting 20 min after tracer injection. No-carrier-added 18F-
FLTwas administered i.v. at a dose of 15 MBq/rat, and small
animal PET images were acquired over 30 min, starting
60 min after tracer injection. Every scan was followed by
a 10-min transmission scan using a 57Co source to correct
for attenuation.
PET data were reconstructed using two-dimensional fil-
tered backprojection with a ramp filter and corrected for
photon attenuation.
Small animal MRI
Rats were anaesthetized with isoflurane. A tail vein catheter
was put in place for i.v. injections during MRI acquisition.
Body temperature was measured using a rectal probe and
maintained at 37 °C using a feedback controlled system
(medres, Cologne, Germany). MRI was conducted on a
7.0 T BioSpec animal scanner (Bruker BioSpin, Ettlingen,
Germany) with 20-cm wide actively shielded gradient coils
(200 mT/m). Radiofrequency transmission was achieved
with home-built Helmholtz coils (12 cm diameter); signal
was detected using a 2.2-cm surface coil.
The following protocol was applied: a gradient echo pilot
scan was performed for accurate positioning of the animal.
Afterwards, a spin echo diffusion map, a T2 map and a T2*
map were acquired. Thereafter, the rat was injected i.v. with
superparamagnetic iron oxide (SPIO) nanoparticles (30 mg/kg
Fe, Endorem, Guerbet, Paris, France). After 2 min delay to
ensure a steady-state distribution of contrast agent in the
vascular network, a second T2 map was acquired, followed
by a second T2* map.
Spin echo diffusion maps were acquired with the follow-
ing acquisition parameters: field of view (FOV) = 2.56×
2.56 cm2, image matrix = 128×64, reconstructed to 128×
128 (isotropic in-plane resolution of 200 μm), 8 consecutive
slices of 1 mm, echo time (TE) = 40.7 ms, repetition time
(TR) = 4,000 ms, excitation/refocusing flip angle (FA) =
90°/180°, 1 diffusion direction medial-lateral in the animal
coordinate system, effective b values = 0.26, 600.26 and
1,500.26 s/mm2 and total acquisition time (TA) = 12:48 min.
T2-weighted (T2w) images/T2 maps were acquired using
a multislice multiple spin echo sequence: FOV = 2.56×
2.56 cm2, image matrix = 128×128 (isotropic in-plane res-
olution of 200 μm), 12 consecutive slices of 1 mm (geom-
etry of central 8 slices identical to diffusion map), echo time
spacing (ΔTE) = 13.6 ms, 10 equidistant echo images, TR =
4,000 ms, FA = 90°/180° and TA = 8:32 min.
T2*-weighted (T2*w) images/T2* maps were acquired
using a multiple gradient echo sequence: geometry identical
to T2 maps,ΔTE = 5.0 ms, 8 equidistant echo images, TR =
2,000 ms, FA = 60°, 2 averages and TA = 8:32 min.
MRI data processing
MRI data sets of each imaging session were coregistered with
a rigid body linear transformation to the first echo image of the
multiple spin echo scan pre-SPIO injection using FMRIB
Software Library (http://www.fmrib.ox.ac.uk/fsl/).
MR images were further processed with custom scripts
written in Interactive Data Language (IDL, ITT Visual
Information Solutions, Boulder, CO, USA). T2 and T2*
maps were fitted voxel-wise with a monoexponential decay
curve S(TE) = A*exp(−TE/B) + C, with equilibrium signal
A, relaxation time B = T2 (T2*), signal in each echo image
S(TE) and a constant offset C to reduce bias in areas with
low signal to noise ratio (SNR) [19]. Apparent diffusion
coefficient (ADC) maps were calculated by fitting a
monoexponential decay curve S(b) = A*exp(−b*ADC) +
C to the signal intensities S(b) for different b values (A is the
equilibrium signal and C an offset constant).
ΔR2 [relative blood volume present in microvessels
(μCBV)], ΔR2
* [relative total cerebral blood volume
(tCBV)], microvascular density index (MDI) and vessel size
index (VSI) were calculated as described before [15, 20]. As
we did not measure the iron concentration in the blood, we
used a dimensionless VSI, defined as VSI =
(ADC/Dlit)
1/2*(ΔR2
*/ΔR2)
3/2. The first term denotes the local
variation of ADC from an average diffusivity value in the
healthy rat brain (Dlit = 664 μm
2/s) reported previously in the
literature [21].
To ensure sufficient quality of the underlying data, voxels
with an SNR < 5 in the b = 0.26 s/mm2 image (diffusion
sequence) or first echo image (all T2 and T2* map se-
quences) were excluded from the analysis. Furthermore,
thresholding was applied to voxels with non-physical values
ΔR2 < 0, ΔR2
* < 0 or ΔR2
* < ΔR2. At week 3, 6±7 % of
the voxels within tumours had to be excluded in the tCBV,
μCBV, vessel size and vessel density maps. At week 6, the
percentage of excluded voxels was 9±10 % for the non-
treated rats and 21±20 % for the treated rats where more
necrosis and dilated vessels were observed.
PET and MRI data analysis
Coregistration of the different PET and MR images was
performed using the VINCI software (Vinci v 2.55; http://
www.nf.mpg.de/vinci3/) [22]. T2w images were used to de-
lineate the tumours and to draw the volumes of interest (VOI).
Reference regions were mirror regions of the tumours drawn
in the contralateral brain hemisphere in order to determine
tumour to background (T/B) ratios. PET images were
analysed using VINCI in order to determine the maximal
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and mean per cent of injected dose per cm3 (%ID/cm3) in the
tumours and in the reference regions. Quantification of the
mean tumour and contralateral brain hemisphere values on T2,
ADC, μCBV, tCBV, vessel size and vessel density maps was
performed using ImageJ (ImageJ 1.46o; Rasband WS,
ImageJ, NIH, http://rsb.info.nih.gov/ij).
Immunostaining of paraffin sections
Rat brains fixed in 4 % PFAwere embedded in paraffin, cut in
5-μm sections and prepared for immunohistochemical analy-
ses (three of four non-treated and three of four treated rats).
After rehydrating and heat-induced epitope retrieval for
30 min in citrate buffer (pH 6.0), sections were incubated in
peroxidase blocking solution (S3022, DAKO, Hamburg,
Germany) for 5 min and treated with serum-blocking solution
for 15 min. Sections were incubated overnight at 4 °C with
monoclonal rabbit anti-Ki-67 antibody (dilution 1:100; SP6,
ab16667, Abcam, Munich, Germany) or with polyclonal rab-
bit anti-von Willebrand factor (vWF, dilution 1:250; ab6994,
Abcam, Munich, Germany). Labelling of the primary anti-
body was performed using a commercial avidin-biotin com-
plex detection kit based on a biotinylated anti-rabbit antibody
(Vector Laboratories, Lörrach, Germany) according to the
manufacturer’s manual followed by treatment with 3,3′-
diaminobenzidine (DAB, D-5637, Sigma) for 5 min.
Sections were counterstained with haematoxylin, dehydrated
and mounted using Entellan (Merck, Darmstadt, Germany).
Iron staining was performed using the Prussian blue-based
Accustain Iron Stain kit from Sigma-Aldrich (HT20, Sigma-
Aldrich, Steinheim, Germany) following the manufacturer’s
recommendations. For TUNEL staining, sections fixed in
acetone were permeabilized in sodium citrate solution (0.1 g
in 100 ml). Sample sections were incubated 60 min at 37 °C
with 25 μl TUNEL reaction mixture according to the manu-
facturer’s manual (In situ TUNEL kit assay, Roche Inc.).
Sections were finally covered with 4′-6-diamidino-2-
phenylindole (DAPI) containing mounting medium (Vector).
Histological analysis was performed using a Nikon Eclipse
90i light microscope (Nikon, Düsseldorf, Germany) and the
NIS-Elements software package (Nikon).
Quantification of Ki-67 and vWF stainings (three dif-
ferent areas per tumour and four per contralateral brain)
was performed employing the Fiji software [23]. In brief,
colour images were deconvolved (H-DAB colour
deconvolution) and the resulting monochrome images were
thresholded. Thereafter, the positive counts per FOV were
quantified using the “Analyse particles” plugin. The total
area with positive vWF staining inside the FOV was
divided by the number of vWF-positive particles per
FOV to calculate the average area per vessel in per cent
of FOV.
Statistical analysis
Mean values ± standard deviation of MRI parameters as well as
radiotracer %ID/cm3 and T/B ratios were calculated. Student’s t
test, or Mann–Whitney rank sum test (when the variance tests
failed), as well as Pearson’s correlation test were performed
using SigmaStat 3.0 (SPSS, Inc., Chicago, IL, USA).
Results
Tumour growth-dependent alterations of small animal PET
and MRI parameters
11C-MET and 18F-FLT PET in addition to SSCE-MRI were
performed in nude rats 3 and 6 weeks after implantation of
human GBM spheroids (Fig. 1). At week 3, small tumours
were detected on T2w images. Maps of μCBV and vessel
density revealed higher values in the area of the tumour
compared to healthy brain. Tumour vessel size at this stage
was similar in tumour and healthy brain areas. At this stage,
only a slight increase of 11C-MET and 18F-FLT uptake was
observed in some tumours. At week 6, tumours were char-
acterized by high values of tCBV, μCBV, 11C-MET uptake
and 18F-FLT uptake compared to the contralateral brain
hemisphere (Fig. 1b). In contrast, vessel density was smaller
in the tumour than in healthy tissue. Images were quantified
(Fig. 2, Table 1). At week 3, tCBV and μCBV T/B ratios
were 1.25±0.08 and 1.17±0.02, respectively, with no sig-
nificant (NS) difference between tumour and contralateral
brain hemisphere. Between weeks 3 and 6, μCBV T/B ratios
within the glioma were decreased from 7.2 % (p<0.05),
while tCBV T/B ratios were increased from 40.9 %
(p<0.01). At week 3, the VSI was 8.0±0.3 for the healthy
cortex and 8.7±0.3 for the glioma tissue (Table 1; difference
NS). The average microvessel density (MDI) was
655±99 mm−2 for the healthy cortex and 811±73 mm−2
for the glioma, giving a T/B ratio of 1.25±0.13 (Table 1;
difference NS). The mean tumour VSI was 90.8 % higher at
week 3 than at week 6, with values reaching 16.6±2.1 for
the tumour tissue (T/B ratio of 2.13±0.33, p<0.01). On the
other hand, tumour MDI was significantly decreased from
61.3 % between weeks 3 and 6. At week 6, tumour MDI was
58.9 % lower than the vascularized contralateral healthy
brain (314±62 mm−2 for the tumour versus 770±
167 mm−2 for the contralateral brain, p<0.01). This obser-
vation may be explained by high tumour cell proliferation
leading to increased cell density with increased spacing
between vessels (as demonstrated by Sakariassen et al.
[24]) and by the presence of necrotic regions. At week 3,
11C-MET maximum tumour uptake in the tumour was
0.37±0.08 %ID/cm3 giving a T/B ratio of 1.16±0.08. At
this stage, 18F-FLT maximum tumour accumulation in the
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Fig. 1 Multimodal small
animal PET and MRI. SSCE-
MRI, 11C-MET and 18F-FLT
PETwere performed 3 (a) and 6
(b) weeks after implantation of
human glioma spheroids into
the brain of nude rats. MR
parametric maps were
calculated and coregistered with
the T2w and PET images.
Transaxial sections of the
different coregistered images of
the brain of a representative rat
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Fig. 2 Quantification of small
animal PET and MR imaging
results. MR maps and PET
images were used to determine
T/B ratios of PET tracer uptake
and MR-derived parameters 3
(striped bars) and 6 weeks
(white bars) after spheroid
implantation in nude rats (n=4).
* and **: significant difference
between weeks 3 and 6 (p<0.05
and 0.01, respectively)
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tumour was very low (0.12±0.08 %ID/cm3, T/B ratio of
1.14±0.27). Tumour development between weeks 3 and 6
led to a significant (p<0.01) increase of 11C-MET and 18F-
FLT maximum tumour uptake with T/B ratio reaching 2.47±
0.10 and 5.96±0.87 for 11C-MET and 18F-FLT, respectively.
The quantitative PET tracer uptake values indicated in
Figs. 2, 4 and 6 and Table 1 are the maximum tumour
uptake values. We chose to present the maximum up-
take values for the following reasons: due to the lack of
anatomical information on the PET images, the partial
volume effect and the eventual presence of necrotic
area, the mean tumour uptake is less robust and more
observer dependent than the maximum uptake value. In
addition, tumour progression can be driven by the pro-
liferative rim of a tumour presenting therefore a high
FLT maximum tumour uptake, even if the FLT mean
tumour uptake is low due to the presence of central
necrosis for example. However, the same conclusions
can be drawn from the analyses of the mean tumour
uptake values as from the analyses of the maximum
tumour uptake values (Online Resources 1 and 2).
Treatment-dependent alterations of small animal PET
and MRI parameters
Small animal MR and PET images were acquired for rats
receiving bevacizumab between weeks 3 and 6 (Figs. 3 and
4). In some MR parametric maps (e.g. columns 3, 5 and 6),
black voxels are observed in the centre of the tumour. Those
voxels were excluded during post-processing due to non-
physical values (SNR<5, ΔR2<0, ΔR2*<0 or ΔR2*
<ΔR2). As confirmed by haematoxylin and eosin (H&E)
and TUNEL staining (Fig. 5), they correspond to necrotic
regions, where the assumptions of SSCE-MRI are no longer
valid. ThemeanμCBVT/B ratio (Fig. 4a) was 25.0% smaller
in treated rats compared to non-treated rats (0.81±0.16 versus
1.08±0.03, p<0.05). In contrast, the mean tCBV T/B ratio for
the treated group was similar to the value obtained from the
non-treated rats (T/B ratio of 1.63±0.29 and 1.75±0.08,
respectively, NS). The mean VSI T/B ratio was 60.6 % higher
for the treated compared to the non-treated rats (T/B ratio of
3.42±0.68 for the treated rats versus 2.13±0.33 for the non-
treated, p<0.05). In contrast, the mean tumour vessel density
(MDI) T/B ratio was 39.0 % smaller for the treated versus the
non-treated animals (T/B ratio of 0.25±0.07 for the treated
group versus 0.41±0.06 for the non-treated, p<0.05). 11C-
MET T/B ratio uptake at week 6 was 31.2 % lower in treated
rats compared to non-treated (1.70±0.18 versus 2.47±0.10;,p
<0.01). 18F-FLT T/B ratio uptake was 22.6 % smaller in
treated rats compared to non-treated (4.61±0.36 versus 5.96
±0.87, p<0.05).
11C-MET and 18F-FLT PET T/B ratios were plotted over
MRI measures of T/B ratios of vessel density and size
obtained at week 6 (Fig. 4b). A significant positive linear
correlation was observed between T/B ratios of 11C-MET
uptake and T/B ratios of vessel density and vessel size (11C-
MET and vessel density: r=0.93, p=0.002; 11C-MET and
vessel size: r=−0.89, p=0.008, Pearson’s correlation). T/B
ratios of 18F-FLT uptake and T/B ratios of vessel density and
vessel size were also correlated, which did not reach a
significant level.
Immunohistochemical analyses confirmed the results
of non-invasive imaging
After the last imaging scan, rats were sacrificed for detailed
immunohistochemical analyses. H&E (Fig. 5a) and TUNEL
(Online Resource 3) staining revealed the presence of ne-
crotic areas in the tumours, in particular for the treated
group. Those regions presenting no viable tissue and blood
vessels correspond to the regions where some voxels in the
MR parametric maps had to be excluded due to small SNR
or to non-physical values (ΔR2 < 0, ΔR2* < 0 or ΔR2* <
ΔR2). Only very few iron particles could be observed on
Prussian blue stainings (Online Resource 3) indicating that
leakage of contrast agent was rather limited. Ki-67 staining
(Fig. 5b) revealed active tumour cell proliferation for both
groups of rats. However, proliferation as assessed by
Table 1 Quantification of PET
and MR images (mean ± stan-
dard deviation)
* and **: significant difference
between weeks 3 and 6 (p < 0.05
and 0.01, respectively); # and
##: significant difference be-
tween tumour and contralateral
brain (p < 0.05 and 0.01,
respectively)
Week 3 Week 6
Non-treated Treated Non-treated Treated
Vessel size index Tumour 8.7 ±0.3 8.7 ±0.5 16.6 ±2.1**## 28.5 ±10.7*##
Brain 8.0 ±0.3 8.0 ±1.2 7.9 ±1.1 8.2 ±1.4
Vessel density (mm−2) Tumour 810.8 ±72.6 809.8 ±204.6 314.0 ±62.4**## 206.7 ±55.1**##
Brain 655.1 ±99.4 689.4 ±166.8 770.3 ±166.9 820.2 ±102.3
11C-MET (%ID/cm3) Tumour 0.37 ±0.08 0.40 ±0.11 1.06 ±0.40* 0.68 ±0.09**##
Brain 0.32 ±0.07 0.34 ±0.08 0.43 ±0.18 0.41 ±0.09
18F-FLT (%ID/cm3) Tumour 0.12 ±0.08 0.16 ±0.03 0.75 ±0.44*# 0.44 ±0.01**##
Brain 0.10 ±0.05 0.13 ±0.03 0.13 ±0.08 0.10 ±0.01
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quantification of Ki-67 staining (Fig. 6a) was 37.5 % higher
for the non-treated group than for the treated group (Ki-67
index of 0.53±0.09 versus 0.39±0.08, respectively, p<
0.01). Ki-67 indexes were in good agreement with the 18F-
FLT T/B uptake values (Fig. 6c). vWF staining (Fig. 5c)
revealed the presence of small and large vessels in the non-
treated tumours and confirmed that the vessel density was
lower in the tumour compared to the contralateral brain
0.50
0.02
%
ID
/c
m
3
Non-treated Treated
R
2*
(tC
BV
)
V 
de
ns
ity
Ve
ss
el
 s
iz
e
11
C-
M
ET
18
F-
FL
T
T2
w
R
2
(µC
BV
)
0.90
0.20
%
ID
/c
m
3
1200
0
m
m
-
2
40
0
VS
I
250
0
s-
1
70
0
s-
1
∆
∆
Fig. 3 Impact on vascular targeted therapy on imaging parameters. In
addition to non-treated rats (columns 1–3), SSCE-MRI, 11C-MET and
18F-FLT PET were also performed in rats treated with bevacizumab
between weeks 3 and 6 (columns 4–6). Transaxial sections of the
different coregistered images of the brain of six of eight rats are
presented
Eur J Nucl Med Mol Imaging
	  	  42	  
hemisphere, most likely due to high tumour cell density
(vWF-positive particle per FOV of 150±28 for the brain
versus 108±10 for the tumour, p<0.01). The vessel density
was 38.2 % smaller in tumour growing in treated rats than in
tumour growing in non-treated animals (vWF-positive par-
ticle per FOV of 67±30 for the treated rats versus 108±10
for the non-treated tumours, p=0.012). On the contrary, the
mean size of tumour vessels was 106.1 % higher in treated
than in non-treated rats most likely due to inhibition of small
vessel formation (average area per vessel in % FOVof 0.06
±0.02 for the treated rats versus 0.03±0.01 for the non-
treated tumours, p<0.01), confirming the MRI-derived mea-
sures (Fig. 6d).
Discussion
To our knowledge this is the first study presenting a com-
bination of SSCE-MRI with 11C-MET and 18F-FLT PET in a
rat model of human glioma. The presented imaging protocol
enabled us to non-invasively quantify various important
anatomical, physiological and biochemical features related
to proliferation and neovascularization in gliomas (prolifer-
ation, amino acid uptake, cerebral blood volume,
microvessel density, vessel size). PET- and MRI-derived
parameters were related to each other and were in good
agreement with immunohistochemical findings. Although
our relatively preliminary findings warrant further confir-
mation, they clearly demonstrate the potential of these im-
aging techniques as imaging biomarkers for monitoring the
therapy of patients with gliomas.
Different methods have been developed to non-invasively
image GBM vasculature. In particular, MRI allows the calcu-
lation of physiological parameters such as blood volume,
blood-to-tissue transfer constant, blood–brain barrier integrity
or blood flow [25]. PET imaging, on the other hand, allows the
measurement of biochemical parameters such as for example
the concentration of αvβ3 integrin, a surrogate marker of
angiogenic activity, through the use of the tracer 18F-galacto-
arginine-glycine-aspartic acid (RGD) [26]. As angiogenesis is
a complex mechanism involving formation of abnormally
dilated vessels and proliferation of microvessels [27],
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implementation of methods to measure the size and the den-
sity of tumour vessels can offer additional important informa-
tion. Using SSCE-MRI, we found values of brain vessel
density in reasonable agreement with the histological values
given by Klein et al. (456–497 capillary sections/mm2 for
different cortex regions) [28]. The higher values obtained in
our study may be explained by species differences (Sprague–
Dawley versus nude rat) and the methodology employed for
the histological determination of MDI [29]. In our glioma
model, T/B ratios of tCBV and μCBV were similar at week
3 (1.25±0.08 and 1.17±0.02, respectively), indicating the
appearance and proliferation of microvessels. Upon glioma
development, tumour VSI was increased by a factor of 1.9,
indicating progression of angiogenesis by formation of large
blood vessels. The 2.1-fold higher VSI in tumour compared to
normal brain observed at week 6 is in good correlation with
the study of Pannetier et al. using dynamic susceptibility
contrast (DSC-) and SSCE-MRI [healthy brain: VSI(SSCE)
= 7.5 μm, VSI(DSC) = 6.5 μm; GBM: VSI(SSCE) =
19.4 μm, VSI(DSC) = 16.6 μm] [14]. On the other hand, the
vessel density significantly decreased from 61.3 % over time
in the densely packed gliomas. This result confirms the ob-
servation of von Baumgarten et al. [30]. Using intravital
microscopy, the authors observed an augmentation of the
vessel diameter and vascular volume upon glioma develop-
ment together with a reduction of the number of vessel
branches. Although a good agreement was observed between
imaging-derived parameters and immunohistochemistry, the
validation of the presented methods warrants further extended
studies. In particular, the approximations underlying the
SSCE-MRI theoretical model (e.g. vascular network idealized
as a random distribution of infinite length cylinders, low blood
volume fraction and contrast agent assumed to be truly intra-
vascular) need to be further addressed [13, 31].
The mean tumour vessel density obtained from the rats
receiving bevacizumab was 34.2 % smaller than the values
measured in non-treated rats (p<0.05), whereas the mean
tumour vessel size was 71.7 % higher (NS). These results
indicate that bevacizumab treatment may prevent the forma-
tion of new small vessels in the presented model. Reduction
of microvessels in tumours treated with anti-angiogenic
molecules was also observed in previous studies employing
immunohistochemistry and electron microscopy [32], two-
photon intravital microscopy [30] and SSCE-MRI [15]. It
should be recalled, however, that our aim was the detailed
evaluation of the imaging methodologies. Results
concerning imaging of the response of gliomas to
bevacizumab, although in good agreement with previously
published work [15, 30, 32], should be regarded as prelim-
inary due to the small sample size of animals. The use of
rodents to study GBM angiogenesis suffers from the intrin-
sic limitation coming from the difference between rodent
and human vasculature. Combination of bevacizumab,
mainly targeting the vascular endothelial growth factor
(VEGF) produced by the human tumour cells, with an
antibody targeting the rat VEGF may improve the experi-
mental treatment design and be closer to the clinical situa-
tion. The methodologies presented in this manuscript, in
combination with other methods of vascular imaging, have
a determinant role in characterizing the rodent vascular
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Fig. 5 Immunohistochemistry
of tumour tissue from non-
treated and bevacizumab-
treated rats at week 6. The same
rats are presented here as in
Fig. 3. a H&E staining revealed
the presence of necrotic areas
(asterisks). b Ki-67 staining
showed active tumour cell
proliferation in the treated and
in the non-treated GBM. c vWF
staining revealed the presence
of small and large vessels in the
non-treated tumours and the
presence of large abnormal
vessels in the treated
xenografts. Scale bars 100 μm
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network and understanding possible discrepancies between
preclinical and clinical results.
In addition, it should be pointed out that the measurement
of tumour vasculature may not be sufficient to evaluate the
efficacy of anti-angiogenic treatments in GBM. Indeed,
GBM are able to progress through angiogenic-independent
mechanisms [5, 33]. We therefore combined SSCE-MRI
with 11C-MET and 18F-FLT PET. At early stages, 11C-
MET uptake in the tumour is slightly higher than in normal
brain, whereas almost no contrast could be seen on 18F-FLT
images. Low 18F-FLT tumour uptake at the early time points
may be explained by the limited transport of thymidine
analogues across the intact blood–brain barrier and confirms
the higher sensitivity of 11C-MET compared to 18F-FLT in
the detection of early glioma development [16]. We ob-
served a good correlation between inhibition of
angiogenesis and uptake of PET tracers, showing the rela-
tion between tumour vessel remodelling, L-type amino acid
transporter 1 (LAT1) expression (11C-MET) and tumour
proliferation (18F-FLT). The correlation of 11C-MET uptake
with microvessel density (r=0.93, p=0.002, Pearson) con-
firms previous studies demonstrating high 11C-MET uptake
in areas of high angiogenesis-related microvessel density
[34, 35]. Our results are also in agreement with two pro-
spective clinical studies highlighting the potential of 18F-
FLT PET to predict anti-angiogenic treatment outcome in
patients with gliomas [36, 37].
Our study demonstrates that the changes in tumour ves-
sels during glioma progression and in response to an anti-
angiogenic treatment can be non-invasively assessed by
advanced MR imaging. Combination of SSCE-MRI with
11C-MET and 18F-FLT PET affords anatomical,
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(p<0.05 and 0.01, respectively). Correlation coefficients and signifi-
cance were determined using Pearson’s correlation analysis
Eur J Nucl Med Mol Imaging
	  	   45	  
physiological and biochemical information concerning
markers of angiogenesis and proliferation. Considering the
complexity and the spatial heterogeneity of the glioma re-
sponse to anti-angiogenic therapy, a multimodal imaging
approach appears necessary to fully characterize the induced
changes in the tumour. The presented methods might be
used for monitoring treatments and to further understand
the mechanisms that lead to tumour resistance to therapy.
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Online Resource 1: Quantification of small animal PET imaging results (mean tumour 
uptake). a. PET images were used to determine T/B ratios of mean tumour uptake of the PET 
tracers at 3 week (striped bars) and 6 weeks (white bars: non-treated rats; black bars: treated 
rats) after spheroid implantation in nude rats (n = 4). b. T/B ratios of 11C-MET and 18F-FLT 
mean tumour uptake were plotted over T/B ratios of MRI measures of vessel size/density 
obtained at week 6. c. Ki67 index was plotted over the T/B ratios of 18F-FLT mean tumour 
uptake. d. T/B ratios of vessel density derived from the immunohistochemistry were 
correlated with T/B ratios of 11C-MET mean tumour uptake.
**: significant difference between treated and non-treated rats (P < 0.01). Correlation 
coefficients and significance were determined using the Pearson correlation analysis.
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Week 3 Week 6
Non-treated Treated Non-treated Treated
11C-METmean 
(%ID/cm3)
Tumour 0.31 ±0.06 0.30 ±0.05 0.77 ±0.29* 0.52 ±0.06**
18F-FLTmean 
(%ID/cm3)
Tumour 0.08 ±0.05 0.10 ±0.01 0.37 ±0.18* 0.25 ±0.03**
Online Resource 2
Online Resource 2: Quantification of the mean tumour uptake of the PET tracers (Mean ± 
standard deviation)
* and **: significant difference between weeks 3 and 6 (P < 0.05 and 0.01, respectively)
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Vascular changes after stroke in the rat: a
longitudinal study using optimized magnetic
resonance imaging
Philipp Boehm-Sturma†, Tracy D. Farra†, Joanna Adamczaka, Jan F. Jikelia,b,
Luam Menglera, Dirk Wiedermanna, Therése Kallura, Valerij Kiselevc and
Mathias Hoehna*
During stroke, the reduction of blood ﬂow leads to undersupply of oxygen and nutrients and, ﬁnally, to cell death,
but also to upregulation of pro-angiogenic molecules and vascular remodeling. However, the temporal proﬁle of
vascular changes after stroke is still poorly understood. Here, we optimized steady-state contrast-enhanced
magnetic resonance imaging (SSCE MRI) and followed the dynamic changes in vascular architecture for up to 4
weeks after transient middle cerebral artery occlusion (MCAO) in rats. Using MRI diffusion measurements and the
changes of transversal relaxation rates ΔR2 and ΔR!2 after injection of a superparamagnetic contrast agent, SSCE
MRI provided several hemodynamic parameters: relative cerebral blood volume (rCBV), rCBV in small vessels,
microvascular density, and relative vessel size. Six rats underwent SSCE MRI before MCAO and at 7, 14, 21 and 28
days after surgery. 5-Bromo-20deoxyuridine (BrdU) was injected between days 2 and 7 to label proliferating cells
during this time. SSCE MRI depicted a decrease in microvessel density and an increase in vessel size in the ischemic
striatum after stroke. A persistently decreased MRI vessel density was conﬁrmed with histology at 28 days. BrdU+
endothelial cells were found in regions close to the infarct indicating endothelial cell proliferation during the
ﬁrst week after MCAO; however, late-stage angiogenesis, as would be reﬂected by increased vessel density, was
not detected. The optimized SSCE MRI protocol was used to follow spatio-temporal changes of important vessel
characteristics, which may contribute to a better understanding of the role of angiogenesis at different stages after
stroke. Copyright © 2013 John Wiley & Sons, Ltd.
Supporting information may be found in the online version of this paper
Keywords: steady-state contrast-enhanced MRI; vessel density imaging; vessel size imaging; middle cerebral artery
occlusion; angiogenesis
1. INTRODUCTION
Stroke is characterized by a disturbance in blood supply to the
brain. Reduction of blood ﬂow results in widespread cell death,
but also activation of several molecules and signaling pathways
that are thought to promote angiogenesis, reviewed in (1–3).
Proliferating endothelial cells were ﬁrst observed more than a
decade ago in human post mortem ischemic tissue (4), and
vascular casting in rodent models of middle cerebral artery
occlusion (MCAO) illustrated the formation of vascular buds,
some of which appeared to anastomose with surrounding
vessels (5). However, it is not clear whether or not these new
vessels are functional, or whether they have the capacity to play
a role in stroke outcome.
Magnetic resonance imaging (MRI) has long been used to
observe alterations in cerebral blood supply following stroke.
While resolution is currently lacking to detect formation of new
microvessels directly, under the assumption that these vessels
are functional, MRI can, however, depict cerebral blood volume
(CBV) changes, which in turn can be used to noninvasively
estimate microvessel density and size, as reviewed in Neeman
et al. (6) and Seevinck et al. (7). Here, the term microvessel
usually refers to capillaries (5–10 mm diameter) in contrast to
large arteries and veins (~100 mm diameter). Although the
vascular tree may more accurately be described by self-similar
structures of a wide range of diameters, such simple categoriza-
tion into small and large vessels is under deﬁned conditions
justiﬁed in the context of MRI signal from vasculature (8).
Steady-state contrast-enhanced magnetic resonance imaging
(SSCE MRI) provides measures of blood volume, vessel size, and
vessel density by measuring relaxivity changes (ΔR2 and ΔR!2) in
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tissue following injection of an intravascular superparamagnetic
contrast agent (9–12).
Initial studies applying SSCE MRI in embolic stroke showed
that the microvascular density in the lesion core and adjacent
tissue decreased (13). However, another study reported an
increase in relative cerebral blood volume (rCBV) and density of
microvessels in cortical regions starting 14 days after permanent
distal MCAO, interpreted as late-stage angiogenesis by those
authors (14). Moreover, increased rCBV and vessel size were
found in the ischemic territory of rats after MCAO and were inter-
preted as vasodilation in response to the stroke (15). Further
work is required to better understand the optimal acquisition
and analysis strategies for SSCE MRI in order to obtain deeper
insight into biological processes. In the present study, we
carefully reﬁned the technique of SSCE MRI and applied it to
the monitoring of vascular changes for up to 4 weeks after
transient MCAO in the rat. The results were complemented with
an assessment of endothelial cell proliferation during the ﬁrst
week after MCAO by histological means. Our ultimate aim was
to elucidate the extent of angiogenesis after cerebral ischemia,
which theoretically should be reﬂected by increased MRI-derived
vessel density.
2. MATERIALS AND METHODS
2.1. Animals and experimental design
All animal experiments were conducted according to the guide-
lines laid out in the German Animal Welfare Act and approved by
the authorities (Landesamt für Natur, Umwelt und Verbrau-
cherschutz Nordrhein-Westfalen) under permission number
9.93.2.10.31.07.048 (dated 22 May 2007). Adult male Wistar rats
(body weight 300–350 g, Harlan–Winkelmann GmbH, Borchen,
Germany) were housed in cages under a 12 h light/12 h dark
cycle with access to food and water ad libitum. During all surgical
and scanning procedures animals were anesthetized and main-
tained with isoﬂurane in a 70:30 nitrous oxide–oxygen mixture,
and core body temperature was maintained at 36.7 ! 1.0 "C
using in-house automated feedback systems and heat blankets
(medres GmbH, Cologne, Germany). Animals were scanned with
MRI 4–7 days before and on days 7, 14, 21 and 28 after MCAO,
and were sacriﬁced for histology after the last experimental
session. Additionally, rats received 5-bromo-20deoxyuridine (BrdU,
50 mg kg#1 twice daily i.p., Sigma-Aldrich, Hamburg, Germany)
between days 2 and 7 after MCAO to label proliferating cells.
2.2. Stroke induction
Stroke was induced by occlusion of the middle cerebral artery via
intraluminal ﬁlament technique (16) with the following modiﬁca-
tions. Rats were anesthetized and an incision was made in the
right temporal muscle halfway between the eye and ear. The
animals were subsequently placed in a supine position and a
calibrated 1 mm diameter Laser probe was placed against the
right skull to monitor cerebral blood ﬂow changes in the senso-
rimotor cortex following ﬁlament placement with a laser doppler
perfusion monitor (Perimed, Järfälla, Sweden). A midline incision
was made in the neck, and the mandibular glands, pretrachial
strap, and sternomastoid muscles were retracted. The carotid
artery and external carotid artery were exposed and ligated
with surgical sutures and a microclip was placed on the internal
carotid artery. A small incision was made in the carotid artery
below the external carotid artery and internal carotid artery
bifurcation and a silicone coated monoﬁlament (410 mm diame-
ter, Doccol Corporation, Redlands, CA, USA) was inserted and
advanced up the internal carotid artery until resistance was felt
and a decrease in cerebral blood ﬂow noted (approximately 17
mm). After 60 min the ﬁlament was withdrawn, the suture on
the external carotid artery removed, muscles and glands guided
back into place, wounds sutured and treated with local anes-
thetic. Animals received 2.5 ml of physiological saline s.c. daily
and were provided with moistened food until weight stabilized.
Exclusion criteria stipulated any animals with subarachnoid
hemorrhage, incomplete MCAO (no observable T2 changes
during MRI 1 week after MCAO) were removed from the study.
Six rats entered the study, four of which had a lesion restricted
to the striatum, depicted as hyperintensities on T2 maps; two
animals exhibited cortical and striatal damage. One animal did
not perform the SSCE MRI measurement 2 weeks post MCAO.
2.3. SSCE MRI
2.3.1. Theory
In order to analytically describe the changes in MRI signal owing
to i.v. injection of a paramagnetic substance, the vessel network
is modeled as a set of inﬁnitely long, randomly distributed cylin-
ders (17,18). Proton spins are assumed to be restricted to one of
two compartments: either within vessels (intravascular) or within
the tissue surrounding the vessels (extravascular). Further
assumptions include a small blood volume fraction x0<< 1
and a diffusion length much smaller than the size of a strongly
dephased area around the vessel, that is, do $ r2/D>> 1 (8). D
represents the water diffusivity in the extravascular compart-
ment, r is the vessel radius, and do is the characteristic shift in
Larmor frequency of a magnetized cylinder in an external
magnetic ﬁeld.
Under these assumptions, the change in MRI signal from
before (Spre) to after (Spost) the contrast agent injection can
simply be described by shifts of the relaxation rates measured in
a spin echo (SE) (R2! R2 +ΔR2) and gradient echo (GE) experiment
(R%2 ! R%2 þ ΔR%2) (cgs units) (11):
ΔR2 ¼ 1TE ln
Spre;SE
Spost;SE
! "
( 0:694$do2=3D1=3x0r#2=3 (1)
ΔR%2 ¼
1
TE
ln
Spre;GE
Spost;GE
! "
( 2
3
x0do (2)
Here, TE is the echo time.
In order to assess the important tissue parameters T2 and ΔR2
simultaneously, we decided to use a multi spin echo pulse
sequence (MSME). This results in an effective reduction of the
diffusion effect D!D/n2 depending on the number of refocusing
pulses n (19,20). ΔR2 is then determined with the MRI signal SMSME
of the nth echo of the MSME via the modiﬁed relationship:
ΔR2 ¼ nb 1TE nð Þ ln
Spre;MSME nð Þ
Spost;MSME nð Þ
! "
; b ¼ 2
3
(3)
Neglecting the reduced diffusion effect leads to a high under-
estimation of ΔR2 values. We found a lower exponent b= 0.49 in
the experiment (Supporting Information, Fig. S1), which was
used for all further analysis. The deviation from the theory will
be subject to further studies.
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Equations (1) and (2) show that ΔR2 is a measure of rCBV
in small vessels whereas ΔR!2 reﬂects the rCBV in all vessels.
However, both still depend on the concentration C of the
contrast agent in blood, which usually needs to be assessed
invasively or with dynamic contrast-enhanced measurements
(11). Therefore, Jensen and Chandra introduced the so-called Q
-factor, which is largely independent of C and is a measure of
microvessel density (10).
Q ¼ ΔR2
ΔR!2ð Þ2=3
(4)
Q relates to the number of vessels that punctuate a cross-
section of tissue per unit area. Microvessel density N is counted
in units of [N] = 1 mm%2 and can be calculated when the pres-
ence of large macrovessels can be neglected and taking into
account the water diffusivity in tissue (12):
N ¼ 0:218 Q3=D! "; D½ ' ¼ mm2s%1; Q½ ' ¼ s%1=3 (5)
Furthermore it can be shown that the mean vessel size holds
true (11):
r ¼ 0:425 1
gΔwB0
# $1=2
( Dð Þ1=2 ΔR
!
2
ΔR2
# $3=2
(6)
Owing to the lack of in vivo measurements of the contrast
agent concentration and thus lack of Δw values, we neglected
the ﬁrst term in eqn (6) and used a relative vessel size R (in arbi-
trary units) throughout the article, which is deﬁned as:
R ¼ D
Dlit
# $1=2 ΔR!2
ΔR2
# $3
2:=
(7)
Here, we accounted for local changes in diffusivity in the path-
ologic brain by multiplication with the square root of the quo-
tient of measured diffusivity D and a known value for the healthy
brain Dlit = 6.64) 10%4 mm2 s%1 (21).
2.3.2. MRI acquisition
MRI was carried out on a 4.7 T animal scanner (Biospec47/30,
Bruker BioSpin, Ettlingen, Germany) equipped with actively
shielded gradient coils (BGA 12, 220 mT m%1, 120 ms rise time,
Bruker BioSpin). We used a custom-built surface radiofrequency
coil 30 mm in diameter for reception and a Helmholtz coil for
homogeneous transmission (medres GmbH, Cologne, Germany).
Animals were ﬁxed with tooth bar and ear bars in a custom-
made animal holder (medres). Respiration rate was monitored
with a pressure-sensitive pad under the thorax using DASYlab
(Measurement Computing, Norton, USA) software.
The imaging protocol consisted of apparent diffusion coefﬁcient
(ADC) measurement [spin echo MRI, ﬁeld of view= (2.56 cm)2,
eight contiguous 1 mm thick slices, matrix = 128)64, echo time/
repetition time (TE/TR) = 40.66 ms/4 s, one diffusion direction
medial-lateral in the animal coordinate system, beff = 0.26, 600.26,
and 1500.26 s mm%2, Time of acquisition (TA) = 12:48 min], an
MSME (TE/TR= 13.55 ms/4 s, 10 echoes, TA=8:32 min) and a
multigradient echo pulse sequence (MGE, TE/TR=5 ms/2 s, eight
equidistant echoes, ﬂip angle= 60*, TA=8:32min). The geometries
of the MSME and MGE were matched to the ADC measurement to
allow voxel-wise calculation of vessel density, except that four
additional slices were acquired in order to cover the whole
forebrain in the T2 and T!2 images.
After initial measurements, superparamagnetic iron oxide
particles (Endorem, Guerbet, Sulzbach, Germany, 11.2 mg
Fe ml%1) were injected in the tail vein at a dose of 30 mg
Fe kg%1 without moving the animal. We allowed the contrast
agent to distribute homogeneously over the blood pool for 3
min, and then identical post-contrast MSME and MGE images
were acquired.
2.4. MRI data processing
The MRI data were processed with Interactive Data Language
(IDL, ITT visual information solutions, Boulder, CO, USA) and
FMRIB Software Library (FSL, http://www.fmrib.ox.ac.uk/fsl).
For T2 maps, the MRI signal S(TE) in MSME scans was ﬁtted on a
voxel-wise basis with a monoexponential decay S(TE) = A exp
(%TE/T2) + B with equilibrium signal A, relaxation time T2, and
an offset B to reduce bias introduced by the use of magnitude
images (22). Accordingly, ADC maps were generated by ﬁtting
the MRI signal with S(b) = A exp(%b (ADC) + B. Maps were co-
registered to a template rat brain (an average of 34 high-resolution
T2 -weighted images from 28 rats, scaled tomatch the resolution of
our scans) with FSL’s linear registration tool.
For vessel size and densitymaps, the A0 images (b=0.26 smm
%2)
of the ADC scan and the ﬁrst echo images of the pre- and
post-contrast MSME and MGE scans were segmented with
FSL’s brain extraction tool. The segmented images were co-
registered to the template brain with an afﬁne transformation
(12 degrees of freedom) with FSL. The determined transforma-
tion matrices were applied to the other ADC images, and the
later echoes of the MSME and MGE datasets. Finally, the co-
registered images were used for voxel-wise calculation of ΔR!2 ,
ΔR2, Q, N and R according to equations (2)–(5) and (7), respec-
tively. ΔR2 and ΔR!2 were calculated from the second echo of
the MSME and MGE images, respectively, in order to minimize
error propagation in the data analysis scheme (Supporting
Information, Fig. S2). Voxels with a signal to noise ratio< 5 in
either the A0 image of ADC measurements or in the ﬁrst echo
of the MSME or MGE were excluded from the analysis. Voxels
with negative ΔR2 or ΔR!2 values, or those with ΔR2 > ΔR
!
2 were
also excluded.
Volume-of-interest (VOI) analysis was carried out with the
freeware program ImageJ (http://rsbweb.nih.gov/ ij/). First, for
anatomically selected VOIs, the intact and ischemic striatum
was manually delineated in the coronal slices corresponding to
%0.3 and %1.3 mm from bregma. Second, lesion-based VOIs
were manually drawn in the same two slices for each animal
on T2 maps acquired 1 week post MCAO. The lesion-based VOIs
encompassed voxels with increased T2 values (T2 > mean+ 2
standard deviations of contralateral striatum). Third, a VOI of
the peri-infarct zone was drawn by extension of the lesion VOI
by 0.4 mm in-plane (neglecting ventricles and areas outside
the brain) and by subsequent subtraction of the lesion VOI.
Mirroring of the lesion and peri-infarct VOIs at the midline with
a custom ImageJ macro yielded the contralateral VOIs. Mean
ΔR!2 , ΔR2, Q, N and R values were recorded and presented as a
ratio of the ischemic to intact side.
The incidence maps were generated by normalization (voxel-
wise division) of the post-MCAO parameter maps to the time point
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before surgery. An incidence in a voxel at a certain time point was
counted when that voxel showed a signiﬁcant increase/decrease,
that is, with a normalized parameter of interest larger/smaller
than the mean! 2 standard deviations when compared with
the contralateral striatum. For each SSCE MRI parameter increase/
decrease, incidences of all animals were added voxel-wise.
The resulting incidence map for the group of animals was
smoothed (Gauss ﬁltered, sigma=0.2 mm) and overlaid on the
template brain.
2.5. Immunohistochemistry
After the last MRI session, animals were deeply anesthetized and
perfused transcardially with cooled saline followed by cooled 4%
paraformaldehyde. Brains were post-ﬁxed overnight and cryo-
protected in 30% sucrose solution prior to coronal sectioning
at 40 mm on a freezing microtome (Leica Microsystems, Wetzlar,
Germany). Sections were kept at "20 #C in cryo-protective
solution. For double-label immunoﬂuorescence with BrdU, free-
ﬂoating sections were denatured in 1 mol l"1 HCl for 10 min at
65 #C, followed by 20 min incubation at room temperature and
pre-incubation in appropriate blocking solution: 5% normal sera
and 0.25% Triton X-100 in potassium phosphate-buffered saline
for 60 min at room temperature. Incubation with primary
antisera was carried out overnight at +4 #C and the following
primary antibodies were used: rat anti-BrdU (1:100, Abcam,
Cambridge, MA, USA), and mouse anti-Rat Endothelial Cell
Antigen (RECA; 1:400, AdB Serotec, Oxford, UK). Primary antibo-
dies were detected using either standard diaminobenzidine
(DAB) immunohistochemistry or appropriate ﬂuorescent Cy3
(Jackson ImmunoResearch, West Grove, PA, USA) or biotin-
conjugated (Vector Laboratories, Burlingame, CA, USA) second-
ary antibodies (1:200), the latter of which was detected with
Alexa 488-conjugated streptavidin (1:200, Invitrogen, Carlsbad,
CA, USA). Sections were mounted on poly L-lysine coated slides
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) and coverslipped
with glycerol-based mounting medium.
Microscopic images were acquired and double-immunoreac-
tivity veriﬁed with a confocal laser scanning microscope (Leica
TCS SP5 X, Leica Microsystems). Microvessel density was semi-
quantiﬁed across the entire intact and ischemic striatum from
RECA DAB stained sections located approximately"0.3 mm from
bregma (corresponding to the anterior commissure) (23) using
the Stereo Investigator system (MicroBrightField Europe, E.K.,
Magdeburg, Germany) with a counting frame of 40 mm2 at 20$
magniﬁcation. Microvessel size was estimated by measuring
the diameter at the thickest point of a counted vessel every
100 frames.
2.6. Statistical analysis
Data are expressed as group means! standard deviation of the
means. Statistical analysis was performed using SPSS version 17
software and a p-value< 0.05 was used as the signiﬁcance level.
VOI values in the striatum/lesion/peri-infarct zone were com-
pared using one way repeated measures analysis of variance
with time as the within-subject factor followed by post-hoc
pairwise comparisons with the least signiﬁcant difference test.
For comparison of histology and MRI, microvessel densities in
the intact and ischemic striatum were analyzed using paired
Student’s t-tests.
3. RESULTS
3.1. Impact of noise and echo times on SSCE MRI results
To determine the impact of noise on the most noise-sensitive
parameter N, we performed simulation experiments in which
white noise was added to artiﬁcial MRI datasets. In parallel we
analyzed histograms in experimental MRI datasets from animals
before MCAO. Our simulations also determined that suboptimal
echo times result in non-Gaussian, widespread distribution of
the resulting N values (Supporting Information, Fig. S2). From
this, we anticipated that, in order to detect physiologically
relevant changes in N (as a marker of microvessel density), the
relative change must be in the order of magnitude of 20%.
3.2. Impact of tissue water diffusivity on interpretation of
SSCE MRI results
In the chronic phase after MCAO, necrosis, phagocytosis and
associated cystic formation in tissue are visualized by a steep
increase in ADC values. In all animals with this cyst formation
(n= 3) regions of elevated ΔR2 were observed within or close
to the lesion core (Fig. 1a). According to the theory, increases
in ΔR2 indicate an increase of rCBV in small vessels, but as is
demonstrated by eqn (1), diffusivity also plays a role. Compari-
son of vessel density maps calculated under inclusion of a
constant diffusion value from the literature (21) (Fig. 1b) with
those vessel density maps for which the local diffusivity was
taken into account on an experimentally recorded, voxel-wise
basis (Fig. 1c, d), revealed that the dominant effect leading to the
increased ΔR2 was highly elevated water diffusivity in necrotic
tissue. Vessel staining on histological sections conﬁrmed that
tissue in these regions was not intact at 4 weeks after MCAO
and that the density of small vessels in adjacent regions was
not higher compared with healthy tissue (Fig. 1e, f).
3.3. Vascular changes after stroke
3.3.1. MRI Incidence maps
Incidence maps revealed that decreases in ΔR2 and Q and an
increase in R were most frequent (Fig. 2, bottom three rows).
All six animals were used for map calculations but the highest
number of incidences found in all pixels for any of the SSCE
MRI parameters was three, indicating a regionally and temporally
variable pattern of vascular changes across the different animals.
Other incidence maps did not show a speciﬁc trend.
3.3.2. MRI VOI analysis
Parameter maps from all animals are presented for all time
points in Fig. 3. In all maps except T2 and ADC we observed
global image intensity ﬂuctuations between animals and time
points within the whole brain that followed no deﬁned pattern
and probably reﬂected differences in contrast agent concentra-
tion within the blood, which was not measured in this study.
To account for this, quantitative analysis was carried out in the
striatum (Fig. 4a), within the lesion (Fig. 4b) and within the
peri-infarct areas (Fig. 4c), and values expressed as a percentage
ratio of the ipsilateral (lesioned) to the contralateral (intact)
hemisphere. Only a negligible number of voxels (<0.5 %) were
excluded from the analysis owing to the imposed thresholds
on signal to noise, ΔR2 and ΔR%2.
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As expected, prior to MCAO the calculated MRI parameters
were comparable between the ipsilateral and contralateral side:
rCBV in small vessels ΔR2 (striatum, 101.8! 1.3%; lesion,
101.6! 2.0%; peri-infarct, 98.5! 2.6%), rCBV ΔR"2 (striatum,
100.5! 4.5%; lesion, 103.9! 8.2%; peri-infarct, 98.1! 4.3%), mi-
crovascular density index Q (striatum, 101.3! 3.3%; lesion,
99.1! 4.1%; peri-infarct, 99.7! 2.8%), vessel density N (striatum,
103.8! 9.0%; lesion, 98.3! 17.3%; peri-infarct, 97.3! 6.3%), and
relative vessel size R (striatum, 97.1! 6.2%; lesion, 102.3! 11.4%;
peri-infarct, 99.0! 9.3%) (Fig. 4). After stroke, the overall rCBV
ΔR"2 remained relatively constant over the course of the experi-
ments. There was a signiﬁcant effect of time in rCBV in small
vessels ΔR2 [striatum, F(4,16) 3.890, p= 0.022; lesion, F(4,16)
6.082, p=0.004; peri-infarct, F(4,16) 5.040, p= 0.008]. The
percentage ratio of ΔR2 decreased around 1 week after stroke with
a trend towards subsequent increase by week 2, which was con-
ﬁrmed by post-hoc pairwise comparisons of values within the
lesion before and 1 week post stroke (p=0.05; Fig. 4b).
Signiﬁcant effects of time were also observed for the micro-
vascular density index Q [striatum, F(4,16) 3.342, p= 0.036; lesion,
F(4,16) 6.861, p= 0.002; peri-infarct, F(4,16) 3.339, p= 0.036],
microvessel density N [striatum, F(4,16) 3.586, p= 0.029; lesion,
F(4,16) 6.311, p= 0.003; peri-infarct, not signiﬁcant], and relative
vessel size R [striatum, F(4,16) 3.259, p= 0.039; lesion, F(4,16)
4.727, p= 0.01; peri-infarct, not signiﬁcant]. In line with the
decrease in rCBV in small vessels, Q and N ratios both decreased
around 1 week after stroke, although post-hoc tests failed to
reach signiﬁcance. The decreases in N and Q at week 1 were
accompanied by a dramatic increase in relative vessel size R. This
persisted throughout the course of the experiments, although
less pronounced for later times.
3.4. Immunohistochemistry
RECA staining clearly detected blood vessels in the brain sections
4 weeks after surgery. Photomicrographs from two representa-
tive animals indicate fewer visible vessels in the ischemic
striatum (Fig. 5a and b). Histological microvessel density in the is-
chemic striatum was signiﬁcantly lower than that of the intact
striatum (585! 89 vs 827! 58 vessels mm#2) [t(5) = 4.679,
p=0.005). This corresponded roughly to a ~29% decrease
(Fig. 5c, right), which is within the detectability limits determined
from our simulations. A similar, signiﬁcant decrease of ~27%
[t(5) = 2.705, p= 0.043) was observed in MRI-derived vessel
density N from the VOI analysis at 4 weeks after MCAO, that is,
(209! 81) mm#2 ipsilateral and (289! 75) mm#2 contralateral
(Fig. 5c, left). The mean vessel diameter, and thus size, measured
from brain sections in small vessels (<40 mm) were not signiﬁ-
cantly different between the ischemic (7.4! 1.0 mm) and the
intact striatum (7.0! 1.0 mm; Fig. 5d, right). However, there was
a ~50% increase in R in the ischemic striatum determined from
the MRI VOI analysis, although this failed to reach signiﬁcance
[t(5) =#2.037, p= 0.097; Fig. 5d, left].
We systematically examined sections double-stained for BrdU
and RECA. No double-labeled cells were observed in the hemi-
sphere contralateral to the infarct, and green autoﬂuorescence
within the ischemic core did not permit analysis there. However,
in peri-infarct regions we found occasional individual endothelial
cells that also appeared to be BrdU+ (Fig. 6). Overall, very few
proliferating endothelial cells were detected.
4. DISCUSSION
The present study demonstrates that the temporal proﬁle of
vascular changes after stroke can be assessed noninvasively with
SSCE MRI. However, our data indicate that it is crucial to optimize
MRI acquisition in order to maximize sensitivity of the method.
For the ﬁrst time, we show that when cystic transformation
occurs, inclusion of diffusion measurements on a voxel-wise
basis is essential to prevent overestimation of SSCE MRI-derived
Figure 1. Impact of tissue diffusivity on MRI-derived blood volume and
vessel density. All animals with cyst formation exhibited regions with
highly elevated ΔR2 close to or within the lesion core, which is usually
interpreted as high rCBV in small vessels. Such an area is indicated by
the box on the ΔR2 map from a representative animal 4 weeks after
MCAO (a). Assuming a constant diffusivity value for each voxel that is
comparable to healthy tissue leads to high MRI-derived vessel densities
(box in b). However, ADC values in this region were also elevated, which
indicates necrosis and liquefaction of tissue (box in c). When we took
local tissue diffusivity into account on a voxel-wise basis, the ‘hot spots’
in the MRI-derived vessel densities disappeared (box in d). Histology in
the same region conﬁrmed tissue necrosis (e) and a decrease in micro-
vessel density (e, arrows) compared with the same region on the contra-
lateral side (f). Thus, the high ΔR2 was a result of high tissue diffusivity
and not an indicator of increased rCBV in small vessels.
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Figure 3. Temporal proﬁle of MRI-derived parameters. T2, ADC, ΔR2, ΔR!2, Q, N and R maps before and weekly after MCAO of an animal with a lesion
restricted to the striatum (animal 1) and an animal with both, cortical and striatal damage (animal 2). Most relevant maps (T2, N and R) are shown for all
other animals. ΔR2, Q and N decreased in the ischemic regions in all animals whereas there was an observable increase in relative vessel size R. The
changes were most pronounced 1 week after surgery (arrows) but persisted also at the later time points. Animal 6 did not perform the SSCE MRI
measurement at 2 weeks post stroke.
Figure 2. Incidence maps for the MRI-derived parameters. Maps indicating, for each voxel, the number of animals that exhibited a decrease in ΔR2 or
Q, or an increase in R during the 4 weeks after MCAO. For each time point the two coronal slices shown are those that are most affected by the infarct:
"1.3 (left) and "0.3 mm from bregma (right). A small trend towards the decrease of ΔR2 and Q can be observed in the ischemic hemisphere, as well as
an increase in R (bottom row) mostly in areas of the striatum. The striatum was therefore used for further quantitative volume-of-interest analysis. Other
incidence maps did not show a speciﬁc trend. Although six animals entered the calculations, the maximum number of incidences found in any of the
parameters was three, that is, within any region, a signiﬁcant, simultaneous vascular change occurred only in a subgroup of animals.
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vessel densities. Our major ﬁnding was that there was a signiﬁ-
cant decrease in rCBV in small vessels, leading to a decrease in
vessel density, which was accompanied by an increase in vessel
size 1 week after MCAO in the ischemic striatum that persisted
for several weeks. Microvessel density determination from histo-
logical brain sections conﬁrmed that decreased vessel density
was still present at 4 weeks after the initial insult. If large-scale
angiogenesis occurred in response to stroke, this should have
been reﬂected by an increase in vessel density. This was not
the case, although the presence of sparse numbers of BrdU+/
RECA+ cells in the ischemic striatum indicated that some endo-
thelial cell proliferation occurred during the ﬁrst week after
MCAO. Absence of double-labeled cells on the contralateral
hemisphere indicated that the proliferation was induced by the
stroke and not by natural turnover of endothelial cells.
4.1. SSCE MRI methodological considerations
When this method was ﬁrst employed in a rodent model of stroke
to measure changes in the vascular network (rCBV in small vessels,
overall rCBV, vessel density and size) ΔR2 was assessedwith a turbo
spin echo pulse sequence using multiple refocusing pulses to
speed up the acquisition (14). Subsequent studies employed multi
spin echo sequences in order to obtain measures of T2 and ΔR2
simultaneously and further included ADC measurements (13,24).
This strategy is useful as both T2 and ADC provide important
Figure 4. Quantiﬁcation of MRI-derived parameters. Volume-of-interest analysis in the striatum (a), in the lesion (b), and peri-infarct zone (c) revealed a
decrease in ΔR2, Q and N and an increase in R in the ischemic striatum that was most pronounced 1 week after MCAO. These parameters normalized at
the later time points (weeks 2–4). Values are expressed as a ratio of the ipsilateral to the contralateral side (group means! standard deviation). The
volumes of interest are indicated on coronal slices corresponding to "1.3 and "0.3 mm from bregma on a T2-weighted template image (a) and a
T2-map (b, c) of animal 2. The two slices are illustrated in gray on a schematic sagittal view of the rat brain.
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information about the state of the ischemic tissue. However,
neither of these studies performed any modiﬁcation to the theory
in order to account for the well-known reduction of the diffusion
effect on MR transverse relaxation (19,20,25). Using the theory
modiﬁcation, however, leads to higher ΔR2, Q and N values. In line
with this, we found higher values of these parameters compared
with the reports in which a theory correction was not applied.
Furthermore, we also identiﬁed a major pitfall in the interpretation
of SSCEMRI parameters when the tissue exhibits cystic transforma-
tion. In such cases, ΔR2 is no longer a good measure of rCBV in
small vessels, and neither isQ because of elevated tissue diffusivity.
Our data indicate that it is essential to include local ADC values in
the calculations, otherwise ΔR2 ‘hot spots’ may be misinterpreted
as angiogenic activity.
Despite these improvements in MRI acquisition, our results
show that SSCE MRI is prone to noise, especially for the vessel
density estimate N. Even after optimization of acquisition para-
meters, the relative error in N values is on the order of ~20%.
Although this is in accordance with the previous reports (13), it
represents an inherent limitation of the technique. Further
limitations come from the fact that the ischemic rodent brain
probably violates some of the previously described assumptions
that are made when applying the theory. For example, the
mathematical model underlying SSCEMRI only holds for imperme-
able vessel walls, low blood volume fractions, and vasculature for
which the microvessels can be modeled as rigid long cylinders
(26). Therefore, the use of blood as an intravascular tracer through
the blood oxygen level-dependent contrast seems to be an
appealing alternative, e.g. to overcome problems of contrast agent
leakage and heterogenous water diffusivity in peri-infarct area.
Indeed, quantitative blood oxygen level-dependent approaches
have been developed in order to map important parameters of
oxygenation in vivo (27,28). Furthermore, the use of fast MR imag-
ing during the ﬁrst bolus (dynamic susceptibility MRI) or arterial
spin labeling techniques could help to correlate SSCE MRI with
perfusion and thus functionality of blood vessels.
4.2. Vascular changes after stroke
Using SSCE MRI we observed a decrease in microvessel density
in the ischemic striatum at 1 week after stroke, a situation not
surprising as this tissue has experienced widespread cell death
by this time. Similar ﬁndings were reported as early as 1 day after
ischemia in an embolic (13) and distal occlusion model (14). This
decrease in microvessel density persisted for up to 2 weeks in
the former study, which is also consistent with our results.
Figure 5. Comparison of MRI and histology. Tissue sections stained for vessels (RECA) of an animal with a small striatal lesion (a) and of a rat with a
larger infarct (b). Semi-quantiﬁcation on histological sections revealed a signiﬁcant ipsilateral decrease in microvessel density (c, right) that corre-
sponded well with the MRI results at 4 weeks after MCAO (c, left). Histological vessel diameter (of vessels <40 mm) showed only a small, nonsigniﬁcant
increase in the ipsilateral striatum (d, right), whereas a highly elevated relative vessel size was found in the MRI analysis (d, left), although this failed to
reach signiﬁcance. For better visualization, MRI and histology data are scaled differently. Values are expressed as group means! standard deviation.
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Despite the notion that the decrease in microvessel density
observed in the ischemic region after stroke is persistent, the
SSCE MRI study that employed the distal occlusion model noted
a signiﬁcant increase in microvessel density in the outer cortex of
the ischemic region beginning after about 2 weeks that was
attributed to angiogenesis (14). One potential reason for this
discrepancy could be the choice of stroke model. However, our
ﬁndings suggest that this effect could be artifactual in nature as
we were able to observe a similar phenomenon in animals with
cystic transformation when we employed, rather than the correct
and necessary voxel-wise diffusion measurement, only a constant
diffusion value to determine N maps. Indeed and in line with this,
the authors of that study mentioned that this area of increased
microvessel density was prone to cystic transformation.
In parallel to the decrease in microvessel density, we observed
an increase in vessel sizewith SSCEMRI most pronounced at 7 days
post stroke that was probably due to vasodilation of arterioles in an
effort to maintain autoregulation. This phenomenon probably
occurs earlier, and, indeed, Lin et al. (14) reported this observation
within the ﬁrst week of stroke (1–3 days), which was conﬁrmed by
an increase in the number of vessels with a diameter greater than
30 mm in tissue sections from the same time period. While that
study reported a subsequent decline in vessel size, other groups
suggested that this effect remains between days 7 and 21 (15)
and even up to 6 weeks in the recovery region (24). In the present
study, we only measured animals up to 28 days, and while R was
still elevated at this time, this elevation was not as pronounced
as during the ﬁrst week. In accordance with these ﬁndings, we
were also unable to observe an increase in the mean vessel
diameter in the ipsilateral when compared with the contralateral
striatum at 4 weeks post stroke. While it is possible that this could
be an artifact of our sampling strategy, microvessel is a gross term
that includes capillaries, venules and arterioles, which means that
the size of vessels varies considerably even in the intact brain
(29). Nevertheless, the mean vessel size estimated subcortically at
6 h post symptom onset was recently shown to be a good predic-
tor of ﬁnal infarct size at 6 days in a small cohort of patients that
underwent a modiﬁed dynamic contrast-enhanced protocol simi-
lar to SSCEMRI (30). A follow-up study extended the same protocol
to a larger patient cohort that presented a signiﬁcant perfusion-
diffusion mismatch around 24 h post symptom onset (31). Vessel
size was found to be a poor predictor of infarct growth at 6 days,
but microvessel density proved to be useful at discriminating
infarcted from oligemic or healthy tissue. These studies highlight
the utility of this technique to provide valuable information in
the post-ischemic period.
4.3. Angiogenesis after stroke
Angiogenesis after ischemia is generally characterized at a cellu-
lar level by gene transcription leading to expression of pro-
angiogenic molecules and ﬁnally to endothelial cell proliferation.
We observed some endothelial cell proliferation during the ﬁrst
post-operative week, which is already well described (5), and
another study observed increases in various pro-angiogenic
compounds such as growth factors and endothelial nitric oxide
synthase (14). While stabilization of vessel walls and formation
of new networks have been reported (5), it is unclear if these
processes can lead to truly functional new vasculature (7). Perfu-
sion measurements could help to elucidate if proliferating,
BrdU+ endothelium belongs to functional vasculature. Unfortu-
nately, as SSCE MRI is based on CBV measurements using an
intravascular contrast agent, it is only capable of detecting
perfused vessels. The evidence from the preclinical SSCE-MRI
studies in stroke models consistently indicates that there is an
overall decrease in microvessel density rather than a large-scale
increase. The small number of animals in the present study
renders general conclusions difﬁcult. However, taken together,
this implies that angiogenesis is not occurring at an advanced
level and that new, functional vessel formation is limited. The
histological evidence also supports this as measurements of
microvessel density in tissue sections decrease corresponding
to the same pattern in the MR images. From a translational point
of view this may be discouraging. However, chronic hypoxia
generally leads to angiogenesis and this has been shown for
human stroke (4). Therefore, discrepancies owing to choice of
species and model (transient ischemia in a speciﬁc rat strain
versus human stroke) should further be addressed.
5. CONCLUSION
In conclusion, SSCE MRI is a useful technique to noninvasively
estimate changes in the microvasculature after stroke. Our results
indicate that optimization of the MR acquisition parameters is
essential in order to allow robust conclusions. The focus of our
study in experimental stroke has been to probe for evidence
of angiogenesis in the chronic stages. Immunohistochemistry
revealed endothelial cell proliferation only in peri-infarct regions,
which is a sign for early angiogenesis, but newly formed endothe-
lial cells failed to translate into higher vessel densities and func-
tional vasculature.
Figure 6. Confocal microscopy images of tissue sections stained for
RECA (red) and BrdU (green) 4 weeks after MCAO. BrdU was administered
between days 2–7 after MCAO. Overview (a) and higher magniﬁcation
images (b, corresponds to the white box in a) revealed some red/green
overlap and a confocal microscopy image (c, corresponds to the white
box in b) conﬁrmed this. Strong green ipsilateral staining in the lesion
core (a) is due to ischemia-induced autoﬂuorescence.
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6. SUPPORTING INFORMATION
Supporting information can be found in the online version of
this article.
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 1 
Supplementary Figure 1 
Calculation of ΔR2  values from multi spin echo pulse sequences. ΔR2  values were calculated 
with equation [1] for each of the 10 echo images of the multi spin echo pulse sequences 
before and after injection of the superparamagnetic contrast agent. The resulting ΔR2  values 
(mean ± standard deviation) in the striatum of six healthy rats are plotted (squares). The plot 
shows that using equation [1] leads to severe underestimation of ΔR2 , especially for later 
echoes (compared to the first echo). Therefore, a modification of the theory is necessary 
represented by equation [3]. The theoretical curve ΔR2 ∝ n−2 3  (dashed line) overestimates the 
decrease in ΔR2  for echoes n>2. Instead, an empirical relationship ΔR2 ∝ n−0.49  was found 
(solid line). Since the use of the first echo images would lead to high noise (cf. Supplementary 
Fig. 2) we decided to use the 2nd echo image and to correct our data with the empirical model.  
A more complete theoretical description of these findings will be the subject of future studies. 
Supplementary Figure 2 
Optimization of acquisition and sensitivity of SSCE MRI. The parameter N  is most affected 
by scanner noise. In order to optimize the acquisition to reduce noise propagation, signal 
intensities in the MSME and MGE sequences were simulated using a typical MRI-derived 
vessel density in the healthy striatum of rats N = 300 /mm2 , relaxation times T2 /T2*  (65 
ms/45 ms) and changes in relaxivities ΔR2 /ΔR2*  (20 s-1/95 s-1) due to injection of iron oxide 
agent (30 mg Fe/kg) at 4.7 T. White noise was added to the signal intensities (10 000 
simulation runs, noise level 5% of equilibrium MR signal at TE = 0 ) and N  maps were 
calculated with the same analysis scheme used for the in vivo data. Left: The relative error of 
the mean of N  was plotted as a function of echo times. Note that the relative error ΔN /N  
(standard deviation/mean) is highly dependent on the choice of echo time. Similar to the 
simulations, error propagation was minimized in the experiment at echo times of 10 and 27 
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 2 
ms for TEMGE  and TEMSME , respectively. Right: Comparison of histograms of simulated N  
values for the optimized echo times against slightly varied echo times of TEMGE /TEMSME =5 
ms/54 ms shows that the SSCE MRI method is very sensitive to noise and acquisition 
parameters. Choosing non-optimal echo times leads to a non-symmetric distribution of N  
values, including a shift of the expected mean. We compared the simulated histogram to what 
was obtained during the experiments (2800 data points from the striatum of six healthy rats) 
using the optimized echo times. The histogram from our experiments is normally distributed. 
However, additional physiological noise is introduced during our experiments, and 
simulations did not account for variation in vessel densities in the tissue. Therefore, we 
observed a relatively widespread (but still symmetric) distribution compared to the simulated 
data, for which we took only scanner/thermal noise into account. Given the width of the 
experimentally found distribution, we estimate that a change in vessel density needs to be on 
the order of ~20% to be detectable by SSCE MRI. 
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Abstract
Neural stem cells (NSCs) have attracted major research interest due to their potential use in cell replacement therapy. In patients,
human cells are the preferred choice, one source of human NSCs being the brain of fetuses. The aims of the present study were to
explore the long-term differentiation, mobility and viability of NSCs derived from the human fetal striatum in response to intracerebral
implantation. To investigate long-term spatio-temporal and functional dynamics of grafts in vivo by magnetic resonance imaging,
these cells were labeled with superparamagnetic iron oxide (SPIO) nanoparticles prior to implantation. SPIO-labeling of human NSCs
left the quantitative profile of the proliferation, cell composition and differentiation capacity of the cells in vitro unaltered. Also after
transplantation, the phenotypes after long-term cell differentiation were not significantly different from naı¨ve cells. Upon
transplantation, we detected a hypointensity corresponding to the striatal graft location in all animals and persisting for at least
4 months. The hypointense signal appeared visually similar both in location and in volume over time. However, quantitative
volumetric analysis showed that the detectable, apparent graft volume decreased significantly from 3 to 16 weeks. Finally, the human
NSCs were not proliferating after implantation, indicating lack of tumor formation. These cells are thus a promising candidate for
translationally relevant investigations for stem cell-based regenerative therapies.
Introduction
Stem cell-based therapy aims to restore lost brain function after acute
and chronic neurological conditions by exogenous delivery of stem
cells. Neural transplantation of tissue, obtained from human embryos,
has provided proof of successful restoration of lost brain function in
the human brain (Lindvall & Kokaia, 2009). However, limited tissue
availability and standardization make the use of fetal tissue problem-
atic. Therefore, the discovery that embryo- and adult-derived neural
cells could be expanded in vitro provided a promising route for cell
replacement therapy (Reynolds & Weiss, 1992; Reynolds et al.,
1992). Stem cell research has demonstrated that cells in culture can
generate a wide range of neural cells for this purpose. One source of
human cells for use in cell therapy are neural stem cells (NSCs) of
different origin (Guillaume et al., 2008; Selden et al., 2008; Koch
et al., 2009). Recently, NSCs derived from the fetal striatum have
been expanded continuously in vitro for long periods of time, with
maintained normal karyotype and high capacity to differentiate into
cells with different neuronal phenotypes (Kallur et al., 2006, 2008).
Furthermore, when transplanted as neurospheres, the cells survive in
the stroke-damaged rat striatum, migrate towards the injury and
differentiate into mature neurons without tumor formation (Darsalia
et al., 2007). As such, these cells represent attractive candidates for
cell replacement therapy. However, there are several unanswered
questions, for which exploration is required before progression to full-
scale clinical trials can be made feasible.
One fundamental issue is to determine the optimal proliferation,
survival, differentiation and migration capacity of the grafted cells
(Lindvall & Kokaia, 2010). This is especially important on a long-
term basis and quantitatively. In the experimental setting, complete
characterization of graft proliferation, survival, migration and differ-
entiation capacity requires extensive work. Although immunohisto-
chemistry remains fundamental in this regard, another strategy,
allowing long-term monitoring of grafts non-invasively, is neuro-
imaging. Magnetic resonance imaging (MRI) offers the important
advantage over other imaging modalities of high spatial resolution,
and grafted stem cells have been successfully monitored in vivo when
labeled with contrast agents, such as superparamagnetic iron oxide
(SPIO) nanoparticles (Hoehn et al., 2002; Bulte et al., 2003; Stroh
et al., 2005; Guzman et al., 2008). Some groups are also currently
employing this approach in vivo to look at grafted human fetal-derived
NSCs (Guzman et al., 2007; Neri et al., 2008). Even clinical Phase I
application of human NSCs has been discussed for the treatment of
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neuronal ceroid lipofuscinosis. However, despite the popularity of iron
oxide-based labels, most studies have examined whether these agents
alter the specific characteristics of the stem cells only over short,
subacute periods, rather than over chronic periods. There is also much
debate as to the actual specificity of the signal observed in the
magnetic resonance images, whether iron oxide particles are lost over
time or whether the cells are removed by phagocytic activity.
The aims of the present study were: (i) to carefully assess the
optimal labeling strategies with SPIO particles for minimization or
exclusion of label influence on human striatal NSCs in vitro; (ii) to
quantitatively analyse the long-term behavior of the cell phenotype
and tolerance of the intracellular label in vivo after transplantation into
rat brain; (iii) to observe the spatio-temporal and functional dynamics
of the cells up to 4 months, using in vivo tracking by MRI of
intrastriatally grafted human striatal NSCs; and (iv) to correlate MRI
findings with standard post-mortem immunostainings and histological
methods.
Materials and methods
Culturing of human NSCs
Striatal tissue was obtained from an 8-week-old aborted human fetus
from Malmo¨ ⁄ Lund University Hospitals, according to the guidelines
approved by the Lund ⁄Malmo¨ Ethical Committee. The characteriza-
tion of neurosphere-expanded NSCs from human fetal striatum has
been described in detail elsewhere (Kallur et al., 2006). Briefly, after
microdissection and dissociation of the striatal tissue, cells were
maintained at 37 !C in a humidified atmosphere with 5% CO2. The
expansion medium (DMEM ⁄ F-12; Gibco, Grand Island, NY, USA;
l-glutamine, 2.92 g ⁄ 100 mL; HEPES, 23.8 mg ⁄ 100 mL; NaHCO3,
7.5%; glucose, 0.6%; and heparin, 2%, all from Sigma-Aldrich,
Hamburg, Germany) contained N-2 supplement (1%; Gibco), human
leukemia inhibitory factor (10 ng ⁄mL; Sigma-Aldrich), epidermal
growth factor (20 ng ⁄mL) and fibroblast growth factor (10 ng ⁄mL
(both from Peprotech, Hamburg, Germany).
Labeling cells with MRI contrast agent
SPIO nanoparticles (stock solution 11.2 mg Fe ⁄mL; Endorem";
Guerbet, France) at a concentration of 56, 168, 280 or 560 lg Fe ⁄mL
(5, 15, 25 or 50 lL ⁄mL; Endorem) of medium were added 4 days
after the last passage directly to the NSC culture medium and
incubated overnight. Subsequently, the cell suspension was spun down
at 181 g for 5 min, the pellet was washed twice and finally
resuspended in fresh medium. Labeled cells were either replated in
culture flasks or kept on coated chamber slides.
Determination of detectability and dilution of contrast agent
To determine detectability limits with MRI, the SPIO-labeled neur-
ospheres were spun down, washed in potassium phosphate-buffered
saline (KPBS), fixed with 4% paraformaldehyde (PFA), washed again
and resuspended in KPBS. The fixed, labeled neurospheres were
injected at different cell concentrations into phantoms comprising 3%
gelatin in small, custom-made 22-mm cups, and were subsequently
scanned with MRI.
Dilution of the label through cell division was also examined.
Labeled neurospheres were centrifuged, washed and replated in
culture flasks for 1 week. Thereafter, the spheres were either prepared
as phantoms and scanned, or plated on poly-l-lysine (PLL; Sigma)-
coated eight-well chamber slides, immediately fixed with 4% PFA and
stained with Prussian Blue (PB) for the presence of intracellular iron
deposits. Additionally, dilution of label upon cell differentiation was
examined by plating and differentiating SPIO-labeled neurospheres on
coated chamber slides for 1 week.
Cell preparation for transmission electron microscopy
Cells were fixed in 3% glutaraldehyde in 0.1 m Soerensen’s phosphate
buffer for 22 h, washed with the same buffer overnight, embedded in
2% agarose, followed by 1 h in 1% OsO4 in 17% sucrose buffer,
rinsed with distilled water and dehydrated with increasing concentra-
tions of ethanol. Finally, cell samples were embedded in Epon (Fluka;
Sigma), polymerized for 8 h at 37 !C and 56 h at 60 !C, and cut into
70–100-nm-thick slices. The samples were analysed with a Philips EM
400 T (Philips) at 60 kV and photomicrographs were taken with a
CCD camera (Olympus).
Assessment of label influence on cell survival, proliferation and
differentiation
Cell viability was determined in culture by the trypan blue exclusion
method before, shortly after and at 7 days after labeling with SPIOs.
For determination of the cell phenotypes within the proliferating
culture, SPIO-labeled neurospheres were plated on PLL-coated eight-
well chamber slides, allowed to attach for 3 h, then fixed and
processed for immunocytochemistry. For determination of cell differ-
entiation capacity, growth factors were removed and 1% fetal bovine
serum (Gibco) was added. Labeled cells were differentiated for up to
18 days, then fixed and subsequently stained. Medium was changed
every third day during experiments.
Transplantation procedures
All animal experiments were conducted according to the guidelines
laid out in the German Animal Welfare Act, in accordance with the
European Communities Council Directive 86 ⁄ 609 ⁄ EEC, and were
approved by the local authorities.
Human NSC cultures (passage 21) were labeled with SPIOs as
above. On the day of transplantation, SPIO-labeled neurospheres
(diameter !100 lm) were centrifuged and resuspended in Hank’s
Balanced Salt Solution (Gibco). The neurosphere suspension had a
concentration of approximately 100 000 viable cells ⁄ lL and was kept
on ice during the entire transplantation procedure. To assess that the
hypointensity in T2*-weighted MRI is due to the SPIO-labeled cells
and not due to the implantation process itself, we performed one
control experiment in which cells were treated identically, but labeled
with a substance (CELSENSE 1000; Celsense, Pittsburgh, PA, USA)
inert to T2*-weighted images.
Twenty-two neonatal (postnatal day 3) Sprague–Dawley rats
(Janvier, France) were anesthetized by lowering body temperature
to 1–3 !C and placed in a cooled Cunningham’s stereotaxic frame
with skull surface aligned in the horizontal plane. Using a Hamilton
syringe, the neurosphere suspension (1 lL) was injected unilaterally
into the right striatum at the following coordinates: 0.5 mm anterior
and 2.1 mm lateral to bregma and 3.0 mm from the brain surface.
After injection, the needle was kept in place for 5 min. The wound
was closed and animals were resuscitated. Litters were kept together
with the mother until weaning, and all animals were housed under a
12 ⁄ 12-h light–dark cycle with ad libitum access to food and water.
The rats were perfused at 3 (n = 4), 6 (n = 8; one was control
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animal) and 16 (n = 7) weeks after transplantation. One animal
received cells pre-labeled with a proton-non-sensitive label as sham
control. This was performed to exclude T2*-weighted hypointensity
caused by bleeding from the needle insertion or from air pockets
generated in the course of the cell injection. No cyclosporine
A (CsA) was applied as the immune system was not fully developed
at the time of grafting. Furthermore, we decided against CsA
treatment because we wanted to monitor the cell behavior in a naı¨ve
environment.
MRI acquisition
High-resolution magnetic resonance images were acquired on a
Biospec 11.7-T ⁄ 16-cm dedicated animal scanner system (Bruker
BioSpin, Ettlingen, Germany) equipped with actively shielded
gradient coils (BGA9S, 750 mT ⁄m); Bruker). In vitro MRI was
carried out with a 25-mm single-loop surface coil in transmit ⁄ receive
mode and a three-dimensional (3D) gradient echo fast low-angle
shot (FLASH) sequence: field of view (FOV) = 22 mm2 · 0.88 mm,
matrix = 5122 · 128, TE ⁄ TR = 7 ms ⁄ 200 ms, flip angle (FA) = 30!,
number of averages = 2, with a total acquisition time (TA) of 7:17 h.
For in vivo MRI, animals were anesthetized and maintained with 1–
2% isoflurane in a 70 : 30 nitrous oxide ⁄ oxygen mixture. Respiration
rate was monitored using a pressure-sensitive pad placed under the
thorax together with Dasylab (Germany) software; body temperature
was maintained by an in-house feedback control system. Animals
were fixed with ear bars in standard animal holders (Bruker).
Radiofrequency transmission was achieved with a birdcage quadrature
resonator coil (72 mm diameter) and the signal was detected with
quadrature mouse and rat brain surface coils (Bruker) depending on
the size of the animals. The imaging protocol consisted of an isotropic
3D FLASH sequence: FOV = 19.2 mm3, matrix = 963, TE ⁄ TR =
3.9 ms ⁄ 100 ms, FA = 15!, TA = 15:21 min; a 2D multi-gradient echo
(MGE) sequence: 20 contiguous 0.6-mm slices, FOV = 19.2 mm2,
matrix = 1282, TE ⁄ TR = 3.5 ms ⁄ 4000 ms, 32 echoes, FA = 30!,
TA = 8:32 min; a 2D multi-slice multi spin echo (MSME) sequence:
geometry and resolution identical to MGE, TE ⁄ TR = 10.25
ms ⁄ 4000 ms, 16 echoes, TA = 8:32 min; and a 2D FLASH sequence:
16 contiguous 0.6-mm slices, FOV = 19.2 mm2, matrix = 2562,
TE ⁄ TR = 6 ms ⁄ 400 ms, FA = 30!, TA = 6:49 min.
Image postprocessing and data analysis
MR images were processed to calculate quantitative parameter maps
with a home-written software program written in IDL (ITT Visual
Information Solutions, Boulder, CO, USA). The MRI signal S(TE) in
MSME ⁄MGE scans was fitted on a voxel basis with a monoexpo-
nential decay S(TE) = A*exp()TE ⁄ B) + C with equilibrium signal A,
relaxation time B = T2 (T2
*) for the MSME (MGE) sequence, and an
offset C to reduce bias introduced by the use of power images (Miller
& Joseph, 1993).
Regions of interest (ROI) analysis of the quantitative maps was
performed with the freeware program imagej (http://rsbweb.nih.gov/
ij/). The slice exhibiting strongest T2 and T2
* effect was selected, and
an area containing cells was segmented semi-automatically based on a
T2
* threshold of 10 ms. The resulting ROI was mirrored to the
contralateral side, and the relative changes of mean T2 and T2
* in the
ipsilateral ROI compared with the contralateral one were averaged
over all animals. 3D reconstructions of the grafts were performed with
the software package Amira (Mercury Computer Systems, Chelms-
ford, MA, USA) based on hypointensity in the 3D FLASH images.
The FLASH 3D image was mirrored horizontally, registered to the
original dataset with fmrib Software Library (FSL; http://www.fmrib.
ox.ac.uk/fsl/) and subtracted from the original. The image obtained, in
which the contrast of labeled cells compared with the (mirrored) non-
grafted contralateral side was expressed as a clear hyperintensity, was
then used for manual segmentation.
Immunocytochemistry and histology
Cells were fixed in 4% PFA for 15 min at room temperature followed
by three rinses in KPBS. For staining of tissue sections, animals were
deeply anesthetized and perfused transcardially with saline followed
by 4% PFA. Brains were post-fixed overnight and then kept in 20%
sucrose solution until they sunk. Forty-micrometer-thick sections were
cut in the coronal plane using a freezing microtome (Leica, Germany),
and kept at )20 !C in cryo-protective solution. Before immunostain-
ing, cells and tissue sections were pre-incubated in 5% normal serum,
and 0.025 and 0.25% Triton X-100, respectively, in KPBS for 45 min
at room temperature. Incubation in primary antiserum was carried out
overnight at +4 !C and the following primary antibodies were used –
mouse monoclonal anti-b-III tubulin (Cat. No. T8660; 1 : 333; Sigma-
Aldrich, Lee & Pixley, 1994), mouse monoclonal anti-dextran (Cat.
No. 01403; DX-1; 1 : 100; StemCell Technologies, Vancouver, BC,
Canada, Guzman et al., 2007), goat polyclonal anti-doublecortin (Cat.
No. sc-8066; DCX; 1 : 400; Santa Cruz Biotechnologies, Santa Cruz,
CA, USA, Rao & Shetty, 2004), mouse monoclonal anti-rat CD-68
(Cat. No. MCA341R; ED-1; 1 : 2000; AbD Serotec MorphoSys AbD,
Du¨sseldorf, Germany, Graeber et al., 1990), rabbit polyclonal anti-
GFAP (Cat. No. Z0334; 1 : 500; DakoCytomation, Glostrup, Den-
mark), mouse monoclonal anti-GFAP (Cat. No. G6171; 1 : 400;
Sigma-Aldrich, Reeves et al., 1989), mouse monoclonal anti-human
nucleus (Cat. No. MAB1281; HuNu; 1 : 100; Chemicon, Temecula,
CA, USA, Vescovi et al., 1999), rabbit polyclonal anti-Ki67 (Cat. No.
ab15580; 1 : 500; Abcam, Cambridge, MA, USA, Scholzen &
Gerdes, 2000) and rabbit polyclonal anti-human nestin (Cat. No.
AB5922; 1 : 500; Chemicon; Hockfield & McKay, 1985). Primary
antibodies were detected using appropriate fluorescent Cy3 (Jackson
ImmunoResearch) or biotin-conjugated (Vector Laboratories) second-
ary antibodies (1 : 200), which were then detected with Alexa 488-
conjugated streptavidin (1 : 200; Molecular Probes). To determine the
specificity of the primary antibodies and the level of background
generated from the secondary antibodies, in one well per in vitro-
staining the primary antibodies were omitted as a negative control and
in vivo a negatively stained control section was included. For double
labeling, only one biotinylated secondary antibody was used at a time.
For nuclear staining, Hoechst 33342 (1 : 1000; Molecular Probes) was
added during final incubation with secondary antibodies. Sections
were mounted on PLL-coated slides (Thermo Fisher Scientific,
Germany) and slides coverslipped with glycerol-based mounting
medium.
For PB staining, fixed cells and sections were washed with KPBS
and incubated for 10 min in 10% potassium ferrocyanide [K4Fe(CN)6]
solution and then for 20 min in 4% HCl and 4% K4Fe(CN)6 (2%
Perl’s solution). Following PB incubation, the fixed cells and sections
were rinsed with water and coverslipped with Entellan (Merck,
Darmstadt, Germany). For standard chromogenic visualization,
endogenous peroxidase activity was quenched with KPBS containing
1% H2O2 and 10% methanol. After consecutive rinses, sections were
incubated with primary antibodies overnight. The following day,
sections were incubated with biotinylated secondary antibodies and,
after subsequent rinses, were incubated with an avidin–biotin complex
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(Elite ABC kit; Vector), and developed by intensified reaction with
diaminobenzidine (DAB; Sigma).
Cell quantification and statistical analysis
Quantification of grafted cells in the striatum was carried out in all brain
slices with visible grafts under a 40· objective on a Leica TCS SP2
microscope equipped with a supplementary CCD camera (Leica
Microsystems,Wetzlar, Germany). In vitro cell counting was performed
on 20 randomly chosen fields, counting both total cell number and cells
positive for the protein of interest. Each well was evaluated separately
and at least eight wells per staining were counted. Double-immuno-
reactivity was verified with confocal laser scanning microscopy.
Differences between in vitro SPIO-labeled cells with different
concentrations of Endorem and control cells were evaluated with one-
way analysis of variance (anova) followed by post-hoc pairwise
comparison with a Bonferroni ⁄Dunn correction for multiple compar-
isons. Analysis of the ROI data across all four time points was
performed using a two-way repeated-measures anova using both time
and hemisphere (ipsilateral and contralateral to the graft) as the
independent within-subject measures. Evaluation of the quantitative
3D reconstruction was performed by one-way repeated-measures
anova with a Greenhouse ⁄Geisser correction if sphericity was
violated. Differences between grafted cells at the early and late time
point after transplantation were evaluated with Student’s unpaired
t-test. Data are expressed as means ± SEM and differences are
considered significant at P < 0.05.
Results
Determination of contrast agent concentration, detectability and
dilution in vitro
Human NSCs were readily labeled with both a low (5 lL Endo-
rem ⁄mL) and a high (50 lL Endorem ⁄mL) concentration of SPIOs,
without the need of lipofectant agents (Fig. 1A–D). The intracellular
localization of the iron deposits was clearly visualized as electron-
dense inclusions in the cytoplasm by transmission electron microscopy
(Fig. 1E and F). To assess the detectability of the cells by MRI as a
function of the number of cells, or of differences in the concentration
of SPIOs in the culture medium, we scanned phantoms loaded with
labeled, fixed human NSCs. Higher cell numbers were easily detected
as they produced greater signal changes in the images. However, small
changes in SPIO concentration within a constant number of cells did
not appear to produce distinguishable differences in signal changes in
the images (Fig. 2A). The detection limit in vitro was estimated from a
dilution series using the same phantoms. These experiments, per-
formed under ideal in vitro conditions, showed that as little as
approximately 500 cells labeled with 50 lL ⁄mL could be detected
A B
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Fig. 1. Incorporation of SPIO nanoparticles by human striatal NSCs. Photo-
micrographs of Prussian Blue (PB)-stained human NSCs labeled either with
5 lL (A and B) of Endorem (56 lg Fe ⁄mL) or 50 lL (C and D) of Endorem
(560 lg Fe ⁄mL). Images were acquired with phase contrast (A and C) and
bright field (B and D) microscopy. The PB+ cells contain several punctate
regions of blue deposits (B and D) that correspond to iron in endosomes as
illustrated by transmission electron microscopy images (E–G). The boxed area
in E depicts one SPIO-labeled human cell in F, and the boxed area in F shows
cytosolic deposition of SPIO nanoparticles in G. White asterix indicates the
nucleus. Scale bars in B and D = 50 lm and the scale bar (G) in E = 5 lm,
F = 3 lm and G = 220 nm. For interpretation of color references in figure
legend, please refer to the Web version of this article.
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Fig. 2. (A) Detectability of SPIO-labeled NSCs. MR images of a phantom
containing different amounts of NSCs (50 000 or 15 000) labeled with different
concentrations of Endorem (25, 15 and 5 lL). Note – the amount of SPIO-
labeled cells in the white circles was easily distinguished, but there appeared to
be no differences in the signal intensities between the different doses of contrast
agent employed. Cells without contrast agent (Ctrl) did not result in any
hypointensity in the MR images (A). (B) Phantoms containing different
amounts of cells labeled with 15 lL Endorem revealed that the detection limits
of MRI was around 500 cells. Upon differentiation, the cells labeled with
Endorem (15 lL) maintained the incorporated SPIO particles in the endo-
somes, as shown by PB (C and D), and anti-DX-1 (green) for the dextran
coating of the SPIOs and Hoechst (blue) staining for cell nuclei (E and F).
Arrows depict examples of PB-stained cells and arrowheads the few, non-
stained cells. Scale bars = 50 lm. For interpretation of color references in
figure legend, please refer to the Web version of this article.
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(Fig. 2B) and thus provided a lower threshold of cell number
necessary for detectability (under ideal conditions).
Furthermore, to investigate whether differentiation of the cells
resulted in loss of the SPIO-label, the human NSCs were allowed
to differentiate for up to 6 days in vitro. After fixation and
subsequent staining, in both cases it was clear that the label had
remained within the cells, and the cells with SPIO particles were
distributed evenly over the entire surface area in the chamber wells
(Fig. 2C–F).
Effect of contrast agent-labeling in vitro
To determine whether the cellular phenotypes and the ratio of
proliferating and apoptotic cells within the labeled cultures were
influenced by incorporation of contrast agent or by the concentration
of contrast agent, detailed quantifications of the immunostainings were
performed. Quantification of the proliferating cultures revealed that, of
the total number of cells, around 80% were nestin+ (Fig. 3A and B),
20–25% were GFAP+ (Fig. 3D and E) and 3% were b-III tubulin+
(Fig. 3G and H), and these percentages were not significantly different
between the different concentrations of contrast agent nor from
unlabeled control cell conditions. Moreover, the ratio of dead or dying
cells exhibiting pyknotic or fragmented nuclei (as judged with Hoechst
nuclear dye) was only around 5% (Fig. 3J and K) and the number of
Ki67+ cells was 65% (Fig. 3M and N), irrespective of group.
In addition, cell viability was determined before and after labeling
either directly or at 7 days and compared with unlabeled control cells, as
a ratio of living cells out of the total number of living and dead cells
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Fig. 3. Effect of label on cell phenotypes. Quantitative measurement of the cell phenotypes present in SPIO-labeled compared with non-labeled naı¨ve human NSC
cultures and neural phenotypes generated after in vitro differentiation of labeled and non-labeled cells (percentage of total number of cells ± SEM) (A–I) (light grey
bars, 5 lL; gray bars, 15 lL; black bars, 25 lL Endorem; white bars, non-labeled control cells). Percentage of nestin+ (A), GFAP+ (D) and b-III tubulin+ (G) cells
during proliferation and after 18 days of differentiation of the cultures. Photomicrographs of the labeled cells illustrate the nestin+, GFAP+ and b-III tubulin+ cells
during proliferation (B, E and H) and after differentiation (C, F and I). The differentiated labeled neural cells, irrespective of label concentration, appeared
morphologically similar to the non-labeled control cells. The percentage of cells with shrunken, rounded or fragmented nuclei (J) was similar overall, and is
illustrated during proliferation (K) and after differentiation (L) with higher magnification insets in the respective images. The number of Ki67+ cells (M) and
representative images acquired from proliferation (N) and after differentiation of the cells (O). Scale bar = 50 lm.
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counted by trypan blue exclusion. Prior to labeling the mean viability
was 95.2 ± 2.4 and 93.0 ± 1.5% of the control batch and of the batch for
later labeling, respectively. Immediately after labeling it was
92.9 ± 3.8% for the control and 85.6 ± 3.1% for the labeled batch. At
7 days post-labeling, we observed 87.0 ± 0.4 and 88.0 ± 0.8%of viable
cells for non-labeled control and SPIO-labeled cultures, respectively.
To investigate if the differentiation capacity of the human NSCs
incubated with contrast agent was affected, quantification of the neural
phenotypes generated after 18 days of differentiation was performed.
As expected, the number of nestin+ cells was dramatically decreased
from 80% in all SPIO-labeled differentiated groups to around 4%
following differentiation. However, cultures labeled with 15 lL
Endorem contained significantly less nestin+ cells than the unlabeled
control cells (F3,39 = 6.38, P = 0.0013; Fig. 3A and C). The number
of GFAP+ cells decreased (from approximately 25%) to around 15%
in all groups, and the group labeled with 5 lL Endorem had
significantly more GFAP+ cells than the unlabeled control group
(F3,35 = 9.07, P = 0.0001; Fig. 3D and F). In comparison, after
differentiation there were high numbers of b-III tubulin+ cells,
approximately 20–25%, in all groups compared with the proliferation
experiments (< 10%), with more generated in the group labeled with
15 lL Endorem (Fig. 3G and I). The proportion of dead or dying cells
was similar to what was observed in the proliferation experiments
(Fig. 3J and L). The number of Ki67+ cells in all differentiated groups
decreased (from approximately 65%) to around 30% (Fig. 3M and O).
However, despite the overall decrease of Ki67+ cells, the only group
with a comparable proportion of Ki67+ cells to the unlabeled control
group was the cells labeled with 15 lL Endorem. The other two
groups contained significantly more Ki67+ cells after differentiation
compared with the control group (F3,35 = 9.86, P < 0.0001).
Altogether, the contrast agent did not seem to severely alter the
in vitro character of the human striatal NSCs. However, due to the
smaller proportion of nestin+ and Ki67+ and larger proportion of b-III
tubulin+ cells generated after differentiation, the following in vivo
experiments were conducted with a cell labeling concentration of
15 lL Endorem ⁄mL culture medium.
Qualitative and quantitative longitudinal MRI of transplanted
human neural stem cells
To monitor long-term dynamics of labeled human NSCs in vivo, we
transplanted the cells homotopically into the striatum of neonatal rats
and imaged the animals repetitively at 3, 6, 12 and 16 weeks post-
transplantation. At all time points and in all animals scanned, a
hypointense signal in the striatum was observed at the cell injection
site (Fig. 4). In comparison, when grafting an animal with human
NSCs labeled with a non-proton-based contrast agent, no hypointense
signal at the site of implantation was detected (Fig. 4; bottom), thus
confirming that the observed signal change in the striatum was
produced from the SPIO label and was not an artifact introduced by
the transplantation procedure itself.
Both T2- and T2
*-maps were calculated at all time points (Fig. 5A–
D). ROI selection and subsequent analysis revealed a significant effect
of time (F3,18 = 210, P < 0.0001) and hemisphere (F1,6 = 244,
P > 1.0001) in the T2-images. T2 values decreased over time both
ipsi- and contralateral to the graft, specifically between 3 and 6 weeks
post-transplantation (Fig. 5E). This is considered as due to changes in
relaxivity of the brain during development (Prayer et al., 1997). T2
values were also consistently lower in ROIs in the ipsilateral vs.
contralateral hemisphere. No effect of time was detected in the T2
*
values (F3,18 = 2.46, P = 0.096; Fig. 5E and F). However, the
susceptibility sensitive T2* effects of the iron oxide nanoparticles
produced a substantial decrease in T2* relaxivity in the ipsilateral
hemisphere; a significant effect was observed (F1,6 = 7200,
P < 0.0001; Fig. 5F).
By visual examination of the hypointense areas on the MR images,
we could not detect any substantial migration of the grafted human
cells at the four time points. To estimate eventual migration or
movement of the grafted human NSCs into the naı¨ve brains, we co-
registered the 3D-FLASH datasets from all time points (Fig. 6A–D).
First visual inspection revealed that not only was the volume and
location of the graft similar at 3 (Fig. 6E), 6 (Fig. 6F), 12 (Fig. 6G)
and 16 (Fig. 6H) weeks, but the size of the graft in relation to the
overall volume of the brain appeared comparable (Fig. 6I). In contrast,
A
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E
Fig. 4. Imaging time course of the human cell grafts. FLASH 3D images showing one representative animal grafted with SPIO-labeled human NSCs and scanned at
3 (A), 6 (B), 12 (C) and 16 (D) weeks. The montage for each time point consists of ten consecutive 200-lm-thick slices that were judged to contain the majority of
the hypointense area in the right striatum. Arrows identify the areas in six slices at all four time points. An animal transplanted with human NSCs labeled with a non-
proton-based contrast agent was scanned at 6 weeks (E). No hypointensity was detected at the site of implantation. Note – at 3 weeks post-transplantation a mouse
surface coil was used which has lower penetration depth (and thus the signal-to-noise ratio is much higher dorsal than ventral) than the larger rat surface coil used at
the other time points.
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quantitative analysis of the 3D reconstructions at the four time points
revealed that the absolute volume of the grafts decreased gradually
over time from 3.8 mm3 at 3 weeks to 2.2 mm3 at 16 weeks post-
transplantation (F1.3,7.7 = 9.30, P = 0.014) (Fig. 6J and K). At the
same time, the brains all increased in volume, especially between 3
and 6 weeks (from 659 to 899 mm3), due to rat brain development,
and continued to increase further to 925 mm3 at 16 weeks
(F3,18 = 60.7, P < 0.0001; Fig. 6K). After correction for the increas-
ing brain volume it was evident that the relative graft to brain volume
therefore also decreased over time, from 5.79& at 3 weeks to 2.41&
at 16 weeks (F1.2,7.2 = 20.4, P = 0.002; Fig. 6K).
Survival and fate of SPIO-labeled human NSCs after
transplantation
To investigate the survival and fate of the transplanted SPIO-labeled
human NSCs, animals were killed at 3 and 6 weeks (early; data were
pooled), and 16 weeks (late) after transplantation. Thereafter, double
immunofluorescence labeling was performed with anti-HuNu, for all
grafted human cells, in combination with neural- and proliferation-
specific markers. Quantification of the total number of HuNu+ cells
revealed that survival of the grafted cells was 14.1 ± 2.6 and
6.8 ± 2.8% at the early and late time points after transplantation,
respectively. The difference in survival between both time points was
not statistically significant (t14 = 1.9, P = 0.08). At all time points, PB
staining was present around the site of injection in all the animals
(Fig. 7B, E, I and G), corresponding both to the hypointense regions
detected by MRI (Fig. 7A, D and H) and to the location of the HuNu+
grafted cells (Fig. 7C, F and J). Furthermore, iron deposits stained
with PB were always found within the cytoplasm of cells and never
appeared to be non-specifically located in the brain parenchyma
(Fig. 7G). These results indicated that the hypointense areas seen by
MRI were an effect produced by intracellularly located SPIO
nanoparticles.
To investigate the potential contribution of rat host cells to the
intracellularly located contrast agent, we performed additional stain-
ings for ED1+-activated microglia ⁄macrophages. Overall activation
was low (Fig. 7K, M and O), but both early (3 weeks) and late
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Fig. 5. Sensitivity of the different sequences to the grafted human cells. Montages of images acquired with a high-resolution FLASH 2D, MSME (and
corresponding quantitative T2 maps) and MGE sequences of an animal at 3 (A), 6 (B), 12 (C) and 16 (D) weeks after transplantation of SPIO-labeled human NSCs.
T2 values (ms) for the T2 maps are indicated in the color scale bar below the images. The montages at each time point consist of five consecutive 600-lm-thick slices,
with the slice containing the largest region of hypointensity as the center image. Quantitative T2 (E) and T2* (F) values obtained from the ROI analysis in the
ipsilateral (black bars) and contralateral (clear bars) hemispheres across all time points. There was a significant effect in the T2 images of time (P < 0.0001) and
hemisphere (P > 1.0001).
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(16 weeks) after transplantation there were slightly more ED1+ cells
in the grafted than the non-grafted hemisphere (Fig. 7L, N and P).
Around the injection tract there were a few ED1+ cells with amoeboid
morphology (Fig. 7M and O) and only one or two of these were
somewhat close to PB+ deposits (Fig. 7Q). The majority of the ED1+
cells were located adjacent to the graft location in or around blood
vessels (Fig. 7L, N and P). No cells were observed that were both
HuNu+ and ED1+. By contrast, HuNu+ cells were consistently in
close proximity to PB+ blue deposits (Fig. 7R).
At the early time point after engraftment, of the total number of
HuNu+ cells, approximately 14% were nestin+ (Fig. 8A–D), 13%
were GFAP+ (Fig. 8E–H) and 12% were DCX+ (Fig. 8I–L). At the
late time point after transplantation, the percentage of grafted nestin+
and GFAP+ cells remained at similar levels, around 16 and 11%,
respectively (Fig. 8A–H). By contrast, the proportion of DCX+
grafted human cells significantly decreased over time to approximately
6% (t14 = 2.6, P = 0.0224; Fig. 8I–L). To determine whether the
SPIO-labeled human cells continued to proliferate after engraftment,
the sections were double-stained for HuNu and Ki67. Only approx-
imately 0.5% of the grafted human cells were positive for Ki67,
irrespective of early or late after transplantation.
Discussion
The present investigation is the first to have comprehensively both
determined the influence of SPIO-labeling on human striatal NSCs
both in vitro and in vivo on a long-term basis, and characterized graft
evolution with quantitative MRI post-processing tools. The results
from this comprehensive investigation are of interest because human
NSCs are considered the ideal source for cell replacement therapy of
cerebral lesions. Potential applications span from neurodegeneration
and stroke (Lindvall & Kokaia, 2006; Darsalia et al., 2011) to neural
ceroid lipfuscinosis (Guillaume et al., 2008; Selden et al., 2008). For
all such applications, the profile of the long-term viability and cell
characteristics is essential to assess whether the cells can perform their
expected role in network re-formation or as a supportive role through
protein secretion. For this purpose, we show here that quantitatively
the labeling of human striatal NSCs with SPIO particles does not
influence the short-term proliferation, survival or differentiation
capacities of the human cells in vitro. Second, we can easily detect
a hypointense area in the intact rat striatum up to 4 months after
intrastriatal transplantation, and quantitative measures imply that both
degree of hypointensity as well as volume change over time. Third, we
have correlated our MRI findings with histology, thus confirming that
the MRI hypointensity is indeed produced by cells containing iron
oxide particles and not by free particles within the parenchyma. In
addition, we performed extensive double immunostainings to deter-
mine not only cell viability, but also the proportion of grafted SPIO-
labeled cells that differentiated into various neural lineages at an early
and late time point after transplantation. The methods described here
are important tools for non-invasive, longitudinal evaluation of graft
survival and migration, while the results provide the essential
prerequisite information for further transplantation studies in animals
with neurological lesions.
Effect of MRI label on cell characteristics
The ability to follow the status and location of grafted human cells in
animal models of disease with MRI is important for the future
application of stem cell-based therapies. To visualize the cells, they
need to be labeled with an MRI contrast agent. Although there are
many available contrast agents with different chemical compositions
and magnetic properties (Geraldes & Laurent, 2009), the most
popular choice for ex vivo cell labeling followed by in vivo detection
are SPIO nanoparticles (Hoehn et al., 2002; Bulte et al., 2003;
Magnitsky et al., 2005; Stroh et al., 2005; Guzman et al., 2008;
Li et al., 2010). However, the vast majority of these studies have
been performed on rodent-derived stem cells, which is a disadvan-
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Fig. 6. Estimated volume of human cell grafts over time. Coronal FLASH 3D images (A–D) of a representative animal illustrating the grafted human NSCs and
corresponding 3D reconstruction and surface rendering from high-resolution FLASH 3D images at 3 (E; yellow), 6 (F; green), 12 (G; blue) and 16 (H; red) weeks
after transplantation. (I) A compilation of the grafted cells at all four time points with respective color code maintained. Note the similar volume and shape of the
grafts from 3 to 16 weeks. (J) Quantitative analysis of all animals across the four time points (n = 7) shows a gradual decrease in the absolute graft volume over time
(P = 0.014). (K) Absolute values for both graft and brain volume and the relative size of the graft as per mille (&) of the brain volume at 3, 6, 12 and 16 weeks after
grafting. Note the decrease of both absolute and relative graft volume over time, and the substantial increase in brain volume especially between 3 and 6 weeks after
transplantation. For interpretation of color references in figure legend, please refer to the Web version of this article.
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tage given that human stem cells are the most clinically relevant
source for cell replacement therapy. Furthermore, many studies lack
thorough analysis of the effects of the labeling on the properties and
fate of the cells as well as the MRI data obtained. Even though the
SPIO nanoparticles are composed of biodegradable iron that can,
theoretically, be recycled by the normal biochemical pathways for
iron metabolism (Arbab et al., 2003; Pawelczyk et al., 2006), there
have been reports of incorporated SPIO particles affecting the
biology of mesenchymal stem cells (Kostura et al., 2004). Our
in vitro analysis of the labeled human cells revealed that compared
with the non-labeled control cells, there were no differences in the
general biological characteristics of the cells during proliferation
irrespective of the amount of Endorem used for labeling. These
results concur with previous reports showing that incorporation of
SPIO particles does not affect short-term survival, proliferation, and
multipotency or differentiation capacity of NSCs (Guzman et al.,
2007; Neri et al., 2008). However, after long-term (18 days) in vitro
differentiation, some changes appeared in both the proportion of
neural phenotypes generated as well as in the number of proliferating
cells in some of the labeled cultures as compared with non-labeled
control cell cultures. This could be caused by a delayed toxicity due
to iron overloading, which leads to cellular stress responses that may
have effects on cell characteristics (Glei et al., 2002; Knobel et al.,
2006), manifested only after longer experimental times. Therefore,
for the continued in vivo experiments we chose the labeling
concentration that, under our experimental conditions, introduced
almost no changes compared with the control.
Profile of the graft over time
After transplantation of the SPIO-labeled human NSCs into the non-
neurogenic striatum of naı¨ve neonatal rats, we performed repetitive
MRI for up to 4 months. Detailed quantitative analysis of the 3D
A
H I J K L
M N
O
Q
R
P
DB E
F
G
C
Fig. 7. Location of grafted human cells and iron deposits analysed on post-mortem tissue sections correspond to the hypointensity observed at all time points by
MRI. MR images obtained at 3 weeks (A; sagittal view), 16 weeks (D) and 6 weeks (H) after cell implantation with corresponding PB (B, E and I) and HuNu (C, F
and J) stainings on tissue sections. B and C are photomicrographs acquired in the boxed area in A, E and F in D, and I and J (whole graft; images merged) in H. Iron
is deposited in the cytoplasm of cells and not scattered freely in the parenchyma (G) and insets in E show a closer examinated HuNu+ cell (brown) containing iron as
detected with PB (blue ⁄ green). Microglia activation ⁄macrophage infiltration analysed by ED1 staining (K–P) early (K–N) and late (O and P) after transplantation. In
the contralateral hemisphere (K and L) almost no ED1+ cells can be detected, whereas more can be found in the implanted hemisphere (M–P), in which the needle
tract is indicated by a dotted line. (Q) ED1+ cell (inset) in close proximity to PB-stained iron deposits. Note – almost no ED1+ cells were found to contain or were
close to blue stained deposits. By contrast, almost all HuNu+ cells were found to be near PB staining (R). All black lined corner boxes correspond to higher
magnification insets of the delineated area within the same image. Scale bar (E) in B, C, E and F = 100 lm and in G = 50 lm; scale bar (R) in Q and R = 50 lm;
scale bar (I) in J and I = 100 lm; and scale bar (P) in K, M and O = 200 lm and in L, N and P = 100 lm. For interpretation of color references in figure legend,
please refer to the Web version of this article.
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reconstructions of the overall graft volume revealed that the absolute
volume of the grafts decreased over time (from 3.8 to 2.2 mm3), which
was not discernible by simple visual examination of the 3D FLASH
images. As the brains of the developing animals also increased
significantly in volume during this time (from 660 to 930 mm3),
calculation of the relative graft to brain volume revealed a decrease of
around 50% at 16 weeks as compared with at 3 weeks. This is
supported by quantification of numbers of HuNu+ cells in tissue
sections. Early (up to 6 weeks) and late (16 weeks) after transplan-
tation revealed that approximately 14 and 7%, respectively, of the
grafted cells had survived. The overall number of surviving cells is in
agreement with previous studies with same or similar cells (Englund
et al., 2002; Parmar et al., 2003; Kallur et al., 2006) and is consistent
with an earlier study showing 6–10% survival of cells at 4 months
after grafting (Kallur et al., 2006). The observed, slight decrease in
numbers of HuNu+ cells from the early to late time point after
transplantation is also completely within the range of cell survival
reported earlier for these unlabeled cells under otherwise same
conditions (Kallur et al., 2006). Thus, it can safely be excluded that
the decrease in both signal intensity and volume of the grafts was
caused by compromised survival of the SPIO-labeled grafted human
NSCs over time after implantation, although iron-overload has been
shown to induce a stress response that is known to increase the
formation of reactive oxygen species (Glei et al., 2002; Knobel et al.,
2006), thus affecting the survival of cells when challenged long term
under in vivo conditions.
In addition to the overall shrinkage of the graft volume in the MR
images and tissue sections, we found that there was a significant
decrease in the T2 values within the ROI corresponding to the graft
with time after transplantation. Several possibilities exist to explain
this. As a similar trend in T2 decrease was observed in the contralateral
hemisphere, this response must be due to overall changes in relaxivity
that occur as a consequence of brain development, as has been
reported during the initial weeks after birth (Prayer et al., 1997;
Heiland et al., 2002; Bockhorst et al., 2008). Alternatively, cells may
have lost the label passively to the surrounding brain parenchyma, or
the label was diluted through cell proliferation or migration (Arbab
et al., 2003; Guzman et al., 2007). Our analysis of post-mortem tissue
sections showed that almost none of the grafted human cells was
proliferating after engraftment and therefore it is not plausible that the
decline in T2 values was due to loss of label through cell division. It is
conceivable that some cells may have migrated out from the graft core.
Although no obvious hypointensities were observed in other regions
of the brain, if migration occurred it was below the detection limits of
the MRI, as our phantom experiments suggested that the detection
limit was around 500 labeled cells under ideal in vitro conditions
(Bulte & Kraitchman, 2004; Heyn et al., 2005). In vivo cell cluster
size for detectability will be even substantially larger. Thus, we cannot
exclude that a certain fraction of cells evades inclusion in the graft
volume as the cell density at the outer margin of the graft volume may
decrease below detectability threshold due to partial volume effect. To
clarify this aspect, we have decided to speak of an ‘apparent graft
volume’ because of potential lack of cell detection at the outer rim.
However, using microscopy of immunostained tissue sections, we did
not observe many cells that had migrated to areas outside the graft site.
Thus, migration of grafted cells also represents an unlikely explana-
tion for the decline of T2. In conclusion, we believe that the
T2 decrease over time observed from 3 to 16 weeks can be assigned to
development-dependent changes during growth. This is in line with
our relaxometry studies as a function of rat brain age, showing a
relationship between T2 decrease in early life and cortical cell density
(L. Mengler, personal communication).
Of great concern is the notion that activated microglia and
macrophages will engulf dead, labeled cells or iron nanoparticles
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Fig. 8. Cell fate following transplantation of SPIO-labeled human cells into the neonatal rat brain. Percentage of nestin+ (A), GFAP+ (E) and DCX+ (I) grafted
human cells early (3 and 6 weeks) and late (16 weeks) after transplantation. Photomicrographs (B–D, F–H and J–L) of confocal images with orthogonal
reconstruction of grafted human HuHu+ cells (C, G and K), which are double-immunostained with antibodies for nestin (B and D), GFAP (F and H) and DCX (J and
L) at 16 weeks post-transplantation. Scale bar = 10 lm. * indicates significant difference between early and late time points (P < 0.05).
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dispersed freely in the brain parenchyma, and thus contribute to the
MRI signal (Pawelczyk et al., 2008). At the time points analysed by
immunohistochemistry, we found that there were relatively few,
scattered ED1+ cells overall, although more were located in the
grafted hemisphere and almost exclusively associated with blood
vessels. Some were located close to the needle tract, but almost none
was in direct connection to PB+ iron deposits and none was positive
for HuNu. Although we cannot exclude that some of the PB+ cells
were inflammatory, the overall low levels of ED1+ cells in general
suggests that the inflammatory cells were not a major contributor to
the graft-induced hypointensity in the MRI images at all times
(Guzman et al., 2007; Arbab et al., 2008).
Detection of cell death caused by, for example, graft rejection and
clearance of grafted cells by activated, resident microglia or blood
macrophages will always be a major issue when MRI is applied in
future clinical cell transplantation studies. The recipient animals
(postnatal day 3) used in this xenotransplantation study were not
immunosuppressed, as the immune system is not fully developed by
this time (Lund et al., 1987). However, we cannot completely exclude
some rejection of the grafted cells, especially from 18 days and
onwards when the immune system is mature (Lund et al., 1988;
Marion et al., 1990; Kelly et al., 2009). We performed our first MRI
scans and tissue slices from animals that were around 24 days old
(3 weeks after transplantation) and therefore the loss of cells in the
initial phase may have evaded us.
Fate of grafted cells
Quantification of the fate of the grafted human cells showed that both
early and late after transplantation around 20% of the cells were
nestin+ and 10% were GFAP+, whereas the number of DCX+ cells
decreased three-fold over time after transplantation. This is in
agreement with previous studies using these cells in vivo (Kallur
et al., 2006, 2008). Thus, no major changes in the phenotypes
generated in vivo at up to 4 months after transplantation was detected
in response to cell labeling. Importantly, at all the time points
analysed, only a very small fraction of the grafted human cells (around
0.5%) were positive for the proliferative marker Ki67. Proliferative
activity within grafts is always a concern due to risk of tumor
formation, which is unacceptable for the clinical use of stem cell
replacement therapy (Lindvall & Kokaia, 2010).
Conclusions
The semi-quantitative and quantitative tools presented here are more
accurate for the assessment of survival and migration of implanted
cells by MRI than simple visual inspection of MR images. Using these
quantitation tools, the decreasing number of vital cells of the graft,
determined by quantitative immunohistochemistry, is reflected in the
MRI-derived graft volume change. Thus, essential information about
the human cell graft dynamics can be monitored over long periods of
time.
Our study evaluates the long-term effect of SPIO-labeling on the
biology of human NSCs, derived from the fetal striatum, both in vitro
and in vivo. We have carefully determined the optimal choice of
contrast agent amount with the goal not only to optimize short-term
viability of the cells but also to minimize long-term alterations in
phenotypes of labeled cells. Our study suggests that there are only
minor long-term effects of the label on the biology of the cells and that
the labeled cells show a long-term behavior after grafting, comparable
with naı¨ve cells.
Finally, the observed lack of proliferation, detected by a lack of
graft volume increase and confirmed by quantitative immunohisto-
chemistry, is an essential prerequisite for implantation of cells for
therapeutic purposes as it indicates that they do not have the tendency
to form tumors after cerebral engraftment.
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Abstract
Background: Magnetic resonance imaging (MRI) is a promising tool for monitoring stem cell-based therapy. Conventionally,
cells loaded with ironoxide nanoparticles appear hypointense on MR images. However, the contrast generated by ironoxide
labeled cells is neither specific due to ambiguous background nor quantitative. A strategy to overcome these drawbacks is
19F MRI of cells labeled with perfluorocarbons. We show here for the first time that human neural stem cells (NSCs), a
promising candidate for clinical translation of stem cell-based therapy of the brain, can be labeled with 19F as well as
detected and quantified in vitro and after brain implantation.
Methodology/Principal Findings: Human NSCs were labeled with perfluoropolyether (PFPE). Labeling efficacy was assessed
with 19F MR spectroscopy, influence of the label on cell phenotypes studied by immunocytochemistry. For in vitro MRI, NSCs
were suspended in gelatin at varying densities. For in vivo experiments, labeled NSCs were implanted into the striatum of
mice. A decrease of cell viability was observed directly after incubation with PFPE, which re-normalized after 7 days in
culture of the replated cells. No label-related changes in the numbers of Ki67, nestin, GFAP, or bIII-tubulin+ cells were
detected, both in vitro and on histological sections. We found that 1,000 NSCs were needed to accumulate in one image
voxel to generate significant signal-to-noise ratio in vitro. A detection limit of ,10,000 cells was found in vivo. The location
and density of human cells (hunu+) on histological sections correlated well with observations in the 19F MR images.
Conclusion/Significance: Our results show that NSCs can be efficiently labeled with 19F with little effects on viability or
proliferation and differentiation capacity. We show for the first time that 19F MRI can be utilized for tracking human NSCs in
brain implantation studies, which ultimately aim for restoring loss of function after acute and neurodegenerative disorders.
Citation: Boehm-Sturm P, Mengler L, Wecker S, Hoehn M, Kallur T (2011) In Vivo Tracking of Human Neural Stem Cells with 19F Magnetic Resonance Imaging. PLoS
ONE 6(12): e29040. doi:10.1371/journal.pone.0029040
Editor: Christoph Kleinschnitz, Julius-Maximilians-Universita¨t Wu¨rzburg, Germany
Received June 30, 2011; Accepted November 18, 2011; Published December 2 , 2011
Copyright: ! 2011 Boehm-Sturm et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Financial support from the EU grants HEALTH-F5-2008-201842 (ENCITE) and LSHBCT-2006-037526 (StemStroke), and by funds from the German Federal
Ministry of Education and Research (BMBF-0314104) are gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mathias@nf.mpg.de
Introduction
To achieve translation of experimental stem cell-based therapy
into the clinic, non-invasive imaging modalities are necessary tools.
One such modality, magnetic resonance imaging (MRI), provides
true three-dimensional data at high spatial resolution, enabling
good detection of even small cell numbers in the living, intact
individual. Commonly, contrast is achieved through in vitro
labeling of cells with superparamagnetic iron oxide (SPIO)
nanoparticles [1,2,3]. Although even single cells can be detected
[4] with this procedure, the contrast generated by iron oxide
labeled cells can easily be confounded with other sources such as
bleedings or blood vessels [5]. Furthermore, since contrast is
achieved indirectly through disturbances of the local magnetic
field experienced by surrounding hydrogen nuclei, quantification
of the number of cells in vivo is questionable [6].
A rapidly emerging field to overcome these drawbacks of
ambiguity of contrast assignment and cell quantification is cell
labeling with perfluorocarbon (PFC) nano-emulsions, which can
be detected with 19F MRI [7,8,9]. The 19F nucleus is particularly
suitable for labeling as its relative MR sensitivity is only 17% less
than that of 1H. Furthermore, the signal intensity is directly
proportional to the number of accumulated 19F, hence, allowing in
vivo quantification of 19F labeled cells [10]. In addition, since the
level of background 19F signal in host tissue is virtually absent [10],
overlaying the 19F image on an anatomical 1H image allows for
unambiguous, quantitative tracking of labeled cells in vivo.
However, compared to labeling and tracking with metal-based
contrast agents the technique is considerably less sensitive
requiring a large amount of 19F to accumulate in order to
generate sufficient signal-to-noise ratio (SNR).
The strategy of 19F cell labeling has already been applied to
monitor cells during pathological conditions, e.g. umbilical cord
blood cell localization in tumor-bearing mice [11], T-cell
migration in murine models of diabetes [12], and local
inflammation [13]. More recently, PFCs have proven useful in
19F MRI studies of inflammatory response to cerebral and cardiac
ischemia [14] and in vivo measurements of intracellular pO2 of
glioblastoma cells in response to chemotherapy [15].
In experimental models of human neurodegenerative diseases
cell therapies have shown that neuronal replacement and partial
repair of damaged brain circuitry is possible [16]. For a successful
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29040
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clinical translation, only cells of human origin will be needed, and
one source of human cells are neural stem cells (NSCs) [17]. NSCs
derived from the human fetal striatum have been expanded with
both maintained normal karyotype and high capacity to generate
different neuronal phenotypes for a long time in vitro [18,19]. Upon
implantation, these cells survived in the stroke-damaged rat
striatum, migrated towards the injury, and differentiated into
mature neurons without tumor formation [18].
Since these cells represent a relevant cell source for clinical
translation, the purpose of the present study was to establish a
platform to visualize NSCs in vivo after intracerebral implantation
with 19F MRI. Monitoring the spatio-temporal dynamics of
NSCs grafted into the brain requires the ability to detect even
low cell numbers with high spatial resolution, since pathology-
related migration processes of interest may take place on a small
scale, the graft size may be diluted due to these processes or be
initially relatively small. A first report has already indicated that
it is feasible to detect fluorine labeled, immortalized, murine
neural progenitor cells in the healthy mouse brain with 19F MRI
[20]. The current study is the first to show that these results can
be extended to the tracking of human NSCs. Novelties of our
experiments compared to the previous studies on 19F MRI of
stem cells [11,20] include i) the use of a clinically relevant source
of neural stem cells and detection with in vivo 19F MRI in a proof-
of-concept, ii) a conservative estimate of cell detection limits for
preclinical 19F MRI studies of neural stem cell implantation, and
iii) a careful assessment of potential adverse effects of the 19F
marker on cell viability and function both in vitro and in vivo over
a period of at least one week. We show that under optimized
preclinical conditions low numbers of cells can be detected in vivo
at good resolution and within acceptable scan time. Our results
suggest that 19F MRI may prove useful in monitoring implanted
cells in models of neurodegeneration, thus allowing the
optimization of preclinical protocols of graft induced brain
repair.
Materials and Methods
Culturing of human neural stem cells
NSCs were obtained from the ganglionic eminences of an 8-
week old aborted human fetus from Malmo¨/Lund University
Hospitals, according to the guidelines approved by the Lund/
Malmo¨ Ethical Committee. The full characterization of these
NSCs, derived from the human fetal striatum, has previously been
described in detail [19]. Briefly, after microdissection and
dissociation of the striatal tissue, cells were maintained at 37uC
in a humidified atmosphere with 5% CO2. The neurosphere
expansion medium (DMEM/F-12, Gibco, Grand Island, USA; L-
glutamine, 2.92 g/100 mL; HEPES, 23.8 mg/100 mL; NaHCO3,
7.5%; glucose, 0.6%; and heparin, 2%, all from Sigma–Aldrich,
Hamburg, Germany) contained N-2 supplement (1%, Gibco),
human leukemia inhibitory factor (10 ng/mL, Sigma–Aldrich),
epidermal growth factor, 20 ng/mL and fibroblast growth factor,
10 ng/mL (both from Peprotech, Hamburg, Germany).
Labeling cells with 19F marker and determination of
intracellular 19F content
A few hours prior to labeling, the small neurospheres were
transferred to a Poly(2-hydroxyethyl methacrylate) (Poly-HEMA,
Sigma-Aldrich) coated culture flask, in order to avoid strong
attachment of the cells as a consequence of the label. We
incubated cells with 5 mL, 15 mL, 50 mL, 100 mL, and 150 mL of a
perfluoropolyether (PFPE) nano-emulsion (CELSENSE 1000,
Celsense, Pittsburg, USA, 120 mg PFPE/ml, experimentally
determined concentration of magnetically equivalent 19F c=
3.11 M)/mL culture medium to determine the optimal concen-
tration in terms of fluorine uptake. In the end the emulsion was
added at the empirically determined optimal (see Results)
concentration of 100 ml/mL medium 3 days after the last
passage directly to the NSC culture medium and cells were
incubated for 36 hours. Subsequently, the cell suspension was
spun down at 1846 g for 5 min, the pellet was washed twice
and finally resuspended in either fresh medium or potassium
phosphate-buffered saline (KPBS) or Hank’s Balanced Salt
Solution (HBSS), depending on the application.
In order to determine the amount of intracellular 19F, 10 ml of a
solution containing 10 mg KF/mL H2O (i.e. 1.04*10
18 19F spins)
was added as an internal fluorine reference to the sample, which
was then scanned with magnetic resonance spectroscopy (MRS,
see below). The amount of fluorine was determined by comparing
the integrated area of the PFPE main peak and the KF reference
peak in the 19F MR spectra.
Determination of in vitro cell detectability
To determine the limits of in vitro detectability with MRI, the 19F
labeled, small neurospheres were spun down, washed in KPBS,
fixed with 4% paraformaldehyde (PFA), washed again and
resuspended in KPBS. The fixed, labeled neurospheres were
either transferred to small tubes or injected at different cell
concentrations into phantoms made of 2% gelatin in small,
custom-made cups 22 mm in diameter for subsequent scans with
MRI.
Assessment of label influence on cell viability,
proliferation and differentiation
Cell viability was determined in culture by trypan blue exclusion
method before, shortly after, and at 7 days after labeling, and
compared to unlabeled control cultures. Experiments were
performed in triplicates. For determination of the cell phenotypes
within the proliferating culture, 19F labeled neurospheres were
plated on PLL coated 8-well chamber slides, allowed to attach for
3 h, then fixed and processed for immunocytochemistry. For
determination of cell differentiation capacity, growth factors were
removed and 1% fetal bovine serum (Gibco) was added. Labeled
cells were differentiated for 9 days, then fixed and subsequently
stained. Medium was changed every third day during experiments.
Animal experiments
All experiments were conducted according to the guidelines laid
out in the German Animal Welfare Act and approved by the local
authorities (Landesamt fu¨r Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen) under permission number 9.93.2.10.
31.07.048 (dated 22 May 2007). Four adult male CD 1 mice
(bodyweight 37–42 g, Janvier, Le Genest Saint Isle, France) were
used for the cell implantation and 19F MRI investigations. All
experiments were performed under anesthesia. Animals were
housed in cages under a 12 h light/12 h darkness cycle with access
to food and water ad libitum.
Implantation procedures
Human NSC cultures (passage 14) were labeled with 19F marker
as stated above. At the day of implantation, 19F labeled
neurospheres (diameter<100 mm) were centrifuged and resus-
pended in HBSS (Gibco). The neurosphere suspension had a
concentration of approximately 100,000 viable cells/mL and was
kept on ice during the whole procedure. Mice were anesthetized
with 1–2% isoflurane in a 70/30 nitrous oxide/oxygen mixture
19F MRI of Human Neural Stem Cells
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29040
	  	   85	  
and placed in a stereotaxic frame. A feedback controlled system
maintained the body temperature at 37uC (medres, Cologne,
Germany). The non-labeled and 19F labeled neurosphere
suspensions were injected using a Hamilton syringe into two
deposits per hemisphere into the striatum (1.5 mL i.e. 150,000 cells
per deposit) in two animals. Two further animals were injected
bilaterally with two deposits of 19F labeled cells on the left and one
deposit on the right hemisphere. The following coordinates were
used: AP, +1.0, ML, 62.0 mm from bregma, and DV, 23.0 and
22.0 mm from the brain surface. After each deposit, the needle
was kept in place for 5 min before slow withdrawal. The wound
was closed with suture and animals were allowed to recover in
their cages. To suppress an immune reaction, animals received a
subcutaneous injection of 20 mg/kg Cyclosporine A (Sigma-
Aldrich) every second day starting 2 days before implantation.
MRI acquisition
MRI and MRS were carried out on a Biospec 11.7 T/16 cm
dedicated animal scanner system (Bruker BioSpin, Ettlingen,
Germany) equipped with actively shielded gradient coils (BGA9S,
750 mT m21, Bruker BioSpin). For radiofrequency transmission
and reception, we used custom-built, inductively coupled, single-
loop surface coils of 9 mm diameter for in vitro MRS, 25 mm
diameter for in vitro MRI, and 20 mm diameter for in vivo MRI, all
tunable from 470 MHz for the 19F resonance frequency up to
500 MHz for 1H imaging.
In vitro 19F MRS: For the in vitro quantification of 19F content
with MRS, we used a spin-density weighted pulse-acquire
spectroscopic sequence with short acquisition delay of 0.05 ms,
and with long repetition time (TR) of 20 s to assure full relaxation
recovery (90u rectangular hard pulse, duration/bandwidth
(BW) = 0.01 ms/128 kHz, 163.8 ms acquisition window, spectral
points/BW=8192/50 kHz). We chose the number of averages
(NA) dependent on the strength of PFPE signal, with typically
NA=30, leading to an acquisition time (TA) = 10 min. All
measured 19F concentrations are presented with respect to the
main PFPE frequency (293.2 ppm), i.e. the chemical shift signal
originating from the end group of the PFPE molecule was not
taken into account.
Determination of relaxation times: To optimize sequence
parameters, the relaxation times were measured with the 9 mm
coil on a tube containing either the pure PFPE marker or the
labeled cells. The temperature was kept at 37u throughout the
experiment with a feedback controlled water system (medres). T1
was measured with a pulse-acquire saturation-recovery sequence
(20 experiments, TR=90.3 ms up to 20 s, pulse identical to in
vitro, 66.7 ms acquisition window, spectral points/BW=1000/
15 kHz), T2 with a multi spin echo sequence (TR=4 s, echo
spacing 20 ms, field of view (FOV) = 1661662.5 mm3, 32632
matrix, 15 echoes, NA=4 (PFPE)/100 (cells), TA= 4 min/
3:33 h). The spectral peak area or the signal in the multi-echo
images S were then fitted with the software Origin (OriginLab
Corporation, Northhampton, USA) to the function S~S0
1{exp({TR=T1)ð Þ for T1 or S~S0 exp({TE=T2) for T2, with
the equilibrium signal S0.
In vivo 19F MRS: MRS was performed to determine the exact
PFPE frequency in vivo using a pulse-acquire sequence identical to
the in vitro experiments but with shorter TR (30u pulse,
TR=200 ms, NA=3,000, TA=10 min).
In vitro and in vivo 1H/19F imaging: Anatomical 1H imaging was
performed with a turbo spin echo sequence (TR/effective echo
time (TEeff) = 2200 ms/42.8 ms, 8 echoes per excitation, NA=2,
10 consecutive, 1 mm thick slices, FOV=1.9261.92 cm2,
1286128 matrix, i.e. a resolution of 150615061000 mm3,
TA=1 min, BW=50 kHz, linear phase encoding scheme) [21].
19F images were acquired with the same sequence and matching
geometry, but at lower in-plane resolution and lower BW
(NA=256, 48648 matrix, i.e. a resolution of 40064006
1000 mm3, TA=57 min, BW=10 kHz). The transmission power
needed for a 90u pulse was determined on the 1H channel on a
1 mm thick slice parallel to the coil through the 19F labeled cells
and the same power was used after switching to the 19F frequency.
Approximately the same power is needed for the 1H and the 19F
90u pulse, which we tested on a combined 1H/19F standard
(diluted Trifluoroaceticacid, data not shown).
In vivo measurement protocol: In vivo 19F and 1H imaging was
carried out 2 d after implantation for those mice that received
non-labeled control cells, and 2 d and 6 d after implantation for
the animals that were injected with labeled cells in both
hemispheres. Mice were anesthetized with an intraperitoneal
injection of a ketamine (120 mg/kg) and xylazine (8 mg/kg)
mixture to avoid background signal from fluorinated inhalation of
anesthesia gases. Anesthesia time was prolonged by subcutaneous
administration of 30–60 mg/kg ketamine at 1 h after induction.
Respiration rate was monitored using a pressure sensitive pad
placed under the thorax, together with DASYlab (Measurement
Computing, Norton, USA) software and body temperature was
maintained at 37uC with an in-house feedback controlled system.
Animals were fixed with ear bars in standard animal holders
(Bruker BioSpin) and scanned with 1H MRI, 19F MRS, and 19F
MRI. The total time of the imaging session did not exceed 1.5 h.
Immunocytochemistry/immunohistochemistry
After the last MRI session, animals were deeply anesthetized
and perfused transcardially with saline followed by 4% PFA.
Brains were post-fixed overnight and then kept in 20% sucrose
solution until they sunk. Thirty micrometer thick sections were cut
in the coronal plane using a freezing microtome (Leica Micro-
systems, Wetzlar, Germany), and kept at220uC in cryo-protective
solution. Cells were fixed in 4% PFA for 15 min at room
temperature followed by three rinses in KPBS. Before immuno-
staining, cells and tissue sections were pre-incubated in 5% normal
serum, and 0.025% and 0.25% Triton X-100, respectively, in
KPBS for 45 min at room temperature. Incubation in primary
antiserum was carried out overnight at +4uC and the following
primary antibodies were used: mouse anti-b-III tubulin (1:333,
Sigma-Aldrich), goat anti-doublecortin (DCX, 1:400, Santa Cruz
Biotechnologies, Santa Cruz, USA), mouse anti-rat CD-68 (ED-1,
1:200, AbD Serotec MorphoSys AbD, Du¨sseldorf, Germany),
rabbit anti-GFAP (1:500, DakoCytomation, Glostrup, Denmark),
mouse anti-GFAP (1:400, Sigma-Aldrich), mouse anti-human
nucleus (HuNu, 1:100, Chemicon, Temecula, USA), rabbit anti-
Ki67 (1:500, Abcam, Cambridge, USA), rabbit anti-human nestin
(1:500, Chemicon). Primary antibodies were detected using
appropriate fluorescent Cy3 (Jackson ImmunoResearch Labora-
tories, West Grove, USA) or biotin-conjugated (Vector Laborato-
ries, Burlingame, USA) secondary antibodies (1:200), which were
then detected with Alexa 488-conjugated streptavidin (1:200,
Molecular Probes). In order to determine the specificity of the
primary antibodies and the level of background generated from
the secondary antibodies, in one well per in vitro-staining the
primary antibodies were omitted as negative control. For double
labeling, only one biotinylated secondary antibody was used at a
time. For nuclear staining Hoechst 33342 (1:1000, Invitrogen,
Carlsbad, USA) was added during final incubation with secondary
antibodies. Sections were mounted on PLL-coated slides (Thermo
Fisher Scientific, Waltham, USA) and slides were coverslipped
with glycerol-based mounting medium. Immunostainings were
19F MRI of Human Neural Stem Cells
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controlled, microscopic images acquired and double-immunore-
activities verified with a confocal laser scanning (Leica TCS SP2,
Leica Microsystems) microscope equipped with a supplementary
CCD camera (Leica Microsystems).
MRI data processing and statistical analysis
All MR images were processed with the program ImageJ
(http://rsbweb.nih.gov/ij/).
For SNR analysis of the 19F signal, the measured signal and
noise in the raw 19F images were corrected voxel-wise for non-
Gaussian noise distribution due to the low SNR [22]. Only voxels
with a corrected SNR above 3.5 were considered significant and
included in the analysis.
For display purposes of the merged 1H/19F images, the fluorine
SNR datasets were resized to a 1286128 matrix with bilinear
interpolation, grey-levels were converted to transparency levels of
red, and overlaid on the 1H image.
To estimate the minimum number of cells (Nmin) per voxel to
generate a detectable SNR of 3.5, we assumed a linear correlation
between number of cells and SNR. Knowing the summed SNR of
all voxels (SNRtotal) with significant
19F signal and the overall
number of cells (Ntotal) within this volume the detection limit was
then calculated with the simple relationship Nmin =Ntotal63.5/
SNRtotal, similar to a method described previously [11].
Differences between in vitro labeled and non-labeled cells were
evaluated with Student’s unpaired t-test. Data are expressed as
mean6SEM and differences considered significant at p,0.05.
Results
Labeling of NSCs
NSCs readily took up the PFPE emulsion without the aid of
transfection agents. The intracellular 19F content was maximized
for 100 mL of the 19F marker substance per mL medium as
confirmed with MRS (Fig. 1, A–C). With this protocol labeled cells
contained on average 3.7060.78*1012 (n = 3 biological replicates)
19F spins.
In order to analyze if the cells keep the fluorine marker over
time, we took out 1/3 of the cells (i.e. 1/3 of the internalized 19F)
directly after the labeling procedure and determined the amount
of intracellular 19F with MRS. The remaining 2/3 of the cells were
replated for another 7 days. The incorporated 19F was then again
measured and 2.1060.54 times (n = 4 technical replicates) the
amount of the first sample was found, which is in good agreement
with the expected value of 2 in case there was no significant loss of
label.
The measured relaxation times were T1/T2= (280620) ms/
(15364) ms for the free PFPE marker and T1/T2= (38064) ms/
(6863) ms for the labeled cells.
Detectability and quantification in vitro
MRI of a dilution series of labeled NSCs (20,000, 10,000, 5,000
labeled and 65,000 non-labeled cells for control) suspended in
gelatin clearly detected spots with 20,000 down to 10,000 cells,
while there was no background 19F signal from non-labeled cells.
Figure 1. Optimization of labeling and in vitro detection limits. A–C: 19F MRS of NSCs incubated with 15 mL (A), 50 mL (B), and 100 mL (C) PFPE
emulsion per mL medium together with a KF solution as an internal standard, KF frequency set to2120.9 ppm, main PFPE peak at293.2 ppm, signal
intensity in arbitrary units. The cell signal was maximized at a concentration of 100 mL/mL. D–F: MRI of 20,000, 10,000, and 5,000 labeled, and 65,000
control cells plated in gelatin, D shows the merged 1H and 19F, E the 19F image only. The 20,000 and 10,000 cells spots were clearly detectable,
whereas a significant signal was not detected for the 5,000 cells, probably due to cells spreading over many voxels, thus not exceeding the critical
detection limit. From the summed SNR of the two spots with 19F signal we estimate that approximately 1,000 cells need to accumulate in one image
voxel to overcome the detection limit, as indicated by the crossing of the linear fit in F with the dashed line illustrating an SNR of 3.5. For the fit we
assumed 0 SNR for 0 cells. Error bars in F are over n= 3 technical replicates. Note: The surface coil was adjusted parallel to the paper plane.
doi:10.1371/journal.pone.0029040.g001
19F MRI of Human Neural Stem Cells
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Spots with 5,000 cells could not be detected by in vitro MRI. From
the SNR of the two cell clusters with significant signal
(SNRtotal = 112614, n= 3 technical replicates) we estimate that
the minimum number of cells, which need to accumulate in one
image voxel in order to generate significant signal in vitro, is
approximately Nmin<1,000 cells (Fig. 1, D–F). This finding was
supported by 19F MRI of a dilution series of the 19F marker
(supplementary Fig. S1). Although the 5,000 cell spot is clearly
above the estimated detectable number of cells, it was most likely
not discovered because cells were spread over too many image
voxels.
Effect of the 19F marker in vitro
The labeling procedure had only very minor effects on the cells’
viability and no significant effects on their proliferation (Fig. 2, A–
H) and differentiation (Fig. 2, I–P) capacity. Furthermore, carefully
analyzing both the proportion and morphology of nestin+, GFAP+
and b-III tubulin+ cells, we did not detect any significant changes
compared to the non-labeled control cells. Also, no differences in
the numbers of Ki67+ cells were found either during proliferation
(37.763.2%; directly after the labeling) or after 7 days of
differentiation (27.261.0%) in vitro compared to non-labeled
control cells (44.162.4% for non-differentiated and 29.261.7%
for differentiated cells, n = 3 technical replicates) (Fig. 2, Q).
The percentage of living cells was equal compared to controls
before labeling (95.264.2% and 94.765.0%) but significantly
decreased directly after incubation with the 19F marker
(83.163.7% compared to 92.966.6% for unlabeled cells,
p,0.05). However, this value normalized again after replating
and subsequent culturing of the cells for 7 days (87.065.6% for the
labeled cells and 88.963.2% for controls, n = 3 biological
replicates, Fig. 2, R).
19F signal detectability in vivo
In order to assess whether 19F MRI is a useful tool for the
longitudinal tracking of implanted cells in the brain, we injected
PFPE labeled NSCs and non-labeled control cells into the striatum
of mice and scanned the animals a few days later. We detected
significant 19F signal from the grafts with labeled cells in all
animals, while there was no signal from implanted non-labeled
control cells (Fig. 3, A). Presence of Hoechst+/hunu+ cells allowed
definite assignment of NSC aggregations on histological sections
(Fig. 3, B, D, and F). These cell spots corresponded well, both in
intensity and location, to regions exhibiting significant 19F signal.
In the two mice with labeled cells grafted on both hemispheres, the
19F signal persisted at least 6 days after implantation (Fig. 3, C and
E). Quantitative SNR analysis of these animals revealed that total
19F SNR decreased by <20% from day 2 to day 6.
Figure 2. Effect of the labeling on cell viability, proliferation, and differentiation capacity. Photomicrographs of in vitro samples stained
for Ki67 (A, B, I and J), nestin (C, F E and H), GFAP (D, E G, H, K and N), and bIII-tubulin (L, M, O and P). There were no major qualitative differences in
the viability or proliferation and differentiation capacity of the labeled (B, F, G, H, J, N, O and P) versus non-labeled control cells (A, C, D, E, I, K, L and
M), both during proliferation (A–H), i.e. directly after the labeling procedure, and after 9 days of differentiation (I–P). The percentage of proliferating
Ki67+ cells during proliferation or after differentiation was not significantly altered by the labeling (Q). Quantification of the number of living cells
before, 0 days after, and 7 days after incubation with the 19F marker revealed that the viability was significantly decreased compared to controls at 0
days but normalized at 7 days after labeling (R). The scale bar represents 25 mm for M and P, 50 mm for all others.
doi:10.1371/journal.pone.0029040.g002
19F MRI of Human Neural Stem Cells
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To estimate the in vivo detection limit Nmin at 2 days after
surgery, the overall 19F SNR in all animals was determined
(SNRtotal = 612.5) and used together with the known number of
transplanted cells (Ntotal = 1.5 million) to calculate the minimum
number of detectable cells at an SNR=3.5 (Nmin<9,000).
Effect of the 19F marker in vivo
At the end of the 19F MRI in vivo measurements, the animals
were sacrificed and the brains were processed for immunohisto-
chemistry to study implanted cell phenotypes. Qualitative analysis
of brain sections stained for nestin, GFAP and DCX showed that
Figure 3. In vivo 19F MRI and correlation with immunohistochemistry. 1H, 19F, and merged MR images of a mouse (Animal 1), which had
been injected with non-labeled control cells into the left striatum and labeled NSCs into the right hemisphere (A). Only the labeled cells generated a
19F signal whereas hunu staining confirmed the presence of cell grafts on both sides as indicated by the arrows (B). MRI of another mouse (Animal 2)
2 days (C) and 6 days (E) after grafting showed no major signal loss in the 19F images over time. This animal had received two deposits of labeled cells
in the left striatum and one deposit in the right striatum. The location and intensity of 19F signal from cell clusters, marked with white arrows,
correlated well with hunu staining on histological sections. Note that the 19F resolution allows the distinction of the two clusters on the left
hemisphere (B, F). Only cells that were clearly immunoreactive to both hoechst and hunu were considered as grafted human NSCs (D). Scale bars are
50 mm for D, 1 mm for all others.
doi:10.1371/journal.pone.0029040.g003
19F MRI of Human Neural Stem Cells
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the vast majority of the implanted NSCs were nestin+ and GFAP+
cells (Fig. 4 A–D). We also detected a portion of the implanted cells
that had already differentiated into DCX+ neuroblasts (Fig. 4 E
and F). Overall, these images revealed that the fraction of cells of
each cell phenotype studied was similar for 19F labeled and non-
labeled cell grafts.
Discussion
We show that efficient labeling of NSCs with a PFC-based
marker is possible without impairment of their naı¨ve cell behavior
and thus, in consequence, their therapeutic potential. We have
successfully demonstrated detectability of these human neural stem
cells with high sensitivity after implantation into mouse brain and
the usefulness of this imaging approach for monitoring the cell
dynamics longitudinally because the graft was followed with 19F
MRI for a week, being most likely detectable even much longer.
Efficacy and effects of labeling NSCs with 19F
PFC nano-emulsions are particularly suitable agents for stem
cell tracking because of the excellent MR properties for imaging
and the high biocompatibility [10,23]. Important for a possible
clinical translation, PFCs are chemically stable, biologically inert,
and related compounds have already been evaluated in preclinical
and clinical trials as blood-substitutes [23,24,25].
Our labeling procedure with PFPE lead to an uptake of
3.7*1012 spins/cell, similar to reports on other cell types. For
experimental studies, 19F uptake could potentially be further
Figure 4. Effect of the 19F marker on cell phenotypes in vivo. Photomicrographs of non-labeled control (A, C, E) and PFPE labeled NSCs (B, D, F)
on tissue sections from transplanted animals. The majority of the implanted cells were, at this early time point after injection, still neural stem and
progenitor cells as confirmed by nestin/hunu and GFAP/hunu stainings (A–D). Presence of DCX+/hunu+ (E, F) neuroblasts showed that NSCs were
capable of neuronal differentiation. By qualitative analysis we did not detect major differences in the PFPE labeled cell population compared to
control cells. Scale bars are 20 mm.
doi:10.1371/journal.pone.0029040.g004
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increased through the use of transfection agents, however, most of
these are not approved for use in the clinic [10]. We found a high
T2/T1 ratio both for the free PFPE tracer and for the labeled cells.
This indicates that the MR properties of the tracer are in deed
optimal in terms of maximizing the SNR particularly when using
turbo spin echo sequences. We note however, that the reported
relaxation times may not be universal, e.g. due to slice thinning or
excitation/refocusing flip angle imperfections and echo train signal
variations.
Careful assessment of important immunohistochemical markers
revealed that the label has only minor effects on viability,
differentiation capacity, and proliferation in vitro and in vivo. In
other reports the viability of PFC labeled stem cells was not
different from non-labeled controls [11,20] whereas we observed a
decrease in viability directly after incubation. This could either be
a specific feature of the human NSCs or be due to the relatively
high concentration of 19F marker in the medium compared to
those other studies. We observed a decrease in viability over time,
although non-significant, also in the non-labeled control cells. This
suggests that the impairment in viability may rather be related to
other factors such as the PolyHEMA coating of flasks.
The use of a fluorescent agent, attached to the PFPE, could
provide a more direct proof that the agent is internalized,
analyzing localization by fluorescence microscopy. However, most
fluorophores are not suitable for clinical use and, therefore, we
used an emulsion without fluorescent tag. We included thorough
washing steps in all procedures in order to remove excessive 19F
marker particles. Moreover, a study with a similar, fluorescent
PFC emulsion showed localization of the 19F marker in the cytosol
of murine neural progenitor cells and persistence of 19F MRI
signal over 2 weeks [20]. Importantly, we did not detect a decrease
in MRS-determined 19F content from labeled, replated cells over a
period of one week. In vivo the 19F SNR only slightly decreased
between day 2 and day 6 after implantation. Overall, there is
strong evidence that NSCs retain the label over time and can be
tracked longitudinally, even for longer periods than the time span
of this study. This feature of long-term tracking of cells was not
provided employing alternative fluorine markers such as Poly-L-
lysine CF3, for which labeled cells lost half the
19F signal within 7
days [26,27]. However, thorough long-term evaluations of both
effects of PFCs on grafted stem cells and efficacy of the labeled
cells in the pathological brain e.g. stroke models are needed in the
future.
Cell quantification and detection limits
The 19F MR signal is proportional to the amount of
magnetically equivalent fluorine nuclei within a certain voxel.
This allows quantification of the number of cells. If the total
number of implanted cells is known, one strategy is to link this
number to the sum total of SNR and to assume linear correlation
between both. This way each SNR can be assigned a cell number.
We employed this for the determination of detection limits by
extrapolation of the number of cells generating an SNR of 3.5.
However, the strategy works only under the assumption that cells
are labeled homogeneously, do not lose the label, and do not
proliferate as this leads to a dilution of 19F content/cell, and that
partial volume effects can be neglected. The assumption of a
homogeneous labeling is reasonable when fluorine content per cell
is averaged over a few hundred cells. Further, we have shown
containment of the 19F marker within NSCs over one week under
in vitro conditions. The dilution of label through cell division is a
potential threat to our strategy, since injected cells can divide after
transplantation. However, the cells used here cease to proliferate
shortly after implantation. The previously reported time span of 2
days for proliferation in vivo is rather short considering a doubling
time of approximately 72 hours under ideal in vitro conditions
[18,19,28,29].
With the small graft sizes used in brain implantation studies, an
image voxel is typically only partly filled by labeled cells. This
becomes particularly severe with 19F MRI as one strategy to
enhance sensitivity is to measure with rather low spatial resolution
[10]. As a consequence, quantification in regions with cell densities
below the detection limit leads to underestimated cell numbers,
graft borders are only inaccurately defined on 19F MR images, and
migratory processes on a small scale cannot be monitored. A post-
processing scheme to ease the problem has been applied in models
of T-cell homing to the pancreas or lymph node by dilation of
regions of interest by one-half voxel [12,13]. This scheme could
potentially be included in future MRI studies of 19F labeled NSCs
depending on expected cell distribution. In order to minimize
these partial volume effects in the first place, we used a relatively
high in vivo resolution (160 nL voxel size in the present report
compared to for example 305 nL used before in the mouse brain
[20]). To our knowledge there is only one in vivo study with a
higher resolution, but in mouse hind limb (15.6 nL voxel size
[30]). To compensate the loss of sensitivity at the higher resolution,
we decided for the use of surface radiofrequency coils with
inhomogeneous field profile and T2-weighted turbo spin echo
pulse sequences. Thus the measured 19F signal from a certain
region depended not only on the amount of fluorine contained
therein but also on 19F relaxation times and the region’s distance
from the coil. The use of time-consuming, purely spin-density
weighted pulse sequences can improve quantification only at the
cost of SNR per unit time. A volume coil with more uniform
magnetic field profile may be better suited for quantification.
However, the coil is often larger and less sensitive compared to a
surface coil. To minimize the problem we adjusted the setup in a
way that the cell spots were placed within the same distance from
the coil for the in vitro experiments. For the in vivo experiments cells
were spread over a slightly larger region and further away from the
coil, thereby leading to loss of signal. This may partly explain the
order of magnitude difference of in vitro and in vivo detection limits.
In conclusion, coil design and choice of pulse sequence must be
carefully adapted to the specific application in future studies
employing 19F MRI for cell tracking.
Using a 19F marker with high spin density, using optimized
radiofrequency coils and a very high field of 11.7 T we show
detection of small numbers of cells in a preclinical setting. Our
data indicates that within,1 h acquisition time in vitro detection of
,1,000 cells/voxel is feasible corresponding to less than 1016
fluorine spins/voxel. In vivo we estimate a detection limit in the
order of ,10,000 cells/voxel. The limits are in agreement with
earlier studies [11,12,14]. These numbers are usually sufficient for
imaging the graft core and possibly even for larger cell clusters
migrating away from injection sites in the brain.
Potential of 19F MRI of NSCs in cell replacement therapy
The usefulness of cell tracking with 19F MRI mainly depends on
its sensitivity. Although the 19F marker and MRI methods used in
this study are likely to be safe for clinical translation, detection
sensitivity will be orders of magnitude lower in a clinical setting
due to lower field strengths, larger radiofrequency coils, and
shorter acquisition times [31]. Still, 19F MRI of NSCs may become
clinically relevant in the near future as a result of further advances
in MRI hardware and pulse sequence development.
However, before stem cell based therapy of neurological
disorders can be used in human patients the action of these cells
needs to be further investigated in animal models [16]. 19F labeling
19F MRI of Human Neural Stem Cells
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may prove superior to labeling with magnetic iron oxide
nanoparticles in such preclinical investigations particularly when
the pathology induces changes in 1H relaxation times that make
distinction between diseased tissue and labeled cells difficult.
Possible scenarios include vasogenic edema after ischemic stroke
or lesions involving bleedings, in which heterogeneous background
T1, T2, and T2* impose major challenges in unambiguous
detection of magnetically labeled cells with 1H MRI. As 19F
MRI allows quantification of cell numbers it may also help to
optimize efficacy of stem cell therapy e.g. in terms of injection sites,
monitoring graft size changes [29] and routes of migration.
Conclusion
In future clinical applications, NSCs are one of the most
potential and attractive cell sources for stem cell based treatment
of diseases affecting the central nervous system. However, for the
successful translation of cell therapy additional live imaging
tools such as MRI are a prerequisite. 19F MRI is a promising,
quantitative, and non-invasive technique to monitor NSC grafts
after implantation. We have shown that labeling NSCs with a PFC
marker, potentially suitable for clinical use, does not significantly
impair cell function both in vitro and in vivo. Our high detection
sensitivity and resolution have allowed for the first time true in vivo
tracking of small groups of human NSCs. This is particularly
interesting for studies of brain cell replacement therapy, in which
the graft can initially be small and may become further diluted
through lesion-induced cell migration.
Supporting Information
Figure S1 Dilution series of 19F marker. 19F MRI of six
tubes containing different concentrations of the PFPE agent (1, 2,
3, 4, 5, and 6 times 31.1 mM corresponding to multiples of 3*1015
19F spins/voxel). The tube with 3*1015 spins/voxel can clearly be
depicted (SNR,6). Assuming a labeling efficacy of 3–4*1012
spins/cell this would translate to detection of less than 1,000 cells/
voxel in agreement with the results obtained with our quantifica-
tion strategy (Fig. 1). Pulse sequence parameters were chosen
identical to the cell dilution series in Fig. 1. Note: The surface coil
was oriented parallel to the paper plane.
(TIF)
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a b s t r a c t
Noninvasive in vivo cell tracking is crucial to fully understand the function of mobile and/or transplanted
cells, particularly immune cells and cellular therapeutics. 19F MRI for cell tracking has several advantages;
chief among them are its noninvasive nature which allows longitudinal data acquisition, use of a stable,
non-radioactive isotope permitting long-term tracking, the absence of confounding endogenous signal,
and the ability to quantify cell numbers from image data. However, generation of sufﬁcient signal i.e. 19F
cell loading is a key challenge, particularly with non-phagocytic cells such as lymphocytes and stem cells.
A range of 19F cell labels have been developed, including emulsions, particles, polymers, and agents for
clinical use. Various animal and primary human cells, such as dendritic cells, lymphocytes and phago-
cytes have been successfully labeled and studied in models of autoimmune disease, inﬂammation and
transplant rejection. Primary human cells, particularly dendritic cells as used in vaccine therapy have
been tested for imminent clinical application. Here, we summarize current cell loading strategies and
sensitivity of in vivo cell imaging with 19F MRI, and discuss the processing of image data for accurate
quantiﬁcation of cell numbers. This novel technology is uniquely applicable to the longitudinal and
quantitative tracking of cells in vivo.
! 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Perﬂuorocarbons (PFCs) are C-F polymers with unique proper-
ties: These compounds are extremely inert and stable, even at high
temperatures and pressures, and are singularly immiscible with
both lipophilic and hydrophilic solvents. For example, Teﬂon is
a PFC well-known for its “non-stick” property. The high stability of
PFCs has made them useful as awide range of products including as
lubricants in spacecraft. Their high density has made them useful in
eye surgery, to hold the retina in place. Due to their ability to
dissolve gases, PFCs have been used to formulate artiﬁcial blood
substitutes and are still used in partial liquid ventilation in
premature infants. Thus, PFCs have a long history of varied use,
both in industry and in the clinic.
More recently, the increasingly widespread use of cellular
therapeutics has generated a new role for ﬂuorocarbons as labels
for cell tracking using 19F MRI [1]. MR imaging allows for high
resolution anatomic and functional images, with intrinsic contrast
even in soft tissues. MRI is noninvasive and does not use ionizing
radiation. However, relevant cells must be labeled to distinguish
them from background cells. 19F compounds are excellent labels for
in vivo MRI, as the 19F nucleus is extremely sensitive for MR
imaging, several orders of magnitude higher than 13C or 23Na and
comparable to the 1H nucleus, and there is no detectable back-
ground in vivo [2]. The signal received is directly proportional to the
amount of 19F present. This allows for quantiﬁcation of cell
numbers from the in vivo images, when the average 19F cell loading
is known. Furthermore, the T1 relaxation parameters of some 19F
compounds can vary with oxygen content; this allows for 19F MRI-
based measurement of oxygen levels in vivo, although this T1
variability can also complicate quantiﬁcation.
In order to carry out 19F MRI-based cell tracking, the cells must
be loaded with sufﬁcient 19F for imaging within a reasonable length
of time. This requires the formulation of appropriate labels and the
development of suitable labeling techniques to load the relevant
cells, whether ex vivo or in vivo. A typical outline of the entire
procedure is shown in Fig. 1. In this article, we review the different
types of cell labels developed and the labeling procedures used. We
also discuss the selection of a speciﬁc label for a cell type, as well as
strategies to improve sensitivity during imaging. Finally, we discuss
potential new technologies that may transfer successfully to 19F
MRI in the near future. 19F MRI and NMR have been applied to
tumor oximetry, localizing inﬂammation and other applications,
but here we will focus speciﬁcally on 19F MRI for in vivo cell
tracking.
* Corresponding author. Tel.: þ31 (0)624892288; fax: þ31 24 3540339.
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2. Types of 19F cell labels and their effect on cells
Themain purpose of a 19F cell label is to render the relevant cells
detectable by loading with sufﬁcient 19F for detection. Thus, these
labels are typically large ﬂuorocarbons or aggregates of ﬂuorocar-
bons. General requirements for 19F cell labels are described else-
where [2]; chieﬂy, these include a sufﬁciently large number of 19F
atoms for detection, nontoxicity to the cell and a single (overall)
resonance frequency. In general, labels consist of the ﬂuorinated
molecule and a component to stabilize the ﬂuorocarbon in the cell
environment or make it more accessible for cell uptake. Thus, the
most common labels consist of a perﬂuorocarbon coated with
a lipid surfactant. Additional components, such as ﬂuorescent dyes,
drugs or targeting moieties can be added to these complexes. These
and other types of labels are discussed in the following sections.
Examples of cell labels are shown in Fig. 2, together with corre-
sponding in vitro or in vivo images.
2.1. Emulsions
The majority of cell labels used thus far have been emulsions,
due to their high content of PFC per droplet and the ease of
formulation. Emulsions are droplets of an immiscible compound
surrounded by a surfactant that stabilizes the droplet in the
continuous phase, typically water. Fluorinated compounds, espe-
cially the large PFCs used in cell labels, are not miscible with water
and these must be coated with a suitable surfactant in order to
remain dispersed. Otherwise, the PFC will settle out of the solvent
as a separate layer, analogous to oil and vinegar. The emulsion
droplet therefore consists of a large payload of 19F surrounded by
a lipid coat. Emulsions can be formulated by simple mixing of the
components, or more sophisticated processes such as micro-
ﬂuidization (MF), which yields more homogeneous droplets. Per-
ﬂuorocarbons used for labeling thus far include perﬂuorooctyl
bromide (PFOB), perﬂuoro-15-crown-5 ether (PFCE) and linear
perﬂuoropolyethers (PFPE). PFOB, in particular, has previously been
used in clinical blood substitutes. The surfactants used most
frequently are lipids such as phospholipids and poloxamers. These
data are summarized in Table 1. The biological effects of poloxamers
are described elsewhere [3]. Poloxamers are in active research for
drug delivery, and are known to affect cell membrane properties,
among others. Phospholipids are major components of cell
membranes and are generally considered safe for use.
PFC emulsions have been used for decades as blood substitutes,
althoughwith limited success. Indeed, it was the instability of these
emulsions that hindered their use in the clinic and in other appli-
cations. However, in a preclinical setting, emulsions are still
convenient, as they can be made in smaller batches when neces-
sary. One must keep in mind that any extra moieties added to an
emulsion, such as a dye or an antibody, are more likely to blend
with the surfactant than the PFC and may become separated from
the PFC in vivo or in the cell. Recently, we proposed an alternative
to emulsions to overcome these issues, consisting of polymer-
encapsulated PFC [4]. Here, any dyes or other compounds can be
covalently bound to the particle surface or encapsulated within,
and the particles can be frozen for easy storage. In general, both
types of label result in cell loading in the order of 1011-1013 19F
atoms/cell. Fluorescent, ﬂuorinated micelles have also been
developed, although these have not been applied to cell labeling
[5]. Finally, an expected beneﬁt on cell viability may occur if the 19F
agent can improve oxygenation, as has been shown with some cell
types [6].
2.2. Other types of label
The 19F cellular labels used thus far are summarized in Table 1.
Over two thirds of these studies used PFC emulsions due to their
high content of 19F. Other options include ﬂuorinated peptides or
polymers or ﬂuorinated small molecules, such as sugars; these
often result in much lower cell loading, and thus much lower
detection sensitivity. Fluorinated drugs have been studied using 19F,
even in the clinic. While these drugs were not designed speciﬁcally
to label cells, cellular uptake occurs and it may be possible to
modify these compounds for cell tracking in vivo. However, 19F is
highly reactive and electronegative, and its incorporation in
a compound can signiﬁcantly alter its chemistry. For cell labels,
especially when used in vivo, any metabolism of the compound
must also be considered.
Fig. 1. Key steps in cell labeling for 19F MRI. The ﬁgure shows the most commonly used protocols for each step; variations proposed in the literature are discussed in the text.
Appropriate selection of label and labeling protocol is crucial for success of the experiment (Step 1). Cell labeling (Step 2), may require enhancement through the use of coatings or
transfection agents. After suitable preparation (Step 3) the cells can be imaged. Post-processing leads to quantiﬁcation (Step 4). Finally, various ex vivo analysis can be carried out
(Step 5) to corroborate the in vivo data.
M. Srinivas et al. / Biomaterials 33 (2012) 8830e8840 8831
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The main advantage of smaller labels over emulsions, despite
their lower 19F content, is that they can be adapted to study (or
manipulate) a speciﬁc aspect of cell functionality. Probes have been
developed that are switched on or off by speciﬁc enzyme activity
[7], gene expression [8] and protein binding [9]. Although prom-
ising, these labels tend to have insufﬁcient sensitivity for in vivo
use. Finally, some cell labels applied to 1H MRI may be relatively
easy to adapt for 19F MRI. For example, rationally designed multi-
stage nanovectors [10], dendrimers [11], and even gadolinium
loaded nanoparticles [12].
3. Cell loading strategies
Cell loading is inﬂuenced by the ﬂuorinated compound, the
method of delivery, and cell uptake, which is dependent on the cell
type and status. For purposes of quantiﬁcation, it is important that
average cell uptake is reproducible for a given set of labeling
conditions. Variables in ex vivo labeling conditions include the
point of time at which the label is added, the labeling medium,
surface chemistry of cell culture ﬂasks, length of incubation with
the label, label concentration and washing steps. Non-phagocytic
cells in particular may need extra enhancement to take up sufﬁ-
cient label. This can be achieved with positive lipids, typically
transfection agents, or antibodies (see Table 2).
Phagocytic cells such as dendritic cells and macrophages have
been labeled most often, both due to their biological signiﬁcance
and the relative ease of labeling. Furthermore, these cells are
migratory and thus are relevant for cell tracking studies. In
particular, macrophages have been labeled through simple intra-
venous administration of PFC emulsions (see Table 1). The use of 19F
MRI to study inﬂammation, primarily through tracking macro-
phages, has recently been reviewed [13,14]. These labeled
Fig. 2. Types of 19F cell labels. The main types of cell labels, listed in Table 1, are shown here. Emulsions consist of droplets of ﬂuorocarbon with a lipid bilayer coating; additional
components such as dyes or quantum dots can be added [86]; the inset shows a micrograph of labeled cells with the quantum dots in red, lysosomes in green, nuclei in blue and
scale bar of 10 mm. Particles consist of a perﬂuorocarbon core with a polymer coat, to which additional components can be covalently added [4]. The inset shows in vivo MRI (left)
and ﬂuorescence images (right) of the particles injected in the footpads of a mouse.Micelles typically consist of a polymer in a conformation that only exposes hydrophilic regions, in
this case with the ﬂuorine groups on the inside [5]; the inset shows micrographs of labeled cells with a diffusion interference contrast (DIC) image on the left and a ﬂuorescence
image on the right, where the micelles are blue. Other labels that have been developed include ﬂuorinated small molecules such as sugars [85] or ﬂuorinated peptides [47]; inset
shows in vivo 1H (left) and 19F MR images of labeled cells implanted in the cranial bone of mice. Responsive probes only become detectable upon binding to a speciﬁc protein; R
represents different side groups [9]. Ref. [86] reprinted from Biomaterials, copyright 2010 [4]; from Biomaterials, copyright 2010 [85]; from Arch Biochem Biophys, copyright 2012
[47]; from Biomaterials, copyright 2007; all with permission from Elsevier. Ref. [5] reprinted with permission from Bioconjug Chem, copyright 2008, American chemical Society.
Ref. [9] reprinted from Nat Chem, copyright 2009, with permission from Macmillan Publishers Ltd. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Table 1
Current cell labels. The table lists 19F cell tracking studies carried out thus far, with information on the type of label, its formulation, any additives used, the cell type and the
average loading achieved (where indicated in the publication). All cells are cell lines unless indicated as primary; “lipids” include compounds such as phospholipids;
poloxamers are listed separately. Note that the ﬂuorinated reporter probes are typically assessed using spectroscopy.
Major 19F component Main
surfactant
Formulation Additives Hydrodynamic
diameter (nm)
Cell type Average cell
loading (!1012 19
F atoms/cell)
Ref
Cell tracking:
Ex vivo labeling
Various PFCs PLGA Nanoparticles Dye 200e300 Primary human DCs 30 [4]
PFCE Lipids MF 233 Primary human
stem/progenitor cells
20 [82]
PFOB Lipids 224 0.5
PFCE Lipids MF 100 Murine DCs 20 [81]
PFPE Poloxamer Sonication Dye 120 Primary murine T cells 20 [62]
PFPE Lipids MF Primary human DCs 20 [24]
PFPE Lipids MF 180 Human neural stem cells 4 [16]
PFCE Poloxamer Sonication 130, 245,
365, 560
Primary murine DCs 2 [21]
PFPE Lipids MF Dye 180 Human neural stem cells 2 [15]
PFPE Poloxamer MF Dye 180 Primary murine T cells 0.3 [83]
PFPE Poloxamer MF 180 Primary murine T cells 0.3 [84]
PFCE Poloxamer Sonication Dye Rodent glioma 0.2 [68]
Fluorinated sugars n/a n/a n/a Primary rodent hepatocytes 0.03e0.1 [85]
Perﬂuorodecalin Lipids Sonication &
MF
Quantum dots 250 Human NK and
leukemia cell lines
[86]
PFOB Lipids MF Drug targeting
agent
250 Primary porcine aortic smooth
muscle cells
[87]
PFOB Lipids Sonication &
MF
Drug 225 Primary human
umbilical cord smooth muscle cells
[88]
Various PFCs Fluorinated
\surfactants
MF Fluorinated
quantum dots
200 Murine macrophage;
human carcinoma
[89]
PFCE Lipids MF Targeting peptide 170 Human umbilical cord
vein endothelial cells
[69]
PFOB Lipids Sonication Dye 80 Harvested human
pancreatic islets
[90]
PFCE Lipids Sonication 170
Various PFCs Lipids Sonication &
MF
Quantum dots Murine macrophage
and DC cell lines;
and primary murine
DCs and T cells
[91]
PFOB Lipids Targeting antibody
transfection agent
Human cancer
cell lines
[92] [93]
Fluorinated
poly-L-lysine
Dye n/a Glial cells n/a [48]
Fluorinated
poly-L-lysine
Dye n/a Bone/cartilage
stem cells
n/a [47]
Cell tracking:
In vivo labeling
PFCE Lipid MF Dye 130 Monocyte/macrophages 9 (macrophage
cell line labeled
ex vivo)
[61]
PFCE Lipids Sonication
and MF
Targeting agent
and ﬂuorescent dye
245 Endothelial cells [54]
PFCE Lipids MF 145 Macrophages [94]
PFCE Lipids MF 145 Macrophages [37]
PFCE Lipids MF Monocytes/macrophages [95]
PFCE Lipids Monocytes/macrophages [96]
PFOB Lipids Imagent/
Perﬂurobron
Dye Macrophages (rabbit) [97]
PFCE Lipids MF Dye 145 Macrophages [98]
Other
Hyperbranched
ﬂuorinated
polymer
Speciﬁc
polymers
(micelles)
Drug 20-30 Human glioblastoma
cell line
0.0005 [5]
Fluorinated
colchicine
derivatives
n/a n/a n/a n/a Human leukemia cell line [99]
Fluorinated
nitroimidizole
n/a n/a n/a n/a Tumor retention (humans) [100,101]
Triﬂuoronitroimidazole Primary murine
tumor cells
[102]
Fluorinated reporter
molecules
n/a n/a n/a n/a Various, including bacteria
and human cancer cell lines
[103-107] [76,108]
[8] [109]
On-off probes n/a n/a n/a n/a Red blood cells [9]
Fluorinated prodrug Human cancer cell lines [110]
Fluorouracil Tumor (human trial) [45] [111]
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macrophages accumulate in loci of inﬂammation and can be
imaged. Non-phagocytic cells that have been labeled for 19F MRI
include T cells, stem cells, and smooth muscle cells. In many of
these cases, label uptake was enhanced with transfection agents
used to stimulate DNA uptake in cells (see Table 2). To avoid
stickiness of label or the labeled cells to cell culture dishes, pre-
coating of dishes or addition of serum to culture medium was
necessary in some studies [15e17]. Electroporation has been used
to stimulate uptake with contrast agents (for example [18],). This is
a relatively harsh technique where a transient electric pulse is used
to open cell membrane channels to stimulate uptake. Techniques
for improving cell loading are similar to those used for contrast
agents, and have been reviewed in more detail [19]. In all cases,
labels that are taken up by cells without further interference are
preferred, as viability tends to improve (for example [20],).
However, for some cell types and labels, addition of a transfection
agent or other aid is crucial, resulting in up to a 20-fold increase in
uptake (Table 2).
Finally, it is interesting that most of the (emulsion) labels used
thus far tend to be around 200 nm in diameter, although one study
with dendritic cells found that increasing size to 560 nm resulted in
better loading [21]. With non-phagocytic T cells, it has been shown
that uptake of iron oxide particles was also affected by particle size,
with optimal uptake at 200e300 nm and further enhancement by
the use of a positively-charged coating [22]. These studies suggest
that the majority of labels used thus far may be improved simply by
slightly increasing their size. However, increasing the size of
emulsion droplets also increases their density; this can make it
more difﬁcult to remove excess label from labeled cells by tech-
niques such as centrifugation.
4. Labeling optimization
In vivo, targeted labeling with high speciﬁcity and efﬁciency
would generally be ideal; although currently unachievable for most
cell types. The main issues to consider are whether the expected
19F/voxel will be sufﬁcient for detection, and whether the relevant
cells can be labeled without signiﬁcant toxicity and phenotype
change. An outline of the overall procedure is shown in Fig. 1. Steps
1e3 in particular must be optimized for each cell type and label
combination. Step 4 is dependent on the NMR properties of the 19F
agent, and the available hardware and imaging sequences. The ﬁnal
step may or may not be necessary, dependent on the aims of the
study.
In all studies thus far, the labeled cells are typically assayed for
viability, using trypan blue exclusion or other assays, and for
functionality, such as the expression of typical membrane markers.
These data are compared to those from non-labeled controls. One
aspect that is often overlooked is the effect of the label on cell
migration, as the PFCs are very dense and cells can become
completely engorged with PFC droplets. Migration is vital to the
functionality of cells such as macrophages, and thus should be
assayed in vitro. This can easily be done using microscopy-based or
transwell migration assays. It is now known that cell migration can
be seriously affected by iron oxide loading [23]. In our studies, we
found no signiﬁcant effect of PFC labeling on the migration of
primary human dendritic cells [24]. In the case of PLGA particles
used for cell labeling [4], a vast body of literature already exists on
the engineering of PLGA particles for speciﬁc applications [25,26].
The amount of label taken up by a cell may inﬂuence its intracel-
lular fate and phenotype or functionality of the cell. Iron oxide
labels have been used for cell tracking extensively, but their effect
on the cell and in vivo is only now being uncovered. In particular,
these agents can impact migration [23], proliferation, and the
intracellular redox state [27].
Finally, cell labeling conditions that result in nonhomogeneous
cell uptake may showmixed or inconsistent results in functionality
assays dependent on the cell loading [28]. Cell functionality can
also vary with differences in particle size [21]. Thus, several inter-
dependent factors must be studied and manipulated for optimal
cell labeling.
5. In vivo effects and clearance of perﬂuorocarbons
Cell labels themselves have not been studied in terms of their
long-term fate and clearance in vivo. The tiny concentrations of PFC
used as cell labels, typically nano- or picogram amounts, are usually
undetectable after loss fromthe cells. However,muchworkhas been
done on the clearance of PFCs used as blood substitutes in the 1970’s
and 80’s. In particular, research focused on Fluosol-DA, which was
FDA-approved for use as a clinical blood substitute in early 1980. It
was used in 40,000 patients, but its usewas limited due to problems
with stability and storage of the emulsion. The emulsion consisted
primarily of perﬂuorodecalin, emulsiﬁed with poloxamer F-68 in
saline. Ingeneral, the emulsionwaswell toleratedwith themain side
effects being minor ﬂu-like symptoms [29], when administered to
healthy volunteers at up to 1.2 g PFC/kg. In rodents, the functioning
of the liver and spleen can be decreased temporarily [30,31]. The
emulsion itself is removed from circulation primarily by macro-
phages in the spleen and liver. In general, the emulsion causes
depression of the mononuclear phagocyte system, which results in
temporarily increased susceptibility to infection [32]. It was later
shown that this side effect of Fluosol-DA was mainly caused by the
poloxamer surfactant [33,34] which reduced neutrophil migration
to infection loci, thus resulting in higher mortality due to infection.
It is known that all side effects of PFC emulsions are strongly
dose-dependent [35], and hence may not be applicable to cell
tracking studies with their tiny doses of PFC. Furthermore, all the
side effects are thought to be due to the effect of macrophage
stimulation and are fully reversible. In terms of clearance from
circulation, PFCs are taken up by macrophages, ﬁrst in the liver and
spleen, and then eventually exhaled in the lungs. The half-life is
inﬂuenced by chain length, with heavier PFCs lingering longer [36].
In all cases, there is no metabolism of the PFCs in vivo. A study in
rats found that an emulsion of 30% w/v PFCE with an average
diameter of 145 nm had a circulatory half-life of about 9.5 h after
intravenous transfer [37].
A recent study using PLGA-encapsulated PFOB particles
administered intravenously also found uptake primarily in the liver
and spleen. However, circulation time could be increased by using
a PEG coating to make the particles “stealthy” [38]. This allowed for
accumulation at tumor sites within 7 h post-administration.
Table 2
Improvement of cell loading. The effect of transfection agents or targeting peptides
on increasing cell loading is summarized here, including the fold-increase in cellular
19F content.
Label Loading strategy Cell type Cell loading
improvement
(fold increase)
Ref
Emulsion Transfection agent Murine DCs 26 [81]
Emulsion RGD-peptide Primary human
umbilical cord
vein endothelial cells
6 [69]
Emulsion Transfection agent Primary murine T cells 5 [62]
Emulsion Targeting antibody Primary porcine
aortic smooth muscle
2 [87]
Emulsion Transfection agent Human breast cancer
cell line
w1.2 [93]
Emulsion Integrin targeting In vivo binding to
vascular endothelium
[54]
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Finally, the effect of the surfactants or other components on
a systemic level should also be considered. Typical surfactants, such
as phosphotidylcholine, are generally considered as safe. Polox-
amers and PLGA both have been tested in humans, generally
without major safety concerns.
6. Implementation of in vivo 19F MRI
For most MRI systems an upgrade for in vivo 19F MRI is
available at reasonable cost since the resonance frequency of the
19F nucleus is very close to that of 1H and most of the existing
hardware for 1H MRI can be used. For true dual nuclei detection
or for 1H/19F decoupling experiments, an upgrade would
comprise 19F transmitter and receiver units, combiner and splitter
for 1H/19F signals, and a dual-resonant radiofrequency (RF) coil
[39]. These components are commercially available, however
most research groups rely on custom designed RF coils to
accommodate their speciﬁc needs. With the ﬁrst 19F agent for
in vivo cell tracking being FDA-approved (press release, Celsense
Inc., Pittsburgh, USA) implementation of 19F MRI of labeled cells
at clinical systems will become relevant. Here, lessons can be
learnt from studies on gastrointestinal transit in humans with 19F
capsules [40,41], 19F MRI of lung ventilation in large animals using
ﬂuorinated gases [42], and pharmacokinetic studies of ﬂuorinated
anesthetics or drugs in patients (reviewed e.g. in [43]). For the
latter, the ﬁrst MRS study was reported over two decades ago
[44]. Since then hardware and acquisition strategies have greatly
improved allowing spatially-resolved MRS imaging of these drugs
in the liver of patients despite low in vivo concentrations (for
example [45],).
7. Sensitivity of 19F MRI of labeled cells
Once cellular uptake of a 19F agent has been optimized, the
sensitivity of 19F MRI of labeled cells mainly depends on 1) MR
properties of the 19F agent, i.e. spin density, relaxation times, NMR
spectrum (single/multiple peaks) 2) the MRI system (ﬁeld strength
and RF coil being the most critical components) 3) MRI acquisition,
i.e. RF pulse sequence and 4) post-processing strategies. It is
essential to optimize these since direct detection of nuclear spins
with MRI is inherently insensitive due to low energies between
different spin states when compared to thermal ﬂuctuations in the
electronics and sample. If needed, such optimization must be
carried out under the constraint that accurate quantiﬁcation of 19F
concentrations is still possible. The SNR achievable in 19F MR
spectroscopy of ﬂuorinated compounds has recently been reviewed
extensively [46]. In agreement, sensitivity of cellular 19F MR
imaging is at the order of w1016 19F spins/voxel for small animal
systems and imaging time of 1 h. For typical voxel sizes of (1 mm)3
this translates to 19F concentrations in the mM range and a detec-
tion threshold down to the order ofw1000 cells in vitro depending
on average 19F content per cell (Table 3).
7.1. Enhancing sensitivity: MR properties of 19F agent
So far, PFCs have been used for in vivo 19F MRI almost exclu-
sively, except for two studies using poly-L-lysine-CF3 [47,48]. This is
due to the very high density of 19F in PFCs and relatively high T2/T1
ratio for some of these (w0.5 for the linear PFPE). Interestingly, we
observed an order of magnitude lower T!2 (<10 ms, unpublished)
than T2 (w150 ms, [16]) for a PFPE emulsion, which decreases
sensitivity in gradient echo experiments. The large difference could
be explained by local susceptibilities at the PFC/water surfaces and
longer T!2 might be achievable with susceptibility-matching of the
PFC core with its surrounding.
The main focus to further enhance MR sensitivity from the
chemical synthesis side has been towards manipulation of relaxa-
tion time T1 by adding paramagnetic ions such as Gd3þ, which
would allow shorter measurement times or higher SNR at identical
scan time. Since PFCs are neither hydrophilic nor lipophilic incor-
poration of Gd is not straightforward. Direct incorporation of Gd in
the lipid monolayer of PFC emulsions has been shown to efﬁciently
decrease 19F T1, which translated tow125% increased SNR at 1.5 T
[49]. However, only 19F close to the emulsion droplet surface will
exhibit the short-range T1 reduction. Furthermore, the shortening
in T2 induced by the paramagnetic ion can annihilate the gain in
sensitivity, thus ﬁne-tuning of the ion-19F interaction is essential
[50].
7.2. Enhancing sensitivity: MRI system
The trend towards high and ultra-high magnetic ﬁeld strengths
has certainly contributed to the increasing impact of 19F MRI since
this is a straightforward (but ﬁnancially costly) way to increase SNR
due to enhanced equilibrium magnetization. An alternative way to
boost the magnetization is hyperpolarization which has been
shown to enhance SNR by a factor of 60 in vitro [51]. However, the
decay of enhanced signal in this study was on the order of 1 min;
thus, this technique may only have an impact on in vivo studies of
early metabolites of 19F compounds or lung imaging after inhala-
tion of hyperpolarized 19F gases, but not for long-term cell tracking.
At ﬁxed ﬁeld strength, the RF coil is certainly the most critical
component of the MRI system that determines sensitivity. Sensi-
tivity of the coil mostly depends on the ﬁlling factor, which is
higher when the coil is close to the sample and of small size. In this
context, arrays of small surface coils have revolutionized sensitivity
and sped of 1H MRI in combination with parallel imaging tech-
niques. First reports exist using custom-made 19F array coils for cell
imaging [52] but broader application to 19F MRI is still missing.
Another emerging technology to improve SNR in small animal MRI
are cryogenically cooled RF coils since these coils are now
commercially available (see review [53]). For in vivo 1H MRI of the
mouse brain a factor 2.4 gain in sensitivity has been reported and
similar improvements would be expected for a 19F cryo-coil, which
may become available with increasing demand. Importantly, the
gain in SNR is higher for lower magnetic ﬁeld strengths due to their
higher coil-dominant noise, which can be reduced by cooling. Thus,
the cryo-technology may also greatly improve sensitivity of 19F MRI
at clinical systems.
7.3. Enhancing sensitivity: MRI acquisition
One of the main advantages of MRI is the ﬂexibility of acquisi-
tion and resulting contrast in the image, e.g. generation of spin
density-, T1-, T2-, T!2-, and diffusion-weighted images. For example,
introduction of diffusionweighting in a conventional 19F MRS pulse
sequence was used to selectively image nanoparticles bound to
amolecular target whereas the signal frommoving nanoparticles in
the blood stream was eliminated by the diffusion weighting [54].
Finding the right pulse sequence for an in vivo application may
become very complex and will not be discussed here. However, for
19F MRI the task is usually simpler: Find a pulse sequence that
maximizes SNR efﬁciency (SNR divided by square root of acquisi-
tion time) at the given relaxation times of a 19F compound. This
generally narrows down the choice to fast pulse sequences, such as
fast gradient echo, fast spin echo or steady-state-free-precession
sequences. For example, a framework to overcome the problems
of extremely short T2/T!2 relaxation of paramagnetic
19F complexes
by using fast ultrashort echo time (UTE) and zero echo time (ZTE)
pulse sequences was recently presented [55]. The authors were
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able to synthesize lanthanide 19F compounds with T!2/T1 ratio up to
themaximum ofw1, which boosted SNR by a factor of 27 compared
to non-paramagnetic compound using these special sequences,
whereas the SNR gain in conventional fast gradient echo MRI was
only 11.
For compounds with 1H-19F coupling, SNR can further be
improved by using the Nuclear Overhauser Effect and proton
decoupling, although this has not been exploited yet for in vivo 19F
MRI [56].
7.4. Data reconstruction and post-processing
Many 19F compounds such as linear PFC molecules have more
than one resonance frequency due to chemical shift or coupling to
other 19F or 1H atoms in the samemolecule. Conventionally, for MRI
only the signal of one of the peaks is used by frequency-selective RF
pulses for excitation of the desired peak, by saturation of undesired
peaks [57] or by choosing an echo time at which J-modulation
annihilates signal from undesired peaks [58]. This leads to either
decrease of SNR since not all 19F signal can be exploited or to
chemical shift artifacts if more than one peak contributes to the
signal. Chemical shift imaging records for each voxel a whole NMR
spectrum and thus avoids the artifact but it presents an SNR-
inefﬁcient alternative. Early studies have shown that deconvolu-
tion techniques can potentially remove these artifacts and improve
SNR although ﬁnding a post-processing method which is robust
against noise is challenging [59].
A problem in the in vivo situation, especially when imaging the
abdomen, is the presence of motion over the long 19F MR imaging
times, which leads to blurring, motion artifacts, and decreased SNR.
Respiratory gating is an SNR-inefﬁcient solution due to the dead
time during parts of the respiratory cycle. In a study using a setup
for simultaneous 1H/19F MRI, the motion could be measured on low
resolution 1H images reconstructed for different time points during
19F MRI acquisition and this information could be used to retro-
spectively correct the acquired data [39].
Recently, for the ﬁrst time the potential of compressed sensing
has been investigated for 19F MRI and applied to speed up in vivo
19F MRI of PFC accumulation in a brain lesion in the mouse [60].
Under deﬁned conditions, compressed sensing allows reconstruc-
tion of MR images from undersampled data, i.e. within shorter
acquisition times. It has had an immense impact on anatomical and
functional 1H MRI, e.g. MR angiography. Despite signiﬁcant reduc-
tion of imaging times at comparable image quality, the authors
remained skeptical of the proﬁt for 19F MRI in situations of low SNR.
Sufﬁcient signal is one of the prerequisites for a successful
Table 3
Reported detection limits of 19F MRI-based cell tracking. Reported detection limits of 19F labeled cells in dependency of 19F compound and relaxation times, cellular uptake of
19F, MRI system and MR acquisition.
19F label Cell type Average
cell loading
["1012 19
F’s/cell]
Field
strength
(T)
T1/T2
[ms]a
RF coil
(diameter)
Pulse
sequence
Imaging
time
[min]
Reported
detection
limit
Detection
limit
["1016 19
F’s/voxel]b
SNR Estimated
detection
limit (SNR¼5)
at 9.4 T within
1 h ["1016 19
F’s/voxel]c
Reference
PLGA-PFCE
nanoparticles
Human
dendritic cells
25 7 n/a Surface coil
(10 mm)
TSE n/a <30,000 cells n/a n/a n/a [4]
PFPE emulsion Murine T-cells 22 11.7 n/a Birdcage
volume
resonator
TSE 68 7500 cells in
vitro/30,000
cells in vivo
17 2.5 44 [62]
PFPE emulsion Human
dendritic cells
17 7 350/40 Surface coil
(10 mm)
Spin echo 82 2000 cells 3.4 3 4.9 [24]
PLGA-PFCE
nanoparticles
Human
dendritic cells
7 7 950/50 Solenoid
(15 mm)
MRSI 60 5000 cells 3.5 3 4.3 [112]
PFCE emulsion Primary human
stem/progenitor
cells
6.2 11.7 800/- Solenoid
(5 mm)
FLASH 7 6100 cells
in vitro
3.8 3 2.7 [82]
PFPE emulsion Human neural
stem cells
3.70 11.7 380/70 Single loop
surface
Tx/Rx
(25 mm)
TSE 57 1000 cells in
vitro/10,000
cells in vivo
0.37 3.5 0.64 [16]
PFPE emulsion Human neural
stem cells
2 7 425/82 Quadrature
volume coil
TSE 60 17,000 cells
in vitro
3.3 1.25 9.9 [15]
PFCE emulsion Murine dendritic
cells
1.66 9.4 n/a 4-turn
solenoid
FLASH 106 106 cells 170 n/a n/a [21]
PFCE emulsion Murine
macrophages
0.44 9.4 n/a Birdcage
volume
resonator
(30 mm)
TSE 19 200 cells 0.18 3 0.17 [61]
avb3-targeted
Gd/PFCE
emulsion
Human umbilical
vein-derived
endothelial cells
6.3 800/
varying
with [Gd]
Solenoid
Tx/Rx
(5 mm)
FLASH 10 200 mM cell-
internalized 19F
0.59 5 0.16 [69]
PFCE emulsion Murine neural
stem cells
11.7 580/540 Slotted tube
volume
resonator
TSE 8 30 mM 19F
agent at 20 mL
voxel
n/a n/a [17]
PFPE emulsion Human
pancreatic
islets
9.4 n/a Solenoid
Tx/Rx
TSE 37 10 islets/w
20000 cells
n/a n/a n/a [90]
a Intracellular T1/T2 times when available.
b If minimum detectable 19F concentration c19F,min was reported we used c19F,min " voxel size, if minimum number of detectable cells ncells,min was reported we used
ncells,min " (19F/cell).
c For better comparison of detection limits, the minimum detectable 19F/voxel at 9.4 T and 1 h imaging time and an SNR ¼ 5 is stated assuming SNR linear with 19F
concentration, a linear SNR increase with ﬁeld strength (sample dominant noise) and inverse square root dependency on imaging time.
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reconstruction. Thus, it is questionable if cell tracking with 19F MRI
can proﬁt from compressed sensing.
7.5. Cell quantiﬁcation
The signal in a voxel of a 19F MR image is proportional to the
amountof 19F therein. This linear relation can thenbeused toquantify
signal on in vivo images by an in vitro calibration curve acquired in
a separate experiment [61]or byplacing a reference tubewithdeﬁned
19F concentration in the ﬁeld of view [62]. If the 19F content per cell is
known, signal in 19F MR images can be used to calculate cell number
(reviewed in [2]). A small coil that is inductively coupled to the signal-
receiving RF coil can be used to “inject” an artiﬁcial reference signal
alternatively to using a reference tube [63]. Before quantiﬁcation, 19F
image data should bepre-processed to account for non-linearnoise at
lowsignal intensities either byan analytical correction scheme [64] or
by simulated calibration curves [62]. Unfortunately, accurate cell
quantiﬁcationbecomes challenging for lowSNRdue topartial volume
effects which cannot easily be corrected for. For example, if the
number of cells within a voxel is just below the detection limit this
informationwill under certain circumstances be completely lost. We
estimated the resulting variability in 19F signal to be up tow30% by
measuring the signal in 19F MR images of a phantom containing
a small pellet of 19F labeled neural stem cells after stepwise
displacement of the imaging slices in a 2D pulse sequence. However,
localized 19F MRS in the whole volume of interest could be used to
overcome partial volume effects at the cost of spatial resolution [65].
The extensive use of surface coils for quantiﬁcation of 19F
concentration is problematic. For superﬁcial tissue these coils are
superior in sensitivity over larger volume coils and they are rela-
tively easy to design. However, due to the inhomogeneous
magnetic ﬁeld proﬁle (B1 proﬁle) the 19F MR image intensity
depends not only on 19F concentration but also on the distance
from the coil. The bias could be corrected by spatially mapping the
B1 on the 19F channel, although this is very time-consuming at low
19F concentrations and hence not applicable in vivo. We have
recently presented a workﬂow to correct in vivo 19F MR images of
neural stem cell grafts acquired with a 1H/19F surface coil by
mapping the B1 on the 1H channel, which allowed to spatially
resolve cell densities in vivo [66]. The strategy is easily imple-
mented if a coil is used with identical B1 proﬁle for 1H and 19F and if
sufﬁcient 1H background signal is provided in regions of the cell
implant. Fast B1 mapping methods developed in the context of
parallel imaging could further improve quantitative in vivo 19F MRI
with double-tuned surface coils [67].
8. Future of cellular 19F MRI: molecular and multimodal
imaging strategies
One of the main advantages of 19F MRI is the lack of endogenous
19F. On the other hand, the signal on 19F MR images needs to be
generated by an exogenously delivered 19F agent and is only an
indirect marker of the cells. A single 19F MRI experiment of ex vivo
labeled cells using a non-targeted 19F marker provides cell
anatomical location and possibly density but information on cell
function such as gene expression or viability is missing. However,
these parameters are crucial for a successful action of cells deliv-
ered for a therapeutic purpose. If the agent is contained within cells
over longer times, changes in signal location over time can be
linked to migratory capacity, which is an indicator of viability at
least for the migrating fraction of cells. Furthermore, when using
PFC nanoemulsions intracellular pO2 can be exploited as another
marker of cell function in vivo [68].
To make 19F MRI more speciﬁc to a certain cell population,
molecular process, or micro-environment two major strategies
exist in the literature 1) the functionalization of 19F agents with
surface molecules to promote cell/molecule speciﬁc accumulation
of 19F and 2) the generation of “smart” 19F agents or “reporter
molecules” that change chemical properties upon interaction with
a molecular target.
Functionalizing PFC emulsions with an antibody against the
integrin avb3 has been used to speciﬁcally enhance uptake by
endothelial cells [69] and to detect angiogenesis [70]. Other
molecular targets included VCAM-1 [71] and ﬁbrin [72] for detec-
tion and quantiﬁcation by 19F MRS. Importantly, these nano-
particles can be loaded with drugs, which allows simultaneous
monitoring and mediation of therapy (reviewed in [73]). Binding of
the agent to a surface molecule is, however, limited, i.e. accumu-
lation 19F above detection limits for in vivo MRI is challenging,
although improved MRI acquisition allowed the true in vivo
detection of targeted agents in preliminary studies [74,75]. A wide
range of 19F reporter molecules, so-called “smart” or responsive
agents, have been developed for 19F MRS including markers of gene
activity, hypoxia, pH, metal ions, temperature, diffusion and more
(reviewed in [76]). In vivo proof-of-concepts were shown for 19F
MRS detection of lacZ gene expression in transgenic tumor cells
[77,78]. However, many of these compounds are not easily taken up
by cells and detailed toxicity and biocompatibility proﬁles are
unknown. Moreover, lack of sensitivity has hampered the use of
responsive agents for in vivo 19F MRI but this may soon be feasible
with improvements in MRI hardware and acquisition.
An alternative strategy to assess cell function in vivo is the
combination of 19F MRI with other modalities that can be more
sensitive, such as 1H MRI, X-ray imaging, ﬂuorescence imaging
(FLI), bioluminescence imaging (BLI) or positron emission tomog-
raphy (PET). 19F agents containing Gd3þ, ﬂuorophores, emulsiﬁed
PFC core, or bromide have been synthesized for in vivo multimodal
detection with 1H MRI, optical imaging, ultrasound or CT respec-
tively. Multimodal nanoparticles are useful to conﬁrm 19F MRI
results and to visualize the 19F agent for immunohistochemistry,
although the in vivo information from other imaging modalities
again provides only indirect measures of cell function. In a different
approach, we have recently shown efﬁcient 19F labeling of neural
stem cells transduced with luciferase for BLI detection ([79], Fig. 2).
Since the transgene is only expressed in vital cells and the light
reaction is ATP-dependent, the BLI signal is a marker of cell
viability. Bimodal in vivo detection of the transgenic, 19F labeled
cells with 19F MRI and BLI was possible after implantation in the
mouse brain, which allowed noninvasive assessment of cell graft
location, density, and viability under normal conditions and after
stroke.
Interestingly, and perhaps distressingly, we found that the 19F
signal persisted even after the BLI signal was lost at 28 days, indi-
cating that the 19F data was of either dead cells or of label that was
no longer within the relevant cells. This is a key issue that must be
resolved before 19F MRI can mature as an in vivo cell tracking
technique. Some attempts in this direction have been made, for
example through the addition of a ﬂuorescent dye for histology at
late time points to localize the 19F agent precisely [80]. This is
especially necessary for cell tracking studies that stretch over
longer periods of time - one of the unique advantages of 19F MRI.
9. Conclusion
It has been just over 5 years since the introduction of 19F MRI for
in vivo cell tracking [81]. The explosion in label developments and
advances in MRI technology have allowed 19F MRI to become
established in this short time. Although sensitivity remains a key
hurdle, probes such as reporter molecules and other responsive
probes are very promising. As a ﬁnal point, it is necessary to keep in
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mind that comprehensive validation is crucial both in vitro (for
example, cell functionality, ﬂuorescence microscopy) and in vivo
(post-mortem histology and multimodal imaging).
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3 Discussion	  and	  outlook	  
The	   topics	   of	   papers	   underlying	   this	   dissertation	   can	   be	   categorized	   in	   two	   relatively	  self-­‐contained	  major	   topics,	   MRI	   of	   angiogenesis	   and	   MRI	   of	   stem	   cell	   implantations.	  Therefore,	  these	  topics	  will	  first	  be	  discussed	  individually.	  Implications	  for	  biology	  and	  regenerative	   medicine	   and	   perspectives	   for	   methodological	   improvements	   will	   be	  discussed	  including	  presentation	  of	  data	  not	  contained	  in	  the	  papers	  of	  this	  dissertation.	  Finally,	   there	   is	   significant	   overlap	   in	   these	   topics	   and	   suggestions	   will	   be	   made	   on	  noninvasive	  imaging	  of	  stem	  cell	  interaction	  with	  the	  vasculature.	  
3.1 MRI	  of	  angiogenesis	  
3.1.1 Biological	  aspects	  
Temporal	  profile	  of	  vascular	  changes	  in	  tumors	  As	   the	   temporal	   continuity	   of	   information	   is	   an	   exclusive	   advantage	   of	   noninvasive	  imaging,	  one	  of	  the	  main	  goals	  of	  this	  dissertation	  was	  to	  identify	  relevant	  time	  frames	  during	  which	  vascular	  changes	  occur	  in	  tumor	  and	  after	  stroke.	  	  In	   the	   subcutaneous	   lung	   tumor	  model,	  microvessel	   density	   peaked	   at	   around	   8	   days	  post	   implantation	   of	   the	   tumor	   cells	   but	   increased	   vessel	   densities	   at	   the	   tumor	   rim	  could	   be	   found	   as	   early	   as	   one	   day	   post	   implantation	   (paper	   I).	   An	   effect	   of	   anti-­‐angiogenic	   treatment	  was	  observed	  within	   the	   first	  week	  after	  PTK787	   injections.	  For	  the	  glioblastoma	  model,	  the	  relevant	  time	  frame	  for	  important	  vascular	  changes	  seems	  to	  be	  longer	  (paper	  II).	  Small	  signs	  of	  angiogenesis	  could	  first	  be	  detected	  3	  weeks	  post	  implantation	   of	   tumor	   cells	   via	   an	   increase	   in	   blood	   volume	   in	   small	   vessels	   but	  extensively	   increased	   blood	   volume	  was	   only	   observed	   at	   6	  weeks	   post	   implantation	  although	  –	  in	  contrast	  to	  paper	  I	  -­‐	  mainly	  in	  large	  vessels.	  The	  differences	  are	  certainly	  due	   to	   genetic	   differences	   of	   tumor	   types	   but	   may	   also	   be	   due	   to	   the	   differences	   in	  microenvironment	  (skin	  vs.	  brain)	  since	  it	  is	  known	  that	  host	  cells,	  e.g.	  fibroblasts,	  play	  a	  major	  role	  in	  tumoral	  angiogenesis	  [81].	  
Anti-­‐angiogenic	  treatment	  of	  tumors	  Interestingly,	   it	   seems	   to	   be	   a	   common	   feature	   of	   both	  models	   (paper	   I+II)	   that	   anti-­‐angiogenic	   treatment	   efficiently	   decreases	   the	   number	   of	   small	   vessels	   and	   induces	   a	  shift	   towards	   large	   vessels.	   These	   findings	   are	   in	   agreement	   with	   other	   studies	   on	  squamous	  cell	  carcinoma	  [82],	  renal	  cell	  carcinoma	  [83],	  and	  melanoma	  [84].	  However,	  the	   formation	   of	   abnormally	   large	   vessels	   is	   distressing	   for	   the	   widely	   propagated	  concept	   of	   vascular	   normalization	   under	   anti-­‐angiogenic	   therapy	   [85].	   This	   concept	  states,	   that	   inhibition	   of	   pro-­‐angiogenic	   molecules	   in	   angiogenic	   tumors	   leads	   to	   a	  normalization	  of	   tumor	  vasculature	  towards	   less	   leaky	  and	   less	  dilated	  vessels.	  This	   is	  beneficial	   for	   patients	   undergoing	   chemotherapy	   and	   radiotherapy	   in	   parallel	   to	   anti-­‐angiogenic	  treatment	  due	  to	  better	  delivery	  of	  drugs	  through	  functional	  vasculature.	  In	  the	   light	   of	   our	   findings	   and	   those	   of	   other	   groups	   [82–84],	   it	   must	   be	   considered,	  however,	   that	   there	   is	   no	   general	   concept	   that	   can	   describe	   the	   response	   to	   anti-­‐angiogenic	  therapy	  for	  all	  tumor	  types.	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Temporal	  profile	  of	  vascular	  changes	  after	  stroke	  There	   is	  much	  debate	  on	   the	   extent	   of	   stroke-­‐induced	  angiogenesis	   and	   relevant	   time	  frames.	  Focusing	  on	  the	  subacute	  period	  up	  to	  4	  weeks	  after	  the	  infarct,	  we	  found	  very	  few	  signs	  of	  early	  angiogenesis	  (endothelial	  cell	  proliferation)	  but	  no	  signs	  of	  late-­‐stage	  angiogenesis	  as	  would	  be	  reflected	  in	  increased	  vessel	  density	  (paper	  III).	  A	  decrease	  in	  blood	   volume	   in	   small	   vessels	   was	   most	   pronounced	   1	   week	   after	   stroke	   and	   there	  seemed	  to	  be	  very	  little	  change	  from	  2-­‐4	  weeks	  in	  all	  SSCE	  MRI	  derived	  parameters.	  This	  indicates	  that	  most	  changes	  in	  vascular	  architecture	  are	  to	  be	  expected	  during	  the	  first	  two	  weeks	  after	  stroke	  in	  agreement	  with	  an	  earlier	  study	  [86].	  Importance	  of	  early	  time	  frames	   is	   supported	   by	   reports	   on	   strong	   hyperperfusion	   of	   ischemic	   tissue	   [86]	   and	  even	  of	  the	  contralateral	  cortex	  [87]	  within	  the	  first	  week	  after	  stroke,	  which	  correlated	  with	   higher	  microvessel	   densities.	   This	  was	   interpreted	   as	   a	   result	   of	   angiogenesis.	   A	  few	  studies,	  however,	  showed	  changes	  in	  vasculature	  and	  signs	  of	  angiogenesis	  up	  to	  30	  days	  [87]	  or	  even	  3	  months	  [88]	  after	  focal	  cerebral	  ischemia.	  	  In	   summary,	   results	   from	   different	   groups	   are	   very	   variable,	   which	   possibly	   can	   be	  attributed	  to	  differences	  in	  stroke	  models	  and	  lesion	  type.	  Indeed,	  whether	  or	  not	  cyst	  formation	  and	   immune	  cell	   infiltration	  were	  present	  was	  shown	   to	  be	  correlated	  with	  increases	   in	   microvessel	   densities	   in	   rats	   [87].	   The	   variability	   raises	   the	   important	  question	   to	   what	   extent	   results	   from	   rodent	   stroke	   models	   can	   be	   translated	   to	   the	  human	   situation.	   Initial	   MRI	   results	   of	   clinical	   studies	   confirm	   increased	   vessel	  diameters	  and	  decreased	  vessel	  densities	  in	  stroke	  patients	  [89],	  [90]	  in	  agreement	  with	  our	   study	   (paper	   III)	   as	   well	   as	   others’	   using	   the	   filament	  model	   of	   transient	  middle	  cerebral	   artery	  occlusion	   [91],	   [92].	  Noninvasive	   imaging	  of	   vessel	   size	   and	  density	   in	  the	   clinic	   requires,	   however,	   improvements	   in	   MRI	   methodology.	   These	   will	   be	  discussed	  in	  the	  next	  section.	  
3.1.2 Methodological	  aspects	  
SSCE	  MRI	  in	  humans	  For	  SSCE	  MRI	   in	  animals,	  usually	  very	  high	  concentrations	  of	   contrast	  agent	  are	  used.	  This	   is	   due	   to	   two	   reasons.	   First,	   the	   effect	   on	   the	   signal	   is	   small	   compared	   to	   noise	  especially	   for	   the	   spin	   echo	   experiment.	   As	   the	   change	   in	   relaxation	   rate	   scales	   with	  
ΔR2 ~ c2 3 ,	   increasing	  concentration	  is	  efficient	  to	  increase	  effect-­‐to-­‐noise	  ratio.	  Second,	  the	  analytical	  description	  of	   the	  signal	  holds	  only	   for	   the	  static	  dephasing	  regime	  (see	  next	  section).	  The	  system	  is	  in	  this	  regime	  when	  the	  average	  distance	  from	  the	  vessel	  for	  which	  spins	  are	  completely	  dephased	   is	  much	   larger	   than	  the	  average	  diffusion	   length	  
lD / ρ <<1 	  [24].	   ρ 	  can	  be	   interpreted	  as	  an	  effective	  vessel	   radius.	  This	  distance	   scales	  with	   ρ ~ c1 2 	  for	   the	   gradient	   echo	   and	  ρ ~ c1 3 	  for	   the	   spin	   echo.	   Thus	   an	   increase	   of	  concentration	   pushes	   the	   spin	   system	   into	   the	   static	   dephasing	   regime.	   For	   lower	  concentrations,	  vessel	  size	  would	  be	  over-­‐estimated	  [93].	  However,	  the	  typical	  doses	  used	  in	  animal	  experiments	  (30	  mg	  Fe/kg)	  are	  around	  100	  times	   higher	   than	   approved	   for	   human	   use.	   Kiselev	   et	   al.	   have	   therefore	   proposed	   a	  different	   experimental	   strategy	   for	  vessel	   size	   imaging	   in	  patients	   [30].	  A	  bolus	  of	   the	  clinically	   approved	   paramagnetic	   contrast	   agent	   Gd-­‐DTPA	   is	   injected	   intravenously.	  Once	  the	  agent	  has	  spread	  homogeneously	  over	  the	  blood	  pool,	  the	  paramagnetic	  effect	  is	  too	  small	  to	  perform	  vessel	  size	  imaging	  for	  the	  reasons	  above.	  However,	  the	  first	  pass	  of	   the	   bolus	   through	   the	   vessel	   system	   is	   highly	   concentrated.	   A	   special	   echo	   planar	  imaging	   (EPI)	   pulse	   sequence	   is	   used	   to	   quickly	   acquire	   both	   gradient	   echo	   and	   spin	  
CHAPTER	  3:	  DISCUSSION	  AND	  OUTLOOK	  
	   109	  
echo	   MR	   images	   during	   the	   bolus.	   Fitting	   of	   the	   dynamic	   data	   can	   then	   be	   used	   to	  calculate	  vessel	  size	  or	  density	  in	  the	  healthy	  brain	  [94]	  or	  under	  pathological	  conditions	  [30],	   [89],	   [90].	  Although	  the	  quality	  of	  EPI	   images	   is	  much	  lower	  compared	  to	  human	  data	  such	  fast	  imaging	  approaches	  could	  be	  very	  helpful	  for	  vessel	  size	  imaging	  in	  small	  animals	   in	   future	  studies.	  Obviously,	   faster	   imaging	   times	  reduce	  anesthesia	   time	   thus	  stress	   for	   the	   animal.	   Dynamic	   data	   allows	   absolute	   quantification	   of	   blood	   volume	  fraction,	   i.e.	   of	   vessel	   size	   and	   density,	   without	   the	   need	   to	  withdraw	   blood	   samples.	  Furthermore,	   uptake	   of	   contrast	   agent	   by	   host	   cells	   is	   small	   during	   the	   fast	   image	  acquisition.	   This	   uptake,	   e.g.	   by	   cells	   in	   liver	   and	   spleen	   (see	   next	   section)	   leads	   to	  decreasing	   concentration	   of	   contrast	   agent	   in	   the	   blood	   and	   accumulation	   of	   contrast	  agent	  in	  these	  organs.	  For	  long	  acquisition	  times,	  this	  is	  a	  problem	  since	  it	  may	  violate	  the	  assumption	  that	  the	  agent	  is	  in	  a	  steady	  state	  over	  the	  MR	  experiment.	  
Limitations	  of	  vessel	  size	  imaging	  using	  the	  cylinder	  model	  Despite	  its	  success	  and	  wide	  application,	  mainly	  in	  brain	  research	  of	  tumor	  and	  stroke,	  it	  should	  be	   remembered	   that	   the	   cylinder	  model	   is	   based	  on	  very	  distinct	   assumptions	  that	   may	   be	   justified	   in	   normal	   brain	   tissue	   but	   are	   violated	   under	   pathological	  conditions	  or	  for	  other	  parts	  of	  the	  body.	  One	  of	  the	  main	  restrictions	  is	  for	  example	  a	  low	  blood	  volume	  fraction.	  To	  tackle	  these	  problems,	  I	  made	  two	  research	  visits	  during	  my	   doctoral	   thesis	   at	   the	   “MRI	   of	   angiogenesis”	   group	   of	   Prof.	  Michal	   Neeman	   at	   the	  Weizmann	  Institute	  of	  Science	  (Rehovot,	  Israel).	  The	  goal	  of	  these	  visits	  was	  to	  develop	  a	  model	  for	  the	  MR	  signal	  in	  tissues	  with	  non-­‐cylindrical	  vessels	  and	  high	  blood	  volumes.	  Main	   foci	   of	   the	   Weizmann	   group	   are	   vascular	   changes	   during	   fetal	   development,	  pregnancy,	  and	  in	  tumor.	  All	   assumptions	   underlying	   vessel	   size	   imaging,	   the	   rationale	   behind	   them,	   and	  justification	  in	  different	  tissues	  are	  summarized	  in	  Table	  1.	  Six	  different	  tissue	  types	  are	  discussed:	  brain,	  skeletal	  muscle,	  spleen,	  liver,	  placenta,	  ischemic	  brain,	  and	  tumor.	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  Brain	   vasculature	   mainly	   consists	   of	   small	   capillaries	   and	   the	   blood	   brain	   barrier	   is	  impermeable	   for	  most	   contrast	   agent	   particles.	  Water	   diffusion	   in	   brain	   tissue	   is	   not	  isotropic	  [95],	  especially	  in	  white	  matter,	  but	  most	  other	  requirements	  are	  met.	  Skeletal	  muscle	  vasculature,	  e.g.	  back	  muscle,	  mainly	  consists	  of	  small,	  parallel	  capillaries.	  Liver	  and	   spleen	  vessels	   have	  non-­‐cylindrical,	   sinusoidal	   vessels	   and	  generally	  much	  higher	  blood	   volume	   fraction	   than	   brain	   and	   muscle	   [96],	   [97].	   Contrast	   agent	   particles	  accumulate	   in	   cells	   of	   these	   organs	   (Kupffer	   cells	   in	   the	   liver	   and	   monocytes	   in	   the	  spleen)	  since	  they	  act	  as	  blood	  filters	  [97],	  [98].	  The	  main	  part	  of	  the	  placenta	  consists	  of	  the	   sponge-­‐like	   labyrinth,	   with	   cup-­‐shaped	   pools	   of	   blood	   [99].	   Direct	   leakage	   of	  contrast	  agent	  injected	  in	  the	  maternal	  blood	  pool	  is	  impossible	  for	  healthy	  placenta	  due	  to	  the	  placental	  barrier.	  Crossing	  of	  contrast	  agent	  particles	  from	  maternal	  to	  fetal	  blood	  pool	  may	  only	  be	  possible	   through	  cellular	  uptake,	  which	  -­‐	   to	  my	  knowledge	  -­‐	  has	  not	  been	   characterized	   yet.	   Fig.	   8	   shows	   fluorescence	   microscopy	   images	   of	   histological	  sections	   from	   back	   muscle,	   liver,	   and	   placenta	   of	   pregnant	   mice	   to	   illustrate	   the	  differences	   in	   vascular	   geometry	   of	   different	   tissues.	   Tissue	   was	   excised	   after	   i.v.	  
assumption rationale justification 
infintely long cylinders, i.e. 
average branching 
length>>vessel radius 
magnetic field can be 
analytically calculated 
brain (+); muscle (++); liver/spleen (-); placenta (--); 
stroke brain (+); tumor (0) 
number of vessels per 
voxel>>1; size of 
substructures within voxel 
(e.g. vessels)<<voxel 
size; random distribution 
of vessels 
statistical averaging 
possible 
brain (+); muscle (+); liver/spleen (+); placenta (+); 
stroke brain (+); tumor (0) 
blood volume<<1 theory interaction-free, i.e. 
spins in extravascular 
compartment on average 
experience only field of 
one cylinder 
brain (++); muscle (+); liver/spleen (-); placenta (--); 
stroke brain (++); tumor (0)  
contrast agent 
intravascular (no leakage) 
otherwise vessel 
geometry ≠ geometric 
distribution of contrast 
agent 
brain (++); muscle (++); liver/spleen (-); placenta (++); 
stroke brain (+); tumor (-) 
contrast agent 
concentration constant 
over the experiment 
steady-state condition depends on duration of the MR experiment; relevant 
tissue features are leakage and uptake by organ cells; 
brain (++); muscle (+); liver/spleen (--); placenta (n/a); 
stroke brain (+); tumor (0) 
vessel walls impermeable 
for water molecules 
two compartment model, 
avoid exchange terms 
brain (+); muscle (+); liver/spleen (+); placenta (+); 
stroke brain (+); tumor (-) 
distance around vessel for 
which spins are effectively 
dephased>>diffusion 
length 
justifies analytical 
description in static 
dephasing regime 
depends on good adjustment of MRI parameters 
(mainly echo time); relevant tissue parameters are 
average vessel diameter and water diffusivity; brain (+); 
muscle (+); liver/kidney (0); placenta (0); stroke brain 
(+); tumor (0) 
isotropic, free diffusion  diffusion effect can be 
analytically calculated 
brain (0); muscle (+); liver/spleen (++); placenta (++); 
stroke brain (0); tumor (++) 
Table	   1:	   Assumptions	   underlying	   the	   cylinder	  model	   of	   the	   vasculature,	   their	   rationale	   and	   justification	   in	   different	  
tissues.	   Categories	   range	   from	  very	  well	   justified	   (++)	   to	   highly	   violated	   (-­‐-­‐).	   Note	   that	   for	   stroke	   and	   especially	   for	  
tumor	  tissue,	  categories	  may	  very	  much	  depend	  on	  exact	  type	  and	  progression	  of	  the	  disease.	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injection	  of	  the	  fluorescent	  dye	  FITC-­‐Dextran.	  The	  agent	  was	  used	  to	  visualize	  perfused	  vessels	  for	  histology.	  The	  data	  was	  acquired	  in	  experiments	  at	  the	  Weizmann	  Institute	  of	  Science.	  For	  comparison,	  images	  of	  brain	  vasculature	  can	  be	  found	  in	  figures	  of	  paper	  II	  and	  III.	  
	  Brain	   vasculature	   does	   not	   change	   significantly	   (with	   respect	   to	   the	   cylinder	   model	  restrictions)	   after	   stroke	   except	   for	   blood-­‐brain	   barrier	   opening	   during	   the	   first	  hours/days	   and	  permeability	  during	   early	   angiogenesis	   [15],	   [100].	  Tumors,	   however,	  can	   have	   very	   large,	   leaky,	   non-­‐cylindrically	   shaped	   vessels	   depending	   on	   tumor	   type	  and	  progression	  [81].	  
Perspective:	  vessel	  size	  imaging	  beyond	  the	  cylinder	  model	  Improved	  models	  of	  the	  vasculature	  would	  be	  of	  great	  benefit	  for	  many	  fields	  in	  MRI,	  for	  which	   the	   contrast	   or	   signal	   of	   interest	   originates	   from	   blood.	   Examples	   are	   MRI	   of	  perfusion,	   flow,	   functional	   MRI,	   or	   any	   MRI	   method	   that	   uses	   intravascular	   tracers.	  Today,	   powerful	   MRI	   simulators	   exist	   and	   can	   be	   combined	   with	   tissue	   models	   to	  predict	   MRI	   signal	   in	   magnetically	   heterogeneous	   tissue	   for	   any	   given	   MRI	   pulse	  sequence.	   Such	   strategy	   was	   recently	   shown	   for	   quantification	   of	   the	   BOLD	   effect	   in	  functional	  MRI	  with	   spin	   echo	   sequences	   [101],	   [102].	   However,	   vasculature	   in	   these	  studies	   was	   also	   modeled	   as	   infinitely	   long	   cylinders.	   A	   conceptionally	   different	  approach	   is	   the	  use	  of	   fractal	   geometry.	   Instead	  of	  using	   traditional,	   simple	  geometric	  objects,	   e.g.	   spheres	   or	   cylinders	   of	   certain	   diameter	   and	   length,	   the	   vascular	   tree	   is	  assumed	  to	  consist	  of	  self-­‐similar,	  irregular	  objects	  of	  many	  different	  sizes.	  This	  can	  be	  used	   to	   find	  better	  parameters,	   e.g.	   fractal	   dimension,	   to	  describe	   the	   irregular	   tumor	  vasculature	  [103]	  and	  to	  better	  describe	  MRI	  signal	  from	  flowing	  water	  in	  porous	  media	  
	  
Figure	  8:	  Fluorescence	  microscopy	  to	  illustrate	  differences	  in	  vascular	  structure	  of	  back	  muscle,	  liver,	  and	  placenta.	  Top	  
panels	   show	  10x	  magnified,	   lower	  panels	  40x	  magnified	   images	  of	   tissue	   excised	  ~10	  min	   after	   i.v.	   injection	   of	  FITC-­‐
Dextran	  (red)	  into	  a	  living	  pregnant	  mouse	  (embryonic	  day	  17.5).	  Cell	  nuclei	  are	  stained	  with	  Hoechst	  (blue).	  Muscle	  
vessels	  are	  homogeneous,	  long,	  and	  cylindrically	  shaped	  and	  occupy	  a	  low	  fraction	  of	  tissue	  volume.	  Liver	  vasculature	  is	  
more	  heterogeneous	  and	  characterized	  by	  much	  higher	  blood	  volume	  fraction	  and	  presence	  of	  non-­‐cylindrical	  vessels.	  
The	   labyrinth	   of	   the	   placenta	   consists	   of	   a	   network	   of	   non-­‐cylindrical,	   sinusoidal	   spaces	   occupying	   very	   high	   blood	  
volume	  fraction.	  Note	  that	  FITC-­‐Dextran	  cannot	  cross	  the	  placental	  barrier,	  thus	  only	  the	  maternal	  vessels	  are	  stained	  
red	  and	  very	  little	  staining	  is	  seen	  at	  the	  far	  end	  towards	  the	  fetus	  (marked	  with	  F)	  compared	  to	  the	  maternal	  side	  (M).	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[104].	   In	   the	   following,	   preliminary	   data	   of	   a	   more	   experimental	   approach	   will	   be	  presented,	  which	  we	  developed	  at	  the	  Weizmann	  Institute	  of	  Science.	  	  To	   model	   sponge-­‐like	   vasculature	   in	   vitro,	   e.g.	   the	   labyrinth	   of	   the	   murine	   placenta,	  tubes	   filled	   with	   the	   cross-­‐linked	   dextran	   gel	   Sephadex	   (Sigma-­‐Aldrich,	   Hamburg,	  Germany)	   and	  agarose	   gel	  were	  doped	  with	  different	   concentrations	  of	   SPIO	  particles	  (Endorem).	   Iron	   concentrations	   were	   chosen	   equidistantly	   from	   0-­‐1	   mM	   Fe,	   which	  corresponds	   to	   0-­‐55.8	   mg/kg.	   R1 ,	   R2 ,	   and	   R2* 	  relaxation	   rates	   of	   these	   tubes	   were	  measured	   at	   a	   9.4	   T	  MRI	   vertical	   bore	   scanner	   (Bruker	   BioSpin,	   Ettlingen,	   Germany).	  When	   the	   Sephadex	   powder	   beads	   are	   saturated	  with	   water,	   they	   form	   spheres.	   The	  pore	   size	   of	   the	   beads	   is	  well	   below	   the	   diameter	   of	   SPIO	   particles	   (<<200	   nm)	   thus	  contrast	  agent	  particles	  are	  restricted	   to	   the	  space	  between	  beads.	  The	   tube	   therefore	  consists	  of	  two	  compartments.	  The	  beads	  represent	  the	  extravascular	  compartment	  (no	  contrast	   agent)	   and	   the	   spaces	   between	   the	   beads	   represent	   the	   intravascular	  compartment	   (doped	   with	   contrast	   agent).	   Different	   Sephadex	   bead	   sizes	   are	  commercially	   available:	   coarse	   (100-­‐300	   µm),	  medium	   (50-­‐150	   µm),	   fine	   (20-­‐80	   µm),	  and	  superfine	  (20-­‐50	  µm).	  These	  can	  be	  used	  to	  probe	  MRI	  relaxation	  rate	  dependency	  on	   bead	   or	   “vessel”	   size.	  Water-­‐saturated	   beads	   were	   packed	   as	   densely	   as	   possible.	  Then	   the	   volume	   between	   the	   beads	   (the	   “blood	   volume	   fraction”)	   is	   26%	   of	   total	  volume.	   This	   number	   is	   well-­‐known	   from	   dense	   sphere	   packing.	   More	   agarose	   was	  added	  to	  end	  up	  with	  a	  50%	  volume	  of	   inter-­‐bead	  space	  in	  order	  to	  model	  tissue	  with	  very	  high	  blood	  volume.	  A	   Sephadex	   tube	   is	   schematically	   illustrated	   in	   Fig.	   9	   next	   to	  light	  microscopy	  images	  of	  the	  water-­‐saturated	  beads	  of	  different	  sizes.	  
	  For	  the	  cylinder	  model,	  the	  most	  intriguing	  finding	  is	  a	  vessel	  size	  dependency	  of	  ΔR2 	  on	  average	   vessel	   radius	   R 	  due	   to	   the	   diffusion	   effect	   in	   the	   extravascular	   compartment.	  This	   leads	   to	   a	   non-­‐trivial	   relation	   ΔR2 ~ c2 3R−2 3 	  compared	   to	   the	   expected	   trivial	  
	  
Figure	   9:	   Schematic	   illustration	   of	   the	   Sephadex	  model	   of	   sponge-­‐like	   vasculature	   (left)	   and	   microscopy	   images	   of	  
hydrated	  Sephadex	  beads	  of	  different	  sizes	  (right).	  Sephadex	  beads	  represent	  the	  extravascular	  compartment,	  the	  space	  
in	   between	   beads	   represents	   the	   intravascular	   compartment	   and	   can	   be	   doped	  with	  MR	   contrast	   agents.	   Image	   of	  
superfine	  Sephadex	  shown	  in	  20x	  magnification,	  all	  others	  10x.	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proportionality	   to	   iron	   oxide	   concentration	   seen	   for	  ΔR2* ~ c .	   Thus	   it	   was	   interesting	  whether	   or	   not	   a	   non-­‐trivial	   relation	   between	  ΔR2 ,	   iron	   concentration,	   and	   bead	   size	  would	   be	   found	   in	   the	   Sephadex	   model.	   Fig.	   10	   shows	   R1 ,	   R2 ,	   and	   R2* 	  over	   iron	  concentration	   (note	   that	   differences	   ΔR1 ,	   ΔR2 ,	   and	   ΔR2* 	  would	   be	   obtained	   by	  subtracting	  the	  0	  mM	  value).	  Indeed,	  a	  very	  strong	  dependency	  of	  R2 	  on	  bead	  size	  was	  found	   and	   an	   increase	   less	   than	   linear	   with	   concentration.	   Interestingly,	   R1 	  was	   also	  significantly	   different	   for	   different	   bead	   sizes.	   In	   contrast,	   R2* 	  grew	   approximately	  linearly	   with	   concentration.	   As	   expected,	   all	   relaxation	   rates	   grew	   linearly	   with	  concentration	   in	   control	   tubes	   containing	   only	   the	   SPIO-­‐doped	   agarose	   without	  Sephadex	   beads.	   Thus	   it	   was	   truly	   the	   microstructure,	   i.e.	   the	   compartmentalization,	  which	  induced	  the	  deviation	  from	  a	  linear	  relation.	  These	  data	  indicate	  that	  vessel	  size	  imaging	  could	  also	  be	  feasible	  in	  tissue	  with	  sponge-­‐like	  vasculature	  and	  very	  high	  blood	  volume.	  	  
	  To	  test	  whether	  or	  not	  the	  Sephadex	  model	  reflects	  the	  in	  vivo	  situation,	  pregnant	  mice	  (ICR	  strain,	  n=7,	  n=63	  placentas,	  embryonic	  day	  17.5)	  were	  scanned	  with	  MRI	  at	  a	  9.4	  T	  (Bruker	  BioSpin).	  SPIO	  particles	  were	  injected	  i.v.	  in	  3	  accumulating	  doses	  (1.5	  mg/kg	  Fe	  each,	  i.e.	  up	  to	  4.5	  mg/kg).	   R2 	  and	  R2* 	  were	  recorded	  before	  and	  after	  injection	  (Fig.	  11).	  The	  curves	  seem	  to	  resemble	  the	  in	  vitro	  situation	  but	  these	  trends	  are	  not	  statistically	  significant	  due	   to	  high	  variability	   in	   the	  data.	  High	  blood	  volume	  of	  placenta	  and	   liver	  lead	  to	  very	  high	  relaxation	  rates	  thus	  signal	  decays	  extremely	  fast.	  Accuracy	  of	   R2 /R2* 	  measurements	   is	   therefore	   low	  using	   conventional	   spin	   echo	   and	   gradient	   echo	  pulse	  sequences,	   which	   can	   be	   seen	   by	   the	   large	   error	   bars.	   Furthermore,	   since	   SPIOs	  accumulate	  fast	  in	  cells	  of	  the	  liver,	  data	  from	  there	  is	  not	  reliably	  acquired	  in	  a	  steady-­‐state.	  Future	  studies	  need	  to	  validate	  the	  in	  vitro	  findings	  with	  computer	  simulations	  or	  new	  analytical	  models.	   Furthermore,	   animal	   studies	  with	   improved	  MRI	  methodology,	  e.g.	  ultra-­‐short	  or	  steady	  state	  pulse	  sequences,	  are	  proposed	  to	  sample	  the	  fast	  decay	  of	  signal	  in	  placenta	  and	  liver.	  This	  will	  help	  to	  further	  explore	  if	  the	  in	  vitro	  findings	  really	  reflect	  the	  in	  vivo	  situation	  or	  if	  they	  are	  only	  artificial.	  
	  
Figure	   10:	   Relaxation	   rates	   	  (A),	   	  (B),	   and	   	  (C)	   in	   Sephadex	   phantoms.	   Tubes	   were	   doped	   with	   varying	  
amounts	   of	   SPIOs,	   concentrations	   are	   given	   in	   iron	  molarities.	   Different	   bead	   sizes	   were	   used	   and	   agarose	  without	  
Sephadex	   served	   as	   a	   control.	   	  curves	   strongly	   deviate	   from	   trivial	   linear	   increase	   seen	   for	   media	   without	  
microstructure,	   e.g.	   the	   agarose.	   For	   both	   	  and	   	  differences	   were	   found	   for	   the	   various	   bead	   sizes.	   Highest	  
relaxation	   rate	   was	   found	   for	   the	   smallest	   beads	   and	   lowest	   relaxation	   rate	   for	   coarse	   beads.	   This	   indicates	   that	  
distinguishing	  different	  vessel	  radii	  in	  sponge-­‐like	  vasculature	  may	  be	  possible	  in	  analogy	  to	  the	  cylinder	  model-­‐based	  
vessel	  size	  imaging.	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3.2 MRI	  of	  stem	  cell	  implantations	  
3.2.1 Biological	  aspects	  Although	   treatment	   of	   neurological	   diseases	   with	   stem	   cells	   has	   proven	   beneficial	   in	  many	   animal	   studies	   there	   is	   a	  wide	   variety	   of	   parameters	   that	   need	   to	   be	   optimized	  before	  stem	  cells	  can	  be	  used	  in	  patients.	  Certainly,	  optimal	  parameters	  depend	  on	  the	  individual	  pathology,	  e.g.	  lesion	  type,	  and	  the	  patient’s	  biological	  and	  even	  psychological	  status.	  Nevertheless,	  detailed	  standard	  protocols	  need	  to	  be	  defined	  to	  ensure	  safety	  and	  maximum	  benefit	  for	  the	  patient.	  The	  most	  important	  parameters	  are	  the	  source	  of	  stem	  cells,	  stem	  cell	   fate,	  route	  of	  delivery,	  dose,	   timing	  and	  site	  of	  transplantation,	   immune	  suppression	  to	  prevent	  graft	  rejection,	  and	  ethical	  considerations.	   In	  the	  following,	   the	  results	  of	  this	  dissertation	  will	  be	  discussed	  with	  respect	  to	  these	  parameters	  focusing	  on	  stroke.	  The	  source	  of	  stem	  cells	  for	  therapy	  is	  a	  critical	  factor	  for	  successful	  action	  of	  these	  cells	  in	  vivo	  and	  raises	  ethical	  questions.	  To	  prevent	  host	  immune	  response,	  cells	  originating	  from	  the	  same	  species	  as	  the	  host	  are	  tolerated	  best,	   i.e.	   for	  human	  use	  cells	  of	  human	  origin	  are	  most	  promising	  [37].	  For	  large-­‐scale	  use,	  expansion	  of	  cells	  in	  culture	  should	  be	   possible	   since	   the	   use	   of	   primary	   cells	   from	   large	   numbers	   of	   human	   embryos	   or	  fetuses	   is	   ethically	   unacceptable.	   Under	   these	   premises,	   the	   human	  NSCs	   used	   in	   this	  dissertation	   are	   a	   suitable	   source	   for	   therapy	   since	   they	   can	   be	   expanded	   in	  neurosphere	  culture	  for	  long	  times.	  IPS	  cells,	  derived	  for	  example	  from	  a	  patient’s	  skin	  cell,	   would	   be	   an	   optimal	   source	   since	   they	   promise	   unlimited	   access	   to	   stem	   cells,	  ethical	  issues	  would	  be	  practically	  solved	  and	  problems	  with	  immune	  rejection	  would	  be	  minimized,	  but	  the	  field	  is	  still	  young.	  	  A	   homogeneous	   cell	   population	   in	   terms	   of	   differentiation	   status	   is	   of	   utmost	  importance.	  Pluripotent	  embryonic	  stem	  cells	  need	  to	  be	  sufficiently	  pre-­‐differentiated	  towards	  the	  neuronal	  type	  before	  implantation	  as	  too	  immature	  cells	  can	  proliferate	  in	  an	  uncontrolled	  manner	   and	   form	  a	   tumor	   [105],	   [106].	  To	   ensure	  homogeneity,	   cells	  either	  need	  to	  be	  selected,	  e.g.	  by	  differences	  in	  expression	  of	  surface	  markers,	  through	  co-­‐culturing	   with	   cells	   that	   release	   factors,	   or	   through	   addition	   of	   factors	   to	   culture	  medium	  that	  drive	  the	  heterogeneous	  population	  of	  cells	  into	  a	  more	  similar	  state	  [107].	  
	  
Figure	   11:	  Relaxation	   rates	   	  (A)	   and	   	  (B)	   in	   liver,	   placenta,	   and	  muscle	   of	   pregnant	  mice	   after	   i.v.	   injection	   of	  
SPIO	  particles.	  Concentrations	  are	  given	  in	  mg	  iron	  per	  kg	  body	  weight.	   	  in	  liver	  and	  placenta	  seems	  to	  increase	  less	  
than	   linearly	   whereas	   	  increases	   linearly.	   However,	   signal	   decays	   so	   fast	   in	   these	   tissues	   that	  measurements	   are	  
challenging,	  which	   leads	   to	   the	   large	  error	  bars.	  For	  muscle,	  blood	  volume	  and	   iron	  oxide	  doses	  are	   too	   low	  to	  see	  a	  
strong	  effect.	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The	   human	   NSCs	   used	   for	   this	   dissertation	   ceased	   to	   proliferate	   shortly	   after	  implantation	   in	   all	   studies	   and	  did	  not	   form	   tumors.	  However,	   they	   likely	   consist	   of	   a	  heterogeneous	  population	  of	  both	  neural	   stem	  cells	   and	   less	  potent	  neural	  progenitor	  cells	   using	   strict	   definitions	   of	   these	   terms	   [46].	   Cells	   can	   alternatively	   be	   genetically	  modified	  to	  express	  markers	  that	  force	  the	  population	  in	  a	  defined	  state.	  For	  example,	  to	  yield	   more	   cells	   of	   neuronal	   phenotype,	   the	   human	   NSCs	   of	   this	   dissertation	   can	   be	  modified	  to	  overexpress	  the	  factor	  Pax6	  [43].	  For	  stroke,	   there	   is	  much	  debate	  on	   the	  optimal	  dose,	   timing,	  and	  site	  of	   implantation	  and	   no	   general	   answer	   exists.	   In	   perspective	   of	   clinical	   practice,	   early	   intervention	  would	  only	  help	  those	  who	  come	  to	  the	  hospital	  quick	  enough	  and	  would	  thus	  exclude	  a	  large	   patient	   population.	   However,	   it	   has	   been	   hypothesized	   that	   implantation	  within	  the	  first	  days	  would	  maximize	  beneficial	  effect	  for	  host	  tissue	  at	  risk	  through	  release	  of	  trophic	  factors	  by	  the	  grafted	  cells	  [46],	  [108].	  Subacute	  implantation	  (>1	  week)	  is	  most	  likely	   optimal	   to	   stimulate	   endogenous	   repair	  mechanisms	   such	   as	   neurogenesis	   and	  angiogenesis,	  whereas	  optimal	  cell	  survival	  was	  hypothesized	  for	   later	  times	  when	  the	  initial	   immune	   response	   to	   the	   stroke	   has	   declined	   [108].	   However,	   a	   recent	   study	  showed	   better	   survival	   due	   to	   less	   stroke-­‐induced	   immune	   response	   for	   early	  implantation	  at	  48	  h	  compared	  to	  6	  weeks	  [45].	  For	  this	  reason,	  in	  follow-­‐up	  studies	  of	  this	  dissertation,	  NSCs	  were	  implanted	  48	  h	  after	  stroke	  surgery	  (see	  last	  paragraph	  of	  section	  3.2.2).	  Studies	   that	   showed	   stem	   cell-­‐mediated	   recovery	   after	   stroke	   used	   intracerebral,	  intravascular,	   or	   intraventricular	   route	   of	   delivery	   and	   each	   route	   has	   its	   distinct	  advantages	  (reviewed	  in	  [60],	  [108]).	  The	  highest	  delivery	  of	  cells	  to	  the	  brain	  is	  given	  by	   intracerebral	   implantation	   and	   this	   route	   was	   therefore	   chosen	   for	   the	   present	  studies.	  However,	   large	   intracerebral	   implants	   can	  damage	  healthy	   tissue,	   and	   lacking	  supply	   of	   oxygen	   and	   nutrients	   to	   implanted	   cells	   can	   severely	   lower	   graft	   survival.	  Indeed,	  we	  saw	  a	  rim	  of	  glial	  (GFAP	  positive)	  cells	  aligning	  the	  graft	  (Fig.	  4	  of	  paper	  V),	  which	   is	  a	  sign	   for	  glial	   scar	   in	  response	   to	   the	   implantation	  procedure.	  Darsalia	  et	  al.	  speculated	   about	   existence	   of	   a	  maximum	   threshold,	   beyond	  which	   higher	   implanted	  cell	  number	  would	  not	  lead	  to	  higher	  number	  of	  surviving	  cells	  [45].	  Such	  threshold	  is,	  for	  rodents,	  probably	  in	  the	  hundred	  thousands	  range.	  For	   intracerebral	   implantation	   after	   stroke,	   the	   most	   optimal	   implantation	   site	   is	  probably	  intact	  tissue	  adjacent	  to	  the	  lesion	  in	  order	  to	  avoid	  the	  hostile	  environment	  of	  the	  lesion	  core	  whilst	  assuring	  maximum	  infiltration	  of	  damaged	  tissue	  by	  the	  cells	  [46].	  For	  follow-­‐up	  studies	  in	  ischemic	  mice	  we	  therefore	  implanted	  cells	  in	  this	  region	  (see	  last	  paragraph	  of	  section	  3.2.2).	  Cells	  can	  also	  be	  implanted	  directly	  into	  the	  lesion	  cavity	  in	   the	   chronic	   stage	  of	   stroke.	  However,	   since	   the	   cavity	   is	   filled	  with	   fluid,	   structural	  support	  of	  the	  cells	  needs	  to	  be	  provided.	  This	  can	  be	  achieved	  by	  embedding	  them	  in	  extracellular	   matrix	   proteins	   and	   implanting	   a	   mixture	   of	   cells	   and	   such	   scaffold	  proteins	   [52],	   [109],	   [110].	   This	   is	   an	   appealing	   strategy	   as	   intact	   tissue	   is	  minimally	  affected,	  much	  higher	  number	  of	  cells	  can	  be	  implanted,	  and	  the	  scaffold	  can	  be	  doped	  with	  drugs,	  e.g.	  VEGF	  to	  facilitate	  growth	  of	  supporting	  vasculature	  for	  the	  graft	  [52].	  
3.2.2 Methodological	  aspects	  
Cell	  quantification	  Accurate	  cell	  quantification	  in	  vivo	  with	  MRI	  would	  facilitate	  finding	  optimal	  parameters	  as	  discussed	  in	  the	  previous	  section,	  especially	  to	  find	  optimal	  dosage.	  Invasive	  studies	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face	   two	  major	   problems.	   First,	   the	   exact	   number	   of	   cells	   is	   usually	   derived	   from	   cell	  countings	   of	   the	   suspension	   before	   implantation.	   However,	   cells	   can	   be	   lost	   when	  transferred	   from	   one	   tube	   to	   another,	   they	   can	   get	   stuck	   in	   the	   syringe	   used	   for	  implantation,	  or	  cells	  can	  be	  pushed	  back	  through	  the	  injection	  canal.	  When	  animals	  are	  sacrificed	  days	  or	  weeks	  later	  and	  much	  less	  cells	  are	  found,	  it	  is	  unknown	  whether	  they	  were	   lost	   before	   implantation	   due	   to	   imperfect	   preparation/surgery	   or	   after	  implantation	  due	   to	  some	  biological	  process	  of	   interest.	  Quantitative	  MRI	  would	  allow	  controlling	  the	  number	  of	  cells	  that	  truly	  reached	  their	  target	  in	  the	  brain	  directly	  after	  surgery.	   Second,	   cells	   are	   packed	   very	   closely	   in	   intracerebral	   grafts.	   From	   our	  experience,	   counting	   the	   cells	   on	   histological	   sections	   is	   labor-­‐intensive,	   can	   become	  very	   inaccurate	  on	  dense	  cell	   spots,	  and	  requires	  very	  good,	  sensitive	  cell	  markers	   for	  histology	  and	  excellent	  microscopy	  image	  quality.	  Thus,	  noninvasive	  cell	  quantification	  could,	  less	  labor-­‐intensively,	  yield	  more	  accurate	  results.	  For	  SPIO	  labels,	  our	  semi-­‐quantification	  of	  gradient	  echo	  images	  provided	  graft	  volume	  (paper	  IV),	  however,	  absolute	  cell	  number	  could	  not	  be	  assessed	  due	  to	  complete	  signal	  dropout	   in	   regions	   of	   the	   graft.	   Since	   iron	   oxide	   labels	   are	   widely	   used,	   several	  improvements	   in	   MRI	   acquisition	   and	   data	   post-­‐processing	   have	   been	   proposed	   for	  more	  specific	  and	  quantifiable	  contrast	  generated	  by	  labeled	  cells.	   In	  order	  to	  quantify	  relaxation	  rate	  R2* 	  in	  densely	  packed	  cell	  grafts,	  ultrashort	  echo	  time	  sequences	  can	  be	  used	   [111].	   Cell	   number	   is	   yielded	   assuming	   a	   linear	   proportionality	   of	  R2* 	  and	   cell	  density.	   In	  another	  study,	  a	   theoretical	  model	  was	  derived	  and	  confirmed	  in	  vitro.	  Cell	  quantification	  was	  possible	  using	  balanced	  steady-­‐state	  free	  precession	  pulse	  sequences	  but	   validation	   in	   vivo	   was	   missing	   [112].	   The	   utility	   of	  R2* 	  for	   cell	   quantification	   is	  questionable	   due	   to	   large	  macroscopic	  magnetic	   inhomogeneities,	   which	   lead	   to	   very	  heterogeneous	  background	   R2* .	  Strong	  inhomogeneities	  are	  present	  for	  example	  around	  tissue	   to	  air	   interfaces	   [113].	  Therefore,	  other	  groups	  have	  used	  spin-­‐echo	  derived	  R2 	  for	   quantification	   [114].	   However,	   for	   the	   reasons	   stated	   in	   the	   introduction	   (section	  1.4.2),	  the	  signal	  also	  depends	  on	  cell	  distribution	  and	  graft	  shape	  in	  a	  complex	  manner	  and	   it	   is	   questionable	   to	   assume	   a	   linear	   relation	   between	   cell	   density	   and	   relaxation	  rate.	  This	   is	  particularly	  true	  for	  R2 .	  To	  enhance	  specificity	  of	  cell	  contrast,	   the	  shift	   in	  Larmor	  frequency	  around	  iron	  oxide	  particles	  can	  be	  visualized	  by	  suppressing	  the	  basic	  frequency	  of	  water	  signal,	  which	  leads	  to	  bright	  spots	  on	  MR	  images	  in	  regions	  of	   iron	  oxides.	  This	  is	  referred	  to	  as	  “positive	  contrast”	  MRI	  of	  cells	  [113],	  [115].	  To	  summarize	  the	  literature,	  cell	  quantification	  seems	  possible	  in	  vitro	  but	  the	  mechanisms	  of	  contrast	  generation	  using	  magnetic	  labels	  limits	  the	  usefulness	  for	  in	  vivo	  quantification.	  To	   date,	   19F	   MRI	   of	   fluorine	   labeled	   cells	   is	   the	   only	   modality	   that	   promises	   cell	  localization	   and	   quantification	   in	   deep	   tissues	   over	   long	   times.	   Detailed	   experimental	  workflows	  to	  quantify	  transplanted	  cells	  in	  vivo	  have	  been	  reviewed	  elsewhere	  [73]	  and	  in	  paper	  VI	  of	   this	  dissertation.	  Furthermore,	  we	   think	   that	  we	  have	  solved	  one	  of	   the	  pending	   problems	   of	   quantitative	   in	   vivo	   19F	   MRI.	   For	   sensitive	   detection	   of	   19F	   MR	  signal,	  small	  surface	  coils	  are	  extensively	  used.	   In	  contrast	  to	  a	  (less	  sensitive)	  volume	  coil	  with	  homogeneous	  magnetic	  field	  profile,	  the	  intensity	  on	  a	  19F	  image	  from	  a	  surface	  coil	  depends	  on	  the	  distance	  of	  labeled	  cells	  from	  the	  coil.	  For	  example,	  if	  cells	  migrated	  to	  deeper	   regions	   in	   the	  brain	   further	  away	   from	   the	   coil,	   this	  would	   lead	   to	  a	   loss	  of	  signal,	  which	  could	  be	  misinterpreted	  as	  a	  decrease	  in	  cell	  number.	  For	  this	  reason,	  the	  detection	  limits	  of	  1,000	  cells/voxel	  in	  vitro	  and	  10,000	  cells/voxel	  in	  vivo	  reported	  in	  paper	  V	  give	  only	  a	  rough	  order-­‐of-­‐magnitude.	  We	  therefore	  further	  improved	  our	  cell	  
CHAPTER	  3:	  DISCUSSION	  AND	  OUTLOOK	  
	   117	  
quantification	  strategies.	   In	   the	   following,	   I	  will	  present	  our	  experimental	  workflow	  to	  correct	  image	  data	  for	  the	  coil	  profile	  by	  mapping	  the	  RF	  pulse	  flip	  angle	  on	  1H	  images	  [116].	  	  The	  magnitude	  of	  magnetic	   field	  produced	  by	   the	   coil	   is	  proportional	   to	   the	   flip	  angle	  
B1
r( ) ~ FA r( ) .	  A	  1H flip	  angle	  map	  is	  acquired	  using	  the	  double	  flip	  angle	  method	  [117].	  We	  usually	  use	   a	   turbo	   spin	   echo	   sequence	  with	   centric	   encoding	   and	   repetition	   time	  TR>>T1.	  Detailed	  MRI	  parameters	  can	  be	  found	  in	  [116].	  For	  these	  pulse	  sequences	  the	  spin	  echo	  signal	  can	  be	  calculated	  [118].	  As	  a	  result	  of	  imperfect	  RF	  excitation	  (Tx),	  the	  image	  intensity	  is	  attenuated	  by	  a	  factor	  	   attTx r( ) = sin3 FA r( )( ) 	   (5) 	  Due	   to	   Faraday’s	   principle	   of	   reciprocity,	   image	   intensity	   is	   additionally	   attenuated	  during	  signal	  reception	  (Rx)	  by	  a	  factor	  proportional	  to	  the	  B1 	  thus	  FA :	  	   attRx r( ) = FA r( )90° 	   (6) 	  Note	  that	  both	  factors	  are	  normalized	  so	  that	  in	  case	  of	  perfect	  90°	  flip	  angle,	  the	  overall	  attenuation	   att19F = attTx ⋅attRx =1 .	  Consequently	  the	  19F	  signal	  at	   r 	  depends	  not	  only	  on	  19F	  concentration	  but	  also	  on	  the	  flip	  angle	  	   S19F r( ) = A ⋅c19F r( ) ⋅att19F r( ),    A = const. 	   (7) 	  i.e.	  division	  of	  the	  19F	  image	  by	  att19F 	  yields	  a	  B1 	  corrected	  image	  with	  signal	  intensities	  
S19F,corr
r( ) ,	  which	  only	  depend	  on	  19F	  concentrations.	  The	  concentration	  of	  19F	  in	  cells	  m 	  ([m] = mol / cell )	   can	   be	   experimentally	   determined	   by	   19F	  MR	   spectroscopy	   (Fig.	   1	   of	  paper	  V).	   A 	  is	  circumvented	  by	  normalizing	  the	  image	  intensity	  to	  a	  reference	  tube	  with	  known	   19F	   concentration	   c19F,ref ,	  which	   is	  placed	   in	   the	   field	  of	   view	   together	  with	   the	  animal.	  Finally,	  the	  number	  of	  cells	  in	  the	  voxel	  at	   r 	  is	  determined	  via	  	   n r( ) = S19F,corr r( ) ⋅ c19F,refS19F,corr,ref ⋅m 	   (8) 	  This	  workflow	  was	   implemented	   in	  custom	  scripts	  written	   in	  Matlab	  (The	  Mathworks,	  Natick,	  MA,	  USA)	  and	  validated	  in	  vitro	  on	  a	  dilution	  series	  of	  perfluoropolyether	  (PFPE)	  emulsion	  (Fig.	  12).	  Furthermore,	  the	  scheme	  was	  applied	  in	  vivo	  in	  order	  to	  absolutely	  quantitate	  NSC	  densities	  after	  intracerebral	  implantation	  (Fig.	  13).	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Limitations	  of	  external	  MRI	  labels	  External	  MRI	  labels,	  e.g.	  SPIO	  particles	  for	  cell	  detection	  with	  1H MRI	  or	  PFC	  emulsions	  for	   detection	   with	   19F	   MRI,	   can	   have	   a	   negative	   effect	   on	   cell	   function,	   e.g.	   viability,	  differentiation	  or	  migratory	  capacity.	  This	  is	  particularly	  true	  for	  NSCs	  since	  these	  cells	  are	  very	  sensitive	  to	  their	  microenvironment.	  Despite	  the	  extensive	  use	  of	  SPIO	  particles	  for	  over	  a	  decade,	  these	  “side	  effects”	  are	  only	  now	  being	  investigated	  in	  detail.	  Recent	  studies	  showed	  reduced	  viability	  and	  motility	  of	  stem	  cells	  after	  SPIO	  labeling	  and	  these	  reports	   suggest	   an	   optimization	   of	   intracellular	   SPIO	   dose	   to	   minimize	   these	   effects	  [119],	  [120].	  Usually,	  stem	  cell	  function	  is	  assessed	  through	  standard	  in	  vitro	  tests,	  e.g.	  trypan	   blue	   exclusion	   assay	   to	   assess	   viability	   or	   scratch	   assay	   to	   test	   for	   migratory	  capacity.	  These	  and	  similar	  tests	  were	  used	  for	  studies	  of	  this	  dissertation	  and	  we	  found	  minimal	  effects	  on	  cell	  function	  for	  both	  SPIO	  labels	  (paper	  IV)	  and	  PFC	  labels	  (paper	  V).	  However,	   the	   tests	   are	   generally	   carried	   out	   on	   cells	   in	   2	   dimensional	   cultures,	   e.g.	  adherent	   cultures,	   which	   do	   not	   reflect	   the	   3D	   environment	   the	   cells	   face	   in	   vivo.	  Development	   of	   novel	   3D	   cell	   cultures	   that	   better	   simulate	   the	   in	   vivo	   situation	   is	  therefore	  of	  importance	  [121],	  [122].	  On	   the	   other	   hand,	   external	   labels	   can	   have	   adverse	   effect	   on	   the	   host.	   From	   studies	  using	  PFC	  emulsions	  as	  blood	  substitutes,	  it	  is	  known	  that	  PFCs	  are	  well	  tolerated	  by	  the	  human	   body	   (paper	   VI).	   In	   rare	   cases,	   superparamagnetic	   iron	   oxides	   can	   cause	  
	  
Figure	  12:	  Validation	  of	  B1 correction	  scheme	  in	  vitro	  at	  very	  low	  19F	  signal-­‐to-­‐noise	  ratio	  (SNR).	  Tubes	  with	  different	  
concentrations	  of	  perfluoropolyether	  emulsion	  in	  agarose	  were	  imaged	  with	  19F	  MRI.	  The	  19F	  SNR	  map	  (color)	  overlaid	  
on	  a	   1H	   image	  (grayscale)	  was	   corrected	   for	  B1 inhomogeneities	  by	  mapping	  the	   coil	  profile	  on	   the	   1H and	  by	   using	  
equations	  (5)	  and	  (6).	  The	  corrected	  19F	  image	  has	  some	  artifacts	  at	   the	  edges	  of	   tubes	  due	   to	  partial	  volume	  effects	  
(gray	   arrows).	   After	   removal	   of	   artifacts	   by	   taking	   a	   trimmed	   mean	   (mean	   neglecting	   25%	   of	   highest	   and	   lowest	  
values)	   a	   linear	   relation	   of	   19F	   concentration	   and	   signal	   was	   shown	   (red	   line).	   19F	   signal	   was	   not	   proportional	   to	  
concentration	  before	  correction	  due	  to	  attenuation	  for	  tubes	  further	  away	  from	  the	  coil	  (black	  curve).	  
	  
Figure	  13:	  Quantitative	  in	  vivo	  19F	  MRI	  with	  surface	  coils.	  After	  implantation	  of	  19F	  labeled	  cells,	  a	  mouse	  is	  imaged	  with	  
anatomical	  1H MRI	  together	  with	  a	  reference	  tube	  containing	  200	  mM	  19F	  in	  agarose	  (white	  arrow).	  The	  surface	  coil	  is	  
placed	  at	  the	  top	  of	  the	  head.	  A	  1H flip	  angle	  map	  is	  acquired	  and	  a	  19F	  attenuation	  map	  can	  be	  calculated,	  in	  this	  case	  
for	  a	  turbo	  spin	  echo	  pulse	  sequence.	  The	  uncorrected	  19F	  SNR	  map	  shows	  signal	  from	  the	  reference	  and	  the	  cell	  graft	  
(red	  arrow).	  19F	  SNR	  divided	  by	  the	  attenuation	  map	  yields	  the	  B1	  corrected	  19F	  image.	  MR	  spectroscopy	  of	  19F	  per	  cell	  
and	  normalization	  of	  the	  19F	  image	  intensity	  to	  the	  mean	  in	  the	  reference	  tube	  allow	  calculation	  of	  a	  quantitative	  cell	  
density	  map.	  The	  cell	  density	  map	  is	  color-­‐coded	  and	  overlaid	  on	  the	  anatomical	  image	  to	  localize	  and	  quantify	  cells	  in	  
vivo.	  Note	  the	  artifacts	  at	  edges	  of	  the	  reference	   tube	  after	  B1	  correction	  (bright	  spots).	  These	  need	  to	  be	  removed	  in	  
analogy	  to	  the	  procedure	  outlined	  in	  Fig.	  12.	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cardiovascular	  adverse	  events	  and	  back	  pain,	  which	  is	  known	  from	  studies	  using	  large	  i.v.	   injections	   for	   liver	   imaging	   [123].	   However,	   most	   negative	   effects	   are	   dose-­‐dependent	  and	  the	  amount	  of	  contrast	  agent/19F	  agent	  is	  low	  when	  used	  for	  cell	  tracking.	  Still,	   biocompatibility,	   degradation	   and	   clearance	   of	   free	   particles	   by	   host	   cells	   are	  important	  issues	  for	  rightful	  interpretation	  of	  imaging	  data.	  When	  an	  implanted	  cell	  dies,	  the	   label	  will	   be	   released	   and	   still	   be	   detectable	   by	  MRI.	   Directly	   after	   cell	   death,	   the	  signal	  will	   likely	  be	   indistinguishable	   from	  signal	   of	   live	   cells.	   It	   is	   important	   to	   know	  whether	  or	  not	  the	  released	  agent	  will	  be	  removed	  by	  the	  host	  and	  on	  what	  time	  scale	  these	  clearance	  processes	  occur.	  Much	  is	  known	  about	  clearance	  of	  nanoparticles	  from	  the	  blood	   system	   (paper	  VI,	   [124]).	  However,	   few	   studies	   have	   investigated	   clearance	  after	  intracerebral	  implantation.	  SPIO	  particles	  in	  the	  interstitial	  space	  of	  the	  brain	  are	  taken	  up	  by	  host	  phagocytes	  and	  subsequently	  removed	  through	  the	  reticuloendothelial	  system.	  The	  time	  scale	  depends	  on	  particle	  size	  and	  surface	  coating	  [125].	  For	  example,	  complete	   clearance	   of	   free	   USPIOs	   from	   the	   brain	   after	   infusion	   in	   the	   striatum	   was	  shown	  to	  occur	  over	  approximately	  2	  weeks	  [126].	  For	  PFC	  emulsions	  no	  reports	  exist	  for	   clearance	   after	   intracerebral	   implantation.	  We	   therefore	   injected	   a	   PFPE	   emulsion	  (CS-­‐green,	   Celsense,	   Pittsburgh,	   USA)	   stereotactically	   in	   the	   striatum	   of	   healthy	   mice	  (n=3,	  NuNu	   strain).	  Animals	  were	   sacrificed	   for	  histology	   at	   24	  h,	   one	  week,	   and	   four	  weeks.	   Additionally,	   we	   performed	   19F	   MRI	   24	   h	   and	   weekly	   after	   injection.	   In	   the	  animal	   that	   survived	   longest,	  ~50%	  of	   the	   initial	   19F	   signal	  was	   still	   detectable	  by	   19F	  MRI	   four	   weeks	   after	   implantation	   (Fig.	   14).	   Histology	   would	   clarify	   whether	   the	  remaining	  agent	  is	  free	  in	  the	  interstitial	  space	  or	  taken	  up	  by	  host	  cells	  but	  this	  is	  still	  work	  in	  progress.	  However,	  the	  persistence	  of	  19F	  signal	  already	  indicates	  that	  free	  PFCs	  can	  reside	  for	   long	  times	   in	  the	  brain	  and	  that	  removal	  of	  19F	  agent	   is	  very	  slow.	  Thus	  false	  positive	  19F	  MRI	  signal	  is	  expected	  should	  PFPE	  labeled	  cells	  die	  after	  implantation.	  	  
	  External	   MRI	   labels	   thus	   fail	   in	   two	   situations	   that	   can	   occur	   in	   vivo.	   First,	   cells	   can	  proliferate	  and	   this	   is	  not	   reflected	  by	  changes	   in	  MR	  signal	   since	   the	  amount	  of	   label	  does	   not	   double	  when	   cell	   number	   is	   doubled.	   Second,	  when	   cells	   die	  MRI	   signal	   can	  
	  
Figure	   14:	   Clearance	   of	   PFPE	   emulsion	   from	   the	   mouse	   brain.	   Three	   mice	   received	   an	   implant	   (2	   µL)	   of	   the	   pure	  
emulsion	  (125	  mg/mL	  PFPE)	  and	  were	  sacrificed	  for	  histology	  at	  different	  time	  points.	  19F	  MRI	  revealed	  persistence	  of	  
strong	  19F	  MRI	  signal	  up	  to	  four	  weeks	  in	  animal	  #1	  (A).	  All	  coronal	  brain	  slices	  with	  significant	  19F	  signal	  are	  shown	  
from	   caudal	   to	   rostral	   at	   24	   h	   and	   4	   weeks	   after	   implantation.	   The	   colorcoded	   19F	   SNR	   map	   is	   overlaid	   on	   an	  
anatomical	  1H MR	  image	  shown	  in	  grayscale.	  Quantification	  of	  19F	  SNR	  confirmed	  presence	  of	  90%	  signal	  for	  animal	  
#2	  after	  one	  week	  and	  ~50%	  for	  animal	  #1	  after	  4	  weeks	  compared	  to	  the	  24	  h	  time	  point	  (B).	  Animal	  #3	  was	  scanned	  
with	  19F	  MRI	  only	  once	  to	  confirm	  successful	  implantation	  and	  sacrificed	  for	  histology	  at	  the	  first	  time	  point.	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persist	   or	   decrease	   with	   a	   long	   delay.	   The	   delay	   is	   dependent	   on	   clearance	   of	   the	  released	  label.	  However,	  both	  proliferation	  and	  viability	  are	  very	  important	  parameters	  for	  the	  risk	  of	   tumor	  formation	  and	  for	  successful	  action	  of	   implanted	  cells.	  Therefore,	  we	  developed	  a	  multimodal	  imaging	  approach	  that	  combines	  the	  strengths	  of	  MRI	  using	  external	   labels	   and	  optical	   imaging	  using	  genetic	   labels	   in	  order	   to	   image	   localization,	  quantity,	  and	  function	  of	  implanted	  cells	  [127].	  This	  will	  be	  presented	  in	  the	  next	  section.	  
Perspective:	  multimodal	   imaging	  of	  stem	  cell	   location,	  number,	  and	  function	  after	  
stroke	  As	   stated	   in	   section	   1.2.1	   of	   the	   introduction,	   reporter	   genes	   are	   suitable	   to	  noninvasively	  assess	  cell	  function.	  When	  cells	  genetically	  modified	  to	  express	  a	  reporter	  gene	   divide,	   the	   signal	   accordingly	   increases	   since	   each	   clone	   of	   the	   mother	   cell	  produces	   its	   own	   reporter	  molecules.	   If	   a	   cell	   dies,	   gene	   transcription	   ceases	   and	   the	  signal	  is	  turned	  off,	  usually	  with	  little	  delay	  since	  reporter	  molecules	  are	  degraded	  fast.	  This	  is	  particularly	  true	  for	  Bioluminescence	  imaging	  (BLI).	  Here,	  transplanted	  cells	  are	  genetically	   modified	   to	   express	   a	   luciferase.	   After	   implantation,	   the	   cells	   constantly	  produce	  the	  enzyme.	  Upon	  injection	  of	  the	  substrate	  luciferin,	  luciferin	  is	  converted	  via	  enzymatic	  reaction	  with	  the	  luciferase	  to	  oxyluciferin	  under	  emission	  of	  light	  (Fig.	  15).	  This	   light	   can	   be	   detected	   with	   an	   optical	   CCD	   camera.	   Since	   the	   reaction	   is	   ATP	  dependent,	   the	   light	   reaction	   exclusively	   occurs	   in	   cells	   that	   have	   both	   normal	   gene	  expression	   and	  metabolism,	   i.e.	   in	   truly	   viable	   cells.	  When	   care	   is	   taken,	   the	   detected	  light	  can	  be	  used	  to	  quantify	  the	  number	  of	  viable	  cells	  via	  linear	  relation	  to	  number	  of	  photons	   per	   second	   per	   cm2	   per	   steradian	   [128–130].	   However	   in	   deep	   tissues,	  scattering	  and	  absorption	  of	  light	  in	  tissue	  hinder	  absolute	  quantification	  of	  cell	  number.	  Furthermore,	   scattering	   and	   absorption	  usually	   lead	   to	   low	   resolution,	   2D	   (projection	  image)	   data.	   Since	   19F	   labels	   promise	   quantification	   and	   3D	   localization	   of	   cells	   with	  good	  resolution	  (<	  1	  mm)	  in	  deep	  tissues,	  we	  decided	  to	  combine	  the	  strengths	  of	  both	  19F	  MRI	  and	  BLI	  by	  using	  genetic	  luciferase	  labeling	  with	  external	  19F	  labeling	  of	  NSCs.	  
	  Neural	   stem	   cells	   were	   derived	   from	  murine	   embryonic	   stem	   cells	   with	   the	   protocol	  described	  in	  [40]	  and	  transduced	  to	  express	  the	  click	  beetle	  luciferase	  (CBG99)	  for	  BLI	  detection.	  To	   label	   the	   cells	   for	  histology,	  we	   incubated	   them	  with	   the	   red	   fluorescent	  marker	  Cell	  Tracker	  Orange	  (Invitrogen).	  For	  19F	  MRI	  detection,	  cells	  were	  labeled	  with	  the	   PFPE	   agent	   used	   for	   paper	   V	   (CS-­‐1000,	   Celsense,	   Pittsburgh,	   USA).	   The	   labeling	  procedure	  was	   optimized	   using	  NMR	   spectroscopy	   to	   yield	  maximum	   19F	   content	   per	  cell	  in	  analogy	  to	  paper	  V.	  These	  experiments	  resulted	  in	  an	  optimal	  dose	  of	  25	  µL	  agent	  per	   mL	   medium	   and	   incubation	   time	   of	   36	   h.	   For	   some	   experiments	   we	   used	   a	  fluorescent	   PFPE	   agent	   (CS-­‐green,	   Celsense)	   for	   detection	   of	   the	   agent	   on	   histological	  sections	  via	   fluorescence	  microscopy.	  Cells	  were	   implanted	   in	  healthy	  and	   in	   ischemic	  NuNu	  mice	  that	  received	  30	  min	  middle	  cerebral	  artery	  occlusion	  as	  described	  in	  [131].	  For	   ischemic	  mice	   we	   performed	   T2	   weighted	  MRI	   24	   h	   after	   surgery	   to	   identify	   the	  lesion	  and	  implanted	  the	  cells	  in	  tissue	  adjacent	  to	  the	  lesion	  48	  h	  post	  stroke.	  Animals	  were	   scanned	   repetitively	   with	   BLI	   and	   19F	   MRI	   up	   to	   4	   weeks	   after	   implantation.	  
	  
Figure	  15:	  Schematic	  illustration	  of	  the	  luciferase	  reaction.	  Modified	  from	  [128].	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Detailed	  MRI	  parameters	  can	  be	   found	   in	  [116],	   [127].	  The	  procedure	  and	  all	  reporter	  systems	  are	  illustrated	  in	  Fig.	  16.	  
	  
	  
Figure	  16:	  Multimodal	  imaging	  of	  NSC	  graft	  location,	  density,	  and	  function.	  Murine	  NSCs	  were	  genetically	  modified	  to	  
express	  the	  click	  beetle	  luciferase	  and	  labeled	  with	  a	  green	  fluorescent	  19F	  agent.	  For	  later	  identification	  on	  histological	  
sections,	  NSCs	  were	  additionally	  labeled	  with	  the	  red	  fluorescent	  marker	  Cell	  Tracker	  Orange.	  Fluorescence	  microscopy	  
of	  NSCs	  after	  labeling	  confirmed	  high	  intracellular	  accumulation	  of	  19F	  agent	  (A).	  Cells	  were	  implanted	  in	  the	  striatum	  
of	   healthy	   and	   stroke	   NuNu	   mice.	   For	   ischemic	  mice	   the	   lesion	  was	   localized	   on	   T2-­‐weighted	  MRI	   scans	   24	   h	   after	  
surgery	  and	  stereotactic	  coordinates	  adjusted	  for	  peri-­‐infarct	  implantation	  48	  h	  post	  surgery.	  A	  19F	  reference	  tube	  was	  
used	  for	  all	  MRI	  scans	  in	  order	  to	  quantify	  cell	  densities	  with	  the	  protocol	  presented	  in	  Fig.	  13	  (B).	  Repetitive	  19F	  MRI	  
and	  BLI	  was	  carried	  out	  in	  order	  to	  assess	  location,	  density,	  and	  viability	  of	  NSCs	  up	  to	  four	  weeks.	  Images	  of	  a	  healthy	  
mouse	  24	  h	  after	  implantation	  are	  shown.	  BLI	  signal	  colorcoded	  and	  overlaid	  on	  a	  photograph	  of	  the	  mouse	  inside	  the	  
camera	  taken	  from	  top	  view.	  For	  better	  visualization	  of	  depth	  of	  signal	  origin,	  two	  side	  mirrors	  were	  placed	  next	  to	  the	  
animal	   (C).	   After	   in	  vivo	  experiments,	   fluorescent	  markers	  allowed	   to	   identify	  cells	  with	   fluorescence	   imaging	  on	   the	  
excised	  brain	  (top	  view).	  Fluorescence	  microscopy	  on	  coronal	  histological	  sections	  was	  used	  to	  identify	  cells	  (red)	  and	  
19F	  agent	  (green)	  (D).	  R/C:	  rostral/caudal.	  Hoechst	  fluorescence	  staining	  of	  cell	  nuclei	  shown	  in	  blue	  for	  A	  and	  D.	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We	   saw	   a	   massive	   decrease	   in	   cell	   viability	   (BLI	   signal)	   over	   time	   for	   grafted	   NSCs.	  Interestingly,	   this	   was	   independent	   of	   whether	   we	   implanted	   into	   the	   healthy	   or	  pathological	  brain.	  For	  one	  animal	  we	  saw	  an	  increase	  in	  BLI	  signal,	  which	  indicated	  cell	  proliferation	  but	  confirmation	  by	  histology	  is	  still	  pending.	  We	  detected	  no	  signs	  of	  cell	  migration	  using	  19F	  MRI.	  Although	  ~70%	  of	  the	  cells	  died	  over	  4	  weeks,	  19F	  MRI	  signal	  persisted	   for	  healthy	  animals,	  which	  can	  be	  explained	  by	   limited	  clearance	  of	   19F	   label	  once	   released	   from	   dead	   cells	   in	   agreement	   with	   the	   results	   of	   implantation	   of	   pure	  agent	   (Fig.	   14).	   Thus	   19F	  MRI	   alone	  would	   have	   lead	   to	   the	  wrong	   conclusion	   that	   all	  NSCs	   are	   still	   present	   at	   4	  weeks.	   This	   stresses	   the	   importance	   of	   combining	   external	  MRI	   label	   approaches	  with	   other	  modalities	   in	   order	   to	   rightfully	   interpret	   biological	  processes.	  We	  speculate	  that	  immune	  reaction	  as	  a	  response	  to	  the	  implanted	  cells	  is	  the	  key	   factor	   that	   leads	   to	   the	  decrease	   in	  viability.	   Indeed,	  we	  do	  see	  signs	  of	  microglial	  activation,	  however	  thorough	  analysis	  of	  histological	  sections	  is	  still	  in	  progress.	  The	  massive	  reduction	  in	  the	  number	  of	  viable	  cells	  was	  observed	  also	  in	  paper	  IV	  of	  this	  dissertation,	   by	   other	   groups	   [45],	   and	   even	   in	   studies,	   in	   which	   a	   recovery	   of	   brain	  function	  was	   observed	  many	  weeks	   after	   implantation	   [62].	   The	   number	   of	   surviving	  implanted	  cells	  in	  all	  those	  studies	  was	  orders	  of	  magnitude	  lower	  than	  the	  number	  of	  cells	   lost	   during	   an	   infarct.	   This	   supports	   the	   hypothesis	   that	   stem	   cell	   mediated	  functional	  recovery	  is	  not	  a	  result	  of	  direct	  tissue	  replacement	  but	  rather	  due	  to	  indirect,	  paracrine	  effects	  of	  implanted	  cells.	  
CHAPTER	  3:	  DISCUSSION	  AND	  OUTLOOK	  
	   123	  
	  
3.3 Interactions	  of	  angiogenesis	  and	  stem	  cells	  after	  cerebral	  lesions	  Remarkably,	  VEGF-­‐A	  and	  some	  other	  angiogenic	  molecules	  have	  shown	  neuroprotective	  properties	  and	  strong	  interaction	  with	  neurogenesis,	  i.e.	  formation	  of	  new	  neurons	  from	  endogenous	   neural	   progenitor	   cells	   [132].	   Migration	   of	   neuroblasts	   that	   are	   newly	  generated	  in	  the	  subventricular	  zone	  of	  rats	  after	  stroke	  was	  shown	  to	  occur	  along	  blood	  vessels	  [133].	  Migration	  of	  endothelial	  cells	  follows	  along	  the	  gradient	  of	  VEGF	  [5]	  and	  one	  can	  speculate	  that	  molecules	  involved	  in	  angiogenesis	  also	  play	  a	  role	  in	  migration	  of	   other	   cell	   types.	   These	   findings	   highlight	   the	   importance	   of	   angiogenesis	   after	   an	  ischemic	   insult	  and	  exemplify	   the	   tight	   link	  of	  angiogenesis	  with	  other	   stroke-­‐induced	  endogenous	  repair	  mechanisms.	  On	   the	   other	   hand,	   angiogenesis	   is	   important	   in	   order	   to	   provide	   blood	   supply	   for	  transplanted	   cells.	   Graft	   vascularization	   was	   shown	   to	   occur	   very	   slowly	   in	   rats	  implanted	   with	   human	   NSCs	   [134].	   Delivery	   of	   stem	   cells	   could	   help	   to	   facilitate	  vascularization	  through	  expression	  of	   factors.	   Indeed,	  delivery	  of	  VEGF	  overexpressing	  NSCs	   and	   CD34	   positive	   hematopoietic	   stem	   cells	  was	   shown	   to	   induce	   angiogenesis,	  enhance	  graft	  survival,	  and	  improve	  animal	  behavior	  after	  stroke	  [135],	  [136].	  Recently,	  a	   study	   showed	   delayed	   vasodilation	   after	   stroke	   in	   rats	   as	   a	   result	   of	   human	  mesenchymal	  stem	  cell	  transplantation	  [137].	  
	  
Figure	  17:	  Cell	  graft	   location,	  density,	  and	  viability	  after	   implantation	   in	  healthy	  and	  stroke	  mice.	  In	  healthy	  animals	  
BLI	  signal	  (viability)	  dropped	  to	  ~30%	  over	  4	  weeks	  whereas	  19F	  SNR	  (location,	  density)	  remained	  relatively	  constant.	  
The	  persisting	  19F	  signal	  may	  be	  explained	  by	  limited	  clearance	  of	  19F	  label	  when	  cells	  die.	  The	  decrease	  in	  cell	  viability	  
was	  most	   pronounced	  between	  week	   one	  and	  two	  (A).	   A	  similar	   trend	  was	   observed	   in	  stroke	  animals	   although	  one	  
animal	  showed	  an	   increase	   in	  BLI	   signal	   indicating	   cell	   proliferation.	   19F	  MRI	  signal	   decreased	   in	  all	   stroke	  animals	  
except	   for	   animal	   27020,	   which	   exhibited	   large	   scatter	   in	   values	   due	   to	   very	   low	   signal	   (B).	   For	   each	   graph,	  
representative	  images	  of	  one	  animal	  are	  shown	  at	  different	  time	  points.	  For	  19F	  MR	  images,	  the	  slice	  through	  the	  brain	  
with	  highest	  19F	  SNR	  is	  shown.	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The	   imaging	   methods	   developed	   in	   this	   dissertation	   could	   help	   to	   further	   elucidate	  interactions	  between	  grafted	  cells	  and	  the	  vasculature.	  Here,	  19F	  labeling	  presents	  a	  very	  attractive	  way	   to	   visualize	   cells,	   since	   these	   labels	  do	  not	   generate	   contrast	   on	   1H MR	  images	  as	  seen	  in	  the	  control	  animal	  of	  Fig.	  4	  of	  paper	  IV,	  in	  all	  anatomical	  1H MR	  images	  shown	  in	  paper	  V,	  and	  those	  shown	  in	  section	  3.2.2	  of	   this	  dissertation.	  Therefore,	   the	  signal	   of	   1H MR	   contrast-­‐based	   methods,	   e.g.	   mapping	   of	   relaxation	   time,	   diffusion	  imaging,	  BOLD	  MRI,	   fMRI,	  dynamic	  or	   SSCE	  MRI	  would	  be	  untouched.	  Combination	  of	  the	  presented	  cellular	  19F	  MRI	  and	  BLI	  with	  these	  1H	  MRI	  methods	  could	  help	  to	  answer	  pending	   important	   questions:	   Is	   a	   suitable	   vascular	   microenvironment	   inevitable	   for	  good	  graft	  acceptance?	  What	  is	  the	  contribution	  of	  angiogenesis	  –	  or	  of	  cell-­‐vasculature	  interactions	   in	   general	   -­‐	   for	   functional	   recovery	   in	  models	   of	   stem	   cell	   therapy	   of	   the	  damaged	  brain?	  
3.4 Conclusion	  Undoubtedly,	   the	  rapid	  advances	   in	  angiogenesis	  and	  stem	  cell	   research	  have	  had	  and	  will	  have	  a	  major	   impact	  on	  our	  understanding	  of	  neurological	  disease	  and	   treatment.	  However,	   the	   initial	   excitement	   has	   partly	   been	   replaced	   by	   the	   realization	   of	   how	  complex	  molecular	  and	  cellular	  processes	  underlying	  the	  disease	  are	  and	  how	  difficult	  it	  is	   to	  manipulate	   these	   for	   therapy.	   Noninvasive	   imaging	   can	   spatially	   and	   temporally	  resolve	   some	  of	   the	  biological	  processes	  underlying	   the	  pathology	  and	  mechanisms	  of	  therapy	  and	  therefore	  provide	  the	  needed	  complexity	  of	  information.	  In	  this	  dissertation,	  SSCE	  MRI	  to	  image	  angiogenesis	  in	  tumor	  and	  stroke	  was	  optimized	  and	  proved	  useful	  to	  monitor	  vascular	  changes	  and	  response	  to	  therapy	  in	  rodents.	  For	  the	  first	  time,	  the	  importance	  of	  diffusion	  measurements	  for	  rightful	  interpretation	  of	  SSCE	  MRI	  data	  was	  specifically	  assessed.	  The	   impact	  of	  noise	  was	  minimized	   through	  optimization	  of	  MRI	  parameters.	  A	  novel	  modification	  of	  the	  theory	  for	  multi	  spin	  echo	  signal	  from	  a	  vascular	  network	  was	   developed	   in	   collaboration	  with	   theorists.	   An	   in	   vitro	  model	   for	   tissues	  with	   non-­‐cylindrical	   vessels	   and	   high	   blood	   volume	   was	   evaluated	   and	   promises	  feasibility	   of	   vessel	   size	   imaging	   beyond	   the	   cylinder	   model	   of	   the	   vasculature.	   The	  spatio-­‐temporal	   dynamics	   of	   human	  NSCs	  were	   followed	   over	   long	   time	  with	   1H	  MRI	  using	   SPIO	   labels.	   To	   improve	   cellular	   MRI,	   a	   novel,	   comprehensive	   framework	   for	  neural	   stem	   cell	   tracking	   by	   19F	   MRI	   and	   optical	   imaging	   has	   been	   established.	   This	  allowed	   for	   the	   first	   time	   to	   noninvasively	   assess	   grafted	   NSC	   location,	   density,	   and	  viability.	   Combination	  of	   the	   innovations	   of	   this	   dissertation	  with	   established	   imaging	  methods	  will	  help	  to	  better	  understand	  the	  indirect	  mechanisms,	  that	  lead	  to	  stem	  cell-­‐mediated	   functional	   recovery	   after	   stroke,	   e.g.	   interactions	   of	   grafted	   NSCs	   with	   the	  vasculature.	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5 Summary/Zusammenfassung	  
5.1 Summary	  Molecular	   biology	   and	   stem	   cell	   research	   have	   had	   an	   immense	   impact	   on	   our	  understanding	  of	  neurological	  diseases,	   for	  which	   little	  or	  no	  therapeutic	  options	  exist	  today.	   Manipulation	   of	   the	   underlying	   disease-­‐specific	   molecular	   and	   cellular	   events	  promises	  more	  efficient	  therapy.	  Angiogenesis,	  i.e.	  the	  regrowth	  of	  new	  vessels	  from	  an	  existing	  vascular	  network,	  has	  been	  identified	  as	  a	  key	  contributor	  for	  the	  progression	  of	  tumor	   and,	   more	   recently,	   for	   regeneration	   after	   stroke.	   Donation	   of	   stem	   cells	   has	  proved	  beneficial	   to	   treat	  cerebral	   lesions.	  However,	  before	  angiogenesis-­‐targeted	  and	  stem	  cell	  therapies	  can	  safely	  be	  used	  in	  patients,	  underlying	  biological	  processes	  need	  to	  be	  better	  understood	  in	  animal	  models.	  Noninvasive	  imaging	  is	  essential	  in	  order	  to	  follow	  biological	  processes	  or	  stem	  cell	  fate	  in	  both	  space	  and	  time.	  We	  optimized	  steady	  state	   contrast	   enhanced	  magnetic	   resonance	   imaging	   (SSCE	  MRI)	   to	  monitor	   vascular	  changes	  in	  rodent	  models	  of	  tumor	  and	  stroke.	  A	  modification	  of	  mathematical	  modeling	  of	   MR	   signal	   from	   the	   vascular	   network	   allowed	   for	   the	   first	   time	   simultaneous	  measurements	   of	   relaxation	   time	  T2	   and	   SSCE	  MRI	   derived	   blood	   volume,	   vessel	   size,	  and	  vessel	  density.	  Limitations	  of	  SSCE	  MRI	  in	  tissues	  with	  high	  blood	  volume	  and	  non-­‐cylindrically	   shaped	   vessels	   were	   explored.	   SSCE	   MRI	   detected	   angiogenesis	   and	  response	   to	   anti-­‐angiogenic	   treatment	   in	   two	   rodent	   tumor	   models.	   In	   both	   tumor	  models,	   reduction	  of	   blood	  volume	   in	   small	   vessels	   and	   a	   shift	   towards	   larger	   vessels	  was	   observed	   upon	   treatment.	   After	   stroke,	   decreased	   vessel	   density	   and	   increased	  vessel	  size	  was	  found,	  which	  was	  most	  pronounced	  one	  week	  after	  the	  infarct.	  This	  is	  in	  agreement	  with	  two	  initial,	  recently	  published	  clinical	  studies.	  Overall,	  very	  little	  signs	  of	  angiogenesis	   were	   found.	   Furthermore,	   superparamagnetic	   iron	   oxide	   (SPIO)	   labels	  were	  used	  to	  study	  neural	  stem	  cells	  (NSCs)	  in	  vivo	  with	  MRI.	  SPIO	  labeling	  revealed	  a	  decrease	  in	  volume	  of	  intracerebral	  grafts	  over	  4	  months,	  assessed	  by	  T2*	  weighted	  MRI.	  Since	   SPIO	   labels	   are	   challenging	   to	   quantify	   and	   their	   MR	   contrast	   can	   easily	   be	  confounded,	  we	  explored	  the	  potential	  of	  in	  vivo	  19F	  MRI	  of	  19F	  labeled	  NSCs.	  Hardware	  was	  developed	   for	   in	  vitro	  and	   in	  vivo	   19F	  MRI.	  NSCs	  were	   labeled	  with	   little	  effect	  on	  cell	   function	  and	   in	  vivo	  detection	   limits	  were	  determined	  at	  ~10,000	  cells	  within	  1	  h	  imaging	  time.	  A	  correction	  for	  the	  inhomogeneous	  magnetic	  field	  profile	  of	  surface	  coils	  was	   validated	   in	   vitro	   and	   applied	   for	   both	   sensitive	   and	   quantitative	   in	   vivo	   cell	  imaging.	   As	   external	   MRI	   labels	   do	   not	   provide	   information	   on	   NSC	   function	   we	  combined	   19F	   MRI	   with	   bioluminescence	   imaging	   (BLI).	   The	   BLI	   signal	   allowed	  quantification	  of	  viable	  cells	  whereas	  19F	  MRI	  provided	  graft	  location	  and	  density	  in	  3D	  over	   4	  weeks	   both	   in	   the	   healthy	   and	   stroke	   brain.	   A	  massive	   decrease	   in	   number	   of	  viable	   cells	   was	   detected	   independent	   of	   the	   microenvironment.	   This	   indicates	   that	  functional	  recovery	  reported	  in	  many	  studies	  of	  NSC	  implantation	  after	  stroke,	  is	  rather	  due	  to	  release	  of	  factors	  by	  NSCs	  than	  direct	  tissue	  replacement.	  In	  light	  of	  these	  indirect	  effects,	   combination	  of	   the	   imaging	  methods	  developed	   in	   this	  dissertation	  with	  other	  functional	   and	   structural	   imaging	   methods	   is	   suggested	   in	   order	   to	   further	   elucidate	  interactions	  of	  NSCs	  with	  the	  vasculature.	  

CHAPTER	  5:	  SUMMARY/ZUSAMMENFASSUNG	  
	   141	  
5.2 Zusammenfassung	  Die	   Molekularbiologie	   und	   Stammzellforschung	   haben	   unser	   Verständnis	   von	  neurologischen	   Erkrankungen,	   für	   die	   es	   momentan	   kaum	   Therapien	   gibt,	   immens	  verändert.	   Die	  Manipulation	   von	   erkrankungsspezifischen	  molekularen	   und	   zellulären	  Ereignissen	  stellt	  eine	  große	  Hoffnung	  für	  die	  effizientere	  Behandlung	  dar.	  Angiogenese,	  d.h.	   vaskuläres	   Neuwachstum	   ausgehend	   von	   existierenden	   Gefäßen,	   wurde	   als	   ein	  wichtiger	  Beitrag	  zum	  Tumorwachstum	  und	  zur	  Regeneration	  nach	  Schlaganfall	  erkannt.	  Stammzelltransplantationen	   haben	   sich	   als	   förderlich	   für	   die	   Behandlung	   zerebraler	  Läsionen	   erwiesen.	   Um	   angiogenese-­‐	   oder	   stammzellbasierte	   Therapien	   sicher	   in	  Patienten	   benutzen	   zu	   können,	   müssen	   jedoch	   die	   zu	   Grunde	   liegenden	   biologischen	  Prozesse	   in	   Tiermodellen	   besser	   verstanden	   werden.	   Dabei	   spielt	   die	   nicht-­‐invasive	  Bildgebung	   eine	   entscheidende	   Rolle,	   um	   diese	   Prozesse	   bzw.	   die	   Zellen	   sowohl	  räumlich	  als	  auch	  zeitlich	  zu	  verfolgen.	  Wir	  haben	  eine	  Magnet-­‐Resonanz-­‐Tomografie-­‐Methode	   (SSCE-­‐MRT)	   optimiert,	   um	   Änderungen	   der	   Gefäßstruktur	   in	   Maus-­‐	   und	  Rattenmodellen	   des	   Tumors	   und	   des	   Schlaganfalls	   zu	   untersuchen.	   Das	   zu	   Grunde	  liegende	  mathematische	   Modell	   wurde	   erweitert,	   um	   erstmals	   die	   Relaxationszeit	   T2,	  Blutvolumen,	   mittlere	   Gefäßdichte	   und	   Gefäßgröße	   simultan	   messen	   zu	   können.	   Die	  Grenzen	   des	   Modells	   in	   Gewebe	   mit	   hohem	   Blutvolumen	   und	   nicht-­‐zylindrischen	  Gefäßen	   wurden	   erörtert.	   Angiogenese	   wurde	   in	   zwei	   unterschiedlichen	  Tumormodellen	   mit	   Hilfe	   der	   SSCE-­‐MRT	   detektiert	   und	   die	   Wirkung	   anti-­‐angiogenetischer	   Therapie	   untersucht.	   In	   beiden	   Tumormodellen	   induzierte	   die	  Therapie	   die	   Abnahme	   kleinerer	   Gefäße	   und	   Zunahme	   der	   Gefäßgröße.	   Nach	  Schlaganfall	   wurde	   eine	   Abnahme	   der	   Gefäßdichte	   und	   Zunahme	   der	   Gefäßgröße	  gefunden,	   die	   am	   stärksten	   eine	   Woche	   nach	   dem	   Infarkt	   ausgeprägt	   war.	   Diese	  Ergebnisse	   stimmen	  mit	   zwei	   erst	   kürzlich	   veröffentlichten	   ersten	   klinischen	   Studien	  überein.	   Insgesamt	  wurden	  nur	   geringe	  Anzeichen	  von	  Angiogenese	  nach	   Schlaganfall	  beobachtet.	  Darüber	  hinaus	  wurden	  Zellmarker	  basierend	  auf	   superparamagnetischen	  Eisenoxiden	  benutzt,	  um	  neurale	  Stammzellen	  (NSZ)	  in	  vivo	  mit	  MRT	  zu	  verfolgen.	  T2*-­‐gewichtete	   MRT	   zeigte,	   dass	   das	   Volumen	   von	   intrazerebralen	   Eisenoxid-­‐markierten	  NSZ-­‐Transplantaten	   über	   4	   Monate	   abnahm.	   Da	   Zellmarker	   aus	   Eisenoxid	   kaum	   die	  Quantifizierung	   von	   NSZ	   zulassen	   und	   der	   Kontrast	   leicht	   verwechselt	   werden	   kann,	  wurde	   das	   Potenzial	   von	   fluorierten	   Zellmarkern,	   die	  mit	   19F-­‐MRT	   detektiert	   werden	  können,	   untersucht.	   Hierzu	   wurde	   ein	   Aufbau	   für	   in	   vitro	   und	   in	   vivo	   19F-­‐MRT	  entwickelt.	   NSZ	   konnten	  mit	   geringen	   Einschränkungen	   der	   Zellfunktion	   effizient	  mit	  einer	  19F-­‐Verbindung	  markiert	  werden.	  In	  vivo	  wurde	  ein	  Detektionslimit	  von	  ca.	  10.000	  Zellen	   innerhalb	   1	   Std.	   Messzeit	   ermittelt.	   Eine	   Korrektur	   für	   das	   inhomogene	  Magnetfeld	  von	  Oberflächenspulen	  wurde	   in	  vitro	  validiert.	  Die	  Korrektur	  erlaubte	  es,	  NSZ	   sensitiv	   und	   quantitativ	   in	   vivo	   darstellen	   zu	   können.	   Da	   MRT-­‐Zellmarker	   kaum	  Information	   über	   die	   Zellfunktion	   bereitstellen,	   wurde	   die	   19F-­‐MRT	   mit	  Biolumineszenzbildgebung	  kombiniert.	  Diese	  diente	  der	  Quantifizierung	  der	  Zellvitalität.	  Die	   19F-­‐MRT	   ermöglichte	   hingegen	   die	   Messung	   der	   Lage	   und	   der	   Zelldichte	   des	  Transplantats	  in	  3D	  über	  einen	  Zeitraum	  von	  4	  Wochen	  –	  sowohl	  im	  gesunden	  als	  auch	  im	   Schlaganfallhirn.	   Ein	   massiver	   Rückgang	   der	   Zellvitalität	   wurde	   beobachtet	  unabhängig	   davon,	   in	   welche	   Umgebung	   die	   Zellen	   implantiert	   wurden.	   Dies	   ist	   ein	  Anhaltspunkt	  dafür,	  dass	  die	  funktionelle	  Erholung,	  die	  für	  Stammzellimplantation	  nach	  Schlaganfall	   gezeigt	   wurde,	   eher	   darauf	   zurückzuführen	   ist,	   dass	   die	   Zellen	  stimulierende	  Faktoren	  ins	  umliegende	  Gewebe	  absondern.	  Vor	  dem	  Hintergrund	  dieser	  indirekten	  Mechanismen	  wird	   vorgeschlagen,	   die	   Bildgebungsmethoden,	   die	   für	   diese	  Doktorarbeit	   entwickelt	   wurden,	   mit	   anderen	   funktionellen	   und	   strukturellen	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Bildgebungsverfahren	   zu	   kombinieren,	   um	   speziell	   Interaktionen	   von	   NSZ	   und	  Gefäßbett	  zu	  untersuchen.	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6 Appendix	  
Glossary	  and	  abbreviations	  19F	   	   Most	  abundant,	  stable	  Fluorine	  isotope	  in	  nature.	  Nuclear	  spin	  ½.	  
1H	   	   Most	   abundant,	   stable	   Hydrogen	   isotope	   in	   nature.	   Nuclear	  spin	  ½.	  Ang	   	   Angiopoietin.	  Angiogenesis	   	   Regrowth	  of	  new	  vessels	  from	  an	  existing	  vascular	  network.	  Apoptosis	   	   A	   form	   of	   cell	   death	   in	   which	   a	   programmed	   sequence	   of	  events	  leads	  to	  the	  elimination	  of	  cells.	  Arterial	  spin	  labeling	   	   A	  MR	  image	  can	  be	  sensitized	  to	  the	  effect	  of	   inflowing	  blood	  spins	  if	  those	  spins	  are	  in	  a	  different	  magnetic	  state	  to	  that	  of	  the	  static	  tissue.	  Arterial	  spin	  labeling	  techniques	  use	  this	  idea	  by	   magnetically	   labeling	   blood	   flowing	   into	   the	   slices	   of	  interest.	  Bevacizumab	   	   Anti-­‐angiogenic	  drug	  that	  blocks	  VEGF.	  Bioluminescence	   	   The	  production	  of	  light	  by	  living	  organisms.	  BLI	   	   Bioluminescence	  imaging	  Bloch	  equations	   	   Set	   of	   macroscopic	   differential	   equations	   that	   are	   used	   to	  calculate	   the	   nuclear	   magnetization	   M	   =	   (Mx,	   My,	   Mz)	   as	   a	  function	   of	   time	   when	   relaxation	   times	   T1	   and	   T2/	   T2*	   are	  present.	  Bloch-­‐Torrey	  equation	   	   Generalization	   of	   the	   Bloch	   equations,	   which	   includes	   added	  terms	  due	  to	  the	  transfer	  of	  magnetization	  by	  diffusion.	  Blood	  flow	   	   The	   rate	   at	   which	   a	   fluid	   passes	   through	   an	   organ	   or	   part,	  expressed	  as	  volume	  per	  unit	  of	  time.	  BOLD	  effect	   	   Blood	   oxygen	   level	   dependent	   effect.	   In	   MRI	   the	   changes	   in	  blood	   oxygenation	   level	   are	   visible.	   Oxyhaemoglobin	   (the	  principal	   haemoglobin	   in	   arterial	   blood)	   has	   no	   substantial	  magnetic	   properties,	   but	   deoxyhaemoglobin	   (present	   in	   the	  draining	   veins	   after	   the	   oxygen	   has	   been	   unloaded	   in	   the	  tissues)	   is	   strongly	   paramagnetic.	   It	   can	   thus	   serve	   as	   an	  intrinsic	   paramagnetic	   contrast	   agent	   in	   appropriately	  performed	  MRI.	  C17.2	   	   Widely	  used	  murine	  neural	  stem	  cell	  line.	  Transduced	  with	  an	  oncogene	  to	  increase	  proliferation.	  Carcinoma	   	   An	   invasive	   malignant	   tumor	   derived	   from	   epithelial	   tissue	  that	  tends	  to	  metastasize	  to	  other	  areas	  of	  the	  body.	  Cascade	   	   A	  chemical	  or	  physiological	  process	   that	  occurs	   in	  successive	  stages,	  each	  of	  which	  is	  dependent	  on	  the	  preceding	  one,	  and	  often	  producing	  a	  cumulative	  effect.	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Caudal	   	   Situated	  more	  toward	  the	  tail/posterior	  part	  of	  the	  animal	  CD34	   	   Gene	   expressed	   in	   a	   subset	   of	   cells	   of	   the	   human	   body	  including	  hematopoietic	  stem	  cells.	  Cell	  tracker	  orange	   	   Trade	   name	   for	   a	   fluorescent	  marker	   used	   in	   cell	   culture	   to	  label	  cells.	  Cytoplasm	   	   Part	  of	  a	  cell	  between	  cell	  membrane	  and	  nucleus.	  Dentate	  gyrus	   	   Brain	  structure	  within	  hippocampus.	  Differential	  equation	   	   Mathematical	   equation	   for	   an	   unknown	   function	   of	   one	   or	  several	   variables	   that	   relates	   the	   values	  of	   the	   function	   itself	  and	  its	  derivatives	  of	  various	  orders.	  Diffusion	  coefficient	   	   Mathematical	  quantity	  in	  Fick’s	  law	  that	  describes	  diffusion.	  Diffusivity	   	   Ability	   of	   a	   substance	   to	   permit	   or	   undergo	   diffusion.	   Term	  sometimes	  used	  equivalently	  for	  diffusion	  coefficient.	  Dynamic	   susceptibility	  contrast	  MRI	   	   Method	   to	   measure	   blood	   flow	   and	   perfusion	   through	  acquisition	  of	  a	  fast	  series	  of	  MR	  images	  during	  passage	  of	  an	  intravascular,	  (super)	  paramagnetic	  MR	  contrast	  agent.	  Endocytosis	   	   A	  process	  of	  cellular	  ingestion	  by	  which	  the	  plasma	  membrane	  folds	  inward	  to	  bring	  substances	  into	  the	  cell.	  Endosome	   	   Intracellular	   vesicles	   formed	   from	   the	   cell	   membrane	   which	  are	  involved	  in	  intracellular	  transport.	  Endothelial	  cell	   	   Thin,	  flattened	  cell.	  A	  layer	  of	  them	  lines	  the	  inside	  surfaces	  of	  body	  cavities,	  blood	  vessels,	  and	  lymph	  vessels.	  Epo	   	   Erythropoietin.	  Extracellular	  matrix	   	   Any	   substance	   produced	   by	   cells	   and	   excreted	   to	   the	  extracellular	  space	  within	  the	  tissues,	  serving	  as	  a	  scaffolding	  to	   hold	   tissues	   together	   and	   helping	   to	   determine	   their	  characteristics.	  Fluorescence	   	   The	  emission	  of	  electromagnetic	  radiation,	  especially	  of	  visible	  light,	   stimulated	   in	  a	   substance	  by	   the	  absorption	  of	   incident	  radiation	   and	   persisting	   only	   as	   long	   as	   the	   stimulating	  radiation	  is	  continued.	  Fractal	  geometry	   	   Branch	   of	   mathematics	  concerned	   with	   irregular	   patterns	  made	  of	  parts	  that	  are	  in	  some	  way	  similar	  to	  the	  whole,	  e.g.,	  twigs	   and	   tree	   branches,	   a	   property	   called	   self-­‐similarity	   or	  self-­‐symmetry.	  Gadolinium3+	   	   Paramagnetic	   ion	   used	   in	   MR	   contrast	   agents.	   Efficiently	  shortens	  T1	  relaxation	  time	  of	  surrounding	  nuclei.	  Genomics	   	   The	   study	   of	   all	   the	   genes	   of	   a	   cell,	   or	   tissue,	   at	   the	   DNA	  (genotype),	   mRNA	   (transcriptome),	   or	   protein	   (proteome)	  levels.	  GFAP	   	   Glial	   fibrillary	   acidic	   protein.	   Intermediate	   filament	   protein	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that	   is	   expressed	   by	   numerous	   cell	   types	   of	   the	   central	  nervous	  system	  including	  astrocytes	  and	  ependymal	  cells.	  Glia	   	   The	   delicate	   web	   of	   connective	   tissue	   that	   surrounds	   and	  supports	  neurons.	  Gradient	  echo	   	   In	  MRI,	  a	  gradient	  echo	  is	  generated	  by	  using	  a	  pair	  of	  bipolar	  gradient	  pulses	  without	   the	  use	  of	   refocusing	  radiofrequency	  pulses.	   Signal	   in	   a	   gradient	   echo	   experiment	   decays	  exponentially	  with	  T2*.	  Granular	   layer	   of	   the	  dentate	  gyrus	   	   One	   of	   the	   three	   cell	   layers	   of	   the	   dentate	   gyrus.	   Consists	   of	  granule	  cells,	  i.e.	  very	  small	  neurons.	  Growth	  factor	   	   Any	   substance	   that	   promotes	   skeletal	   or	   somatic	   growth,	  usually	  a	  mineral,	  hormone,	  or	  vitamin.	  Gyromagnetic	  ratio	   	   Ratio	  of	  magnetic	  dipole	  moment	  and	  angular	  momentum.	  HIF	   	   Hypoxia	  inducible	  factor.	  Hippocampus	   	   Archicortical	   structures,	   which	   is	   multi-­‐layered	   and	  folded/twisted	  resembling	  a	  hippocampus	  tail.	  Among	  manys	  other	  functions,	  it	  plays	  a	  central	  role	  in	  learning	  and	  memory.	  hNSC	   	   Human	  neural	  stem	  cell.	  Hypoxia	   	   Insufficient	  levels	  of	  oxygen	  in	  blood	  or	  tissue.	  ICR	   	   Outbred	   mouse	   strain.	   ICR	   stands	   for	   “imprinting	   control	  region.”	  In	  vitro	   	   Made	   to	   occur	   outside	   the	   living	   organism	   in	   an	   artificial	  environment.	  In	  vivo	   	   In	  the	  living	  organism.	  IPS	  cell	   	   Induced	  pluripotent	  stem	  cell.	  A	  mature	  cell	  that	  is	  genetically	  modified	  to	  express	  certain	  factors.	  These	  factors	  drive	  the	  cell	  to	  a	  more	  potent	  and	  less	  differentiated	  state.	  Ischemia	   	   Insufficient	   supply	   of	   blood	   to	   an	   organ,	   usually	   due	   to	   a	  blocked	  artery.	  Kupffer	  cell	   	   Specialized	   cells	   in	   the	   liver	   that	   destroy	   bacteria,	   foreign	  proteins,	   and	  worn-­‐out	   blood	   cells.	   Can	   take	   up	  MR	   contrast	  agents.	  Larmor	  frequency	   	   The	  Larmor	  precession	  frequency	  is	  the	  rate	  of	  precession	  of	  a	  spin	  packet	  under	  the	  influence	  of	  a	  magnetic	  field.	  Luciferases	   	   Group	   of	   oxidizing	   enzymes	   that	   acts	   with	   luciferines	   under	  production	  of	  light.	  	  Luciferin	   	   Group	   of	   substances	   that	   are	   oxydized	   by	   luciferases	   in	   an	  enzymatic	  reaction	  under	  production	  of	  light.	  Metabolism	   	   The	  sum	  of	  all	   the	  physical	  and	  chemical	  processes	  by	  which	  living	   organized	   substance	   is	   produced	   and	   maintained	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(anabolism),	   and	   also	   the	   transformation	   by	  which	   energy	   is	  made	  available	  for	  the	  uses	  of	  the	  organism	  (catabolism).	  Middle	   cerebral	   artery	  occlusion	   	   Most	  common	  ischemic	  stroke,	   for	  which	  the	  middle	  cerebral	  artery	   is	   blocked.	   Also	   refers	   to	   a	   certain	   type	   of	   surgery	   to	  model	  stroke	  in	  animals.	  Molecular	  biology	   	   The	   study	   of	   biology	   on	   a	   molecular	   level	   including	   the	  structure,	   function,	   and	   makeup	   of	   biologically	   important	  molecules	  such	  as	  DNA,	  RNA,	  and	  proteins.	  Monocyte	   	   A	   white	   blood	   cell	   that	   has	   a	   single	   nucleus	   and	   can	   ingest	  foreign	  material.	  MRI	   	   Magnetic	  resonance	  imaging.	  MRS	   	   Magnetic	  resonance	  spectroscopy	  Neonate	   	   Newly	  born	  infant.	  Neurogenesis	   	   Generation	  of	  new	  neurons.	  Neuron	   	   Any	  of	   the	   impulse-­‐conducting	  cells	   that	  constitute	   the	  brain,	  spinal	  column,	  and	  nerves,	  consisting	  of	  a	  nucleated	  cell	  body	  with	  one	  or	  more	  dendrites	  and	  a	  single	  axon.	  Neurosphere	   	   A	   primitive	   neural	   tissue	   that	   arises	   when	   embryonic	   stem	  cells	  are	  grown	  in	  certain	  culture	  conditions.	  NSC	   	   Neural	  stem	  cell.	  Multipotent	  cell	  that	  has	  the	  capacity	  for	  self-­‐renewal	  and	  can	  differentiate	  into	  cells	  of	  the	  central	  nervous	  system.	  NuNu	   	   Genetically	   modified	   mouse	   strain	   also	   referred	   to	   as	   nude	  mouse.	   Lacks	   an	   adaptive	   immune	   system	   and	   is	   therefore	  widely	   used	   in	   cell	   implantation	   studies	   to	   minimize	   graft	  rejection.	  Olfactory	  bulb	   	   Structure	  in	  the	  vertebrate	  forebrain	  involved	  in	  perception	  of	  odors.	  Oncogene	   	   A	   gene	   that	   causes	   the	   transformation	   of	   normal	   cells	   into	  cancerous	  tumor	  cells,	  especially	  a	  viral	  gene	  that	  transforms	  a	  host	  cell	  into	  a	  tumor	  cell.	  Paracrine	   	   Secretion	  released	  by	  cells	  into	  adjacent	  cells	  or	  tissue.	  Paramagnetic	   	   In	   an	   external	   magnetic	   field	   the	   induced	   magnetic	   field	   is	  parallel	   and	   proportional	   to	   the	   intensity	   of	   the	  magnetizing	  field.	  Pax6	   	   Gene	  involved	  in	  transcriptional	  regulation.	  Perfusion	   	   Passage	  of	  a	  fluid	  through	  the	  vessels	  of	  a	  specific	  organ.	  PET	   	   Positron	   emission	   tomography.	   Nuclear	   medicine	  tomographic	  imaging	  technique	  using	  positron	  emitters.	  PFC	   	   Perfluorocarbon.	  A	  hydrocarbon	  for	  which	  all	  hydrogen	  atoms	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have	   been	   replaced	   by	   fluorine	   atoms.	   Sometimes	   used	   as	   a	  shortcut	   for	   the	   specific	   perfluorocarbon	   Perfluoro-­‐crown-­‐ether.	  PFPE	   	   Perfluoropolyether.	  Linear	  perfluorocarbon	  molecule.	  Phagocyte	   	   A	   cell,	   such	   as	   a	   white	   blood	   cell,	   that	   engulfs	   and	   absorbs	  waste	   material,	   harmful	   microorganisms,	   or	   other	   foreign	  bodies	  in	  the	  bloodstream	  and	  tissues.	  Phase	  coherence	   	   The	  state	   in	  which	   two	  signals/spin	  packets	  maintain	  a	   fixed	  phase	  relationship	  with	  each	  other.	  Phenotype	   	   The	   observable	   physical	   or	   biochemical	   characteristics	   of	   an	  organism,	   as	   determined	   by	   both	   genetic	   makeup	   and	  environmental	  influences.	  PlGF	   	   Placenta	  growth	  factor.	  Progenitor	  cell	   	   Cell	  that,	  like	  a	  stem	  cell,	  has	  a	  tendency	  to	  differentiate	  into	  a	  specific	   type	  of	   cell,	   but	   is	   already	  more	   specific	   than	  a	   stem	  cell	   and	   is	   pushed	   to	   differentiate	   into	   its	   "target"	   cell.	   The	  most	  important	  difference	  between	  stem	  cells	  and	  progenitor	  cells	   is	   that	   stem	   cells	   can	   replicate	   indefinitely,	   whereas	  progenitor	   cells	   can	   divide	   only	   a	   limited	   number	   of	   times.	  Sometimes	  used	  equivalently	  to	  stem	  cell.	  Proliferation	   	   To	   grow	   or	  multiply	   by	   rapidly	   producing	   new	   tissue,	   parts,	  cells,	  or	  offspring.	  PTK	  787	   	   Anti-­‐angiogenic	  drug	  that	  inhibits	  protein	  tyrosine	  kinase	  and	  VEGF	  receptor	  kinase.	  Relaxation	  rate	   	   Inverse	  of	  relaxation	  time.	  Reporter	  gene	   	   Gene	   coding	   for	   an	   easily	   assayed	   protein,	   which	   is	   used	   to	  detect	  expression	  of	  the	  gene	  under	  different	  conditions.	  Reticuloendothelial	  system	   	   A	   group	   of	   cells	   having	   the	   ability	   to	   take	   up	   and	   sequester	  inert	   particles	   and	   vital	   dyes,	   including	   macrophages	   and	  macrophage	   precursors,	   specialized	   endothelial	   cells	   lining	  the	   sinusoids	   of	   the	   liver,	   spleen,	   and	   bone	   marrow,	   and	  reticular	   cells	   of	   lymphatic	   tissue	   (macrophages)	   and	   bone	  marrow	  (fibroblasts).	  RF	   	   Radiofrequency.	  Rostral	   	   Situated	  towards	  the	  oral/nasal	  region	  Scaffold	   	   A	   support,	   either	   natural	   or	   artificial,	   that	   maintains	   tissue	  contour.	  Scratch	  assay	   	   Widely	   used	   in	   vitro	   test	   for	   wound	   healing.	   A	   corridor	   is	  scratched	   through	   an	   adherent	   cell	   culture	   and	   the	   time	   is	  measured	  until	  the	  corridor	  is	  closed.	  Sephadex	   	   Trade	  name	  of	  a	  cross-­‐linked	  dextran	  gel	  used	  for	  gel	  filtration	  columns.	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Sinusoid	  (blood	  vessel)	   	   A	   form	   of	   terminal	   blood	   channel	   consisting	   of	   a	   large,	  irregular	   anastomosing	   vessel	   having	   a	   lining	   of	  reticuloendothelium	   and	   found	   in	   the	   liver,	   heart,	   spleen,	  pancreas,	   and	   the	   adrenal,	   parathyroid,	   carotid,	   and	  hemolymph	  glands.	  SNR	   	   Signal-­‐to-­‐noise	   ratio,	   mean	   signal	   intensity	   divided	   by	  standard	  deviation	  of	  the	  noise	  SPECT	   	   Single	   photon	   emission	   computed	   tomography.	   Nuclear	  medicine	  tomographic	  imaging	  technique	  using	  gamma	  rays.	  Spin	  echo	   	   In	   MRI,	   a	   spin	   echo	   is	   generated	   by	   one	   or	   a	   series	   of	  refocusing	   radiofrequency	   pulses	   after	   the	   excitation	   pulse.	  Signal	  in	  a	  spin	  echo	  experiment	  decays	  exponentially	  with	  T2.	  SPIO	   	   Superparamagnetic	  iron	  oxide	  Subventricular	  zone	   	   Paired	  brain	  structure	  situated	  throughout	  the	  lateral	  walls	  of	  the	  lateral	  ventricles.	  Superparamagnetic	   	   Form	  of	  magnetism,	  which	  appears	  in	  small	   ferromagnetic	  or	  ferrimagnetic	   nanoparticles.	  Without	   external	  magnetic	   field,	  the	  magnetization	   is	  on	  average	  zero,	  whereas	  magnetization	  is	   much	   higher	   than	   for	   paramagnetic	   substances	   inside	   an	  external	  magnetic	  field.	  Susceptibility	   	   Magnetic	   susceptibility	   is	   a	   proportionality	   constant	   that	  indicates	   the	   degree	   of	   magnetization	   of	   a	   material	   in	  response	  to	  an	  applied	  external	  magnetic	  field.	  T1	   	   Empirical	  constant	  in	  Bloch	  equations.	  Longitudinal	  relaxation	  time.	  T2	   	   Empirical	   constant	   in	  Bloch	   equations.	   Transverse	   relaxation	  time	  neglecting	  time-­‐constant	  magnetic	  inhomogeneities.	  T2*	   	   Empirical	   constant	   in	  Bloch	   equations.	   Transverse	   relaxation	  including	  time-­‐constant	  magnetic	  inhomogeneities	  TGF	   	   Transforming	  growth	  factor.	  Transgene	   	   A	  gene	  that	  is	  transferred	  from	  an	  organism	  of	  one	  species	  to	  an	  organism	  of	  another	  species	  by	  genetic	  engineering.	  Trophic	  factor	   	   Substance	   promoting	   cellular	   growth,	   differentiation,	   and	  survival.	  Trypan	  blue	   	   A	  dye	  that	  does	  not	  color	   intact	  cells	  and	  is	  therefore	  used	  in	  cell	   culture	   to	   measure	   cell	   viability	   through	   exclusion	   of	  stained	  cells.	  	  Ultra	   short	   echo	   time	  sequence	   	   MR	  pulse	  sequence	  with	  radial	  readout	  of	  k-­‐space.	  Since	  each	  line	   acquired	   in	   k-­‐space	   starts	   at	   k=0,	   very	   short	   echo	   times	  are	  possible	  <100	  µs.	  USPIO	   	   Ultrasmall	  superparamagnetic	  iron	  oxide.	  VEGF	   	   Vascular	  endothelial	  growth	  factor.	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White	  matter	   	   The	  part	  of	  the	  brain	  that	  contains	  myelinated	  nerve	  fibers.	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Eigener	  Anteil	  an	  den	  Veröffentlichungen	  Paper	   I:	   Teilweise	   Durchführung	   der	   Experimente,	   teilweise	   Auswertung	   der	   Daten,	  teilweise	  Schreiben	  des	  Manuskripts.	  Paper	  II:	  Entwicklung	  von	  Teilen	  des	  Versuchsaufbaus,	  Planung	  und	  Durchführung	  aller	  MRT	   Experimente,	   Auswertung	   aller	   MRT-­‐Daten,	   Schreiben	   des	   Manuskripts	   und	  Gestaltung	  der	  Abbildungen.	  Paper	   III:	   Entwicklung	   des	   Versuchsaufbaus,	   Planung	   und	   Durchführung	   aller	   MRT-­‐Experimente,	   Auswertung	   der	   Daten,	   Schreiben	   des	   Manuskripts	   und	   Gestaltung	   der	  Abbildungen.	  Paper	   IV:	   Entwicklung	   des	   MRT-­‐Versuchsaufbaus,	   Planung	   und	   Durchführung	   aller	  MRT-­‐Experimente,	  Auswertung	  der	  MRT-­‐Daten,	  Schreiben	  des	  Manuskripts.	  Paper	   V:	   Entwicklung	   des	   19F-­‐MRT-­‐Versuchsaufbaus,	   Planung	   und	  Durchführung	   aller	  MRT-­‐Experimente,	   Auswertung	   der	  Daten,	   Schreiben	   des	  Manuskripts	   und	  Gestaltung	  aller	  Abbildungen.	  Paper	   VI:	   Review,	   Schreiben	   des	  MR-­‐methodischen	   Teils	   und	   des	   Ausblicks,	   Erstellen	  der	  Tabelle	  zum	  Vergleich	  der	  Sensitivitäten.	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  Universität	  zu	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